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In the last decade, major advances have been made on the field of radiation 
oncology, bringing new diagnostic techniques and expanding the number of 
treatment modalities[1]. With a larger number of treatment options comes a 
heightened potential for personalized medicine, however, this has its challenges. 
Traditional evidence based medicine uses randomized trials that are designed to 
represent homogenous populations of patients, and are not based upon patient, 
disease and treatment parameters[2]. 
The challenge in clinical decision making lies in that a physician must take into 
account a large number of characteristics, such as patient biology, pathology, 
medical images, blood test results, given medication, dose in the organs at risk, 
dose in the target volume, fractionation, and genomic data relevant to radiotherapy. 
The decisions should take into account the tumor control rate, the survival rate, 
and the radiotoxicity. The human cognitive capacity is limited however, making 
predictive modeling and big data in radiation oncology an increasingly essential tool 
in decision making[3].
Particle therapy modalities, such as hadron therapy, are expected to be less 
toxic and more effective than the more conventional photon therapy, due to their 
favorable dose distributions[4, 5]. However, planning studies show that not all patients 
would benefit from this more expensive treatment[6, 7], making decision support 
systems (DSS) an important tool to justify patient stratification for particle therapy. 
This chapter will discuss the process of gathering data, training models and 
developing DSS using rapid learning health care (RLHC).
Rapid Learning Healthcare
During clinical trials, certain patient groups are under-represented, causing the 
data to be biased[8, 9]. RLHC uses and reuses medical data from both clinical trials 
and from standard clinical practice to use in novel studies or for decision support 
in new patients[10, 11]. RLHC consists of four sequential phases: the Data, Knowledge, 
Application, and Evaluation phase[3]. Figure 1.1 shows an overview of these phases. 
The first phase includes the obtaining and mining of prior data regarding the patients, 
disease, treatment and outcome. The second phase analyzes this data using methods 
such as machine learning to obtain knowledge from the data. The application phase 
improves clinical practice using this knowledge in the form of DSS. The final phase 
evaluates the DSS with regard to outcome, and uses this assessment as input for the 
first phase.




Figure 1.1: The phases of Rapid Learning Health Care (RLHC): Data collection from clinical 
practice and clinical trials, development of knowledge on the obtained data, application of 
the models via decision support systems (DSS), evaluation of the DSS and the application of 
DSS in clinical practice (Courtesy of  T.P. van Wijk). 
Big data
Ideally, the data obtained in the first phase of RLHC meets the classification 
demands of ‘Big Data’: the data should have Volume so that enhanced knowledge can 
be obtained with large amounts of variables; the data should have Velocity so that the 
gained knowledge remains practicable; the data should have Variety in order to find 
which treatment best fits an individual patient; and the data should have Veracity so 
that trust can be placed in the acquired knowledge[12]. The primary challenge in this 
phase of RLHC is obtaining data that meets these demands. 
CancerLinQ (http://cancerlinq.org/) is an initiative to rise to this challenge by the 
American Society of Clinical Oncology (ASCO)[13]. 
Figure 1.2 shows an overview of the CancerLinQ system. The system collects 
and analyzes all patient data obtained from the complete electronic health records 
(EHRs), and offers the opportunity to learn from previous patients, improving the 
quality of care. The system is built to transfer data including: patient and care provider 
demographics, appointments and visit details, medical and prescription history, 
surgery reports, pathology and lab data, and family history. Using language recognition 





Figure 1.2: CancerLinQ is an initiative by the American Society of Clinical Oncology (ASCO) 
and works in four steps: data is uploaded to CancerLinQ from clinical practice, the data is 
processed on patient level, patient data is de-identified, the data is analyzed and reported 
and made available to clinical practice (Courtesy of  T.P. van Wijk)
Centralization of data faces some difficult challenges, such as differences 
between institutes including language and data storage, and the reluctance 
to share data due to its value, privacy issues and lack of resources[14]. The first 
steps to overcoming these issues are being made through a cooperation between 
radiotherapy institutes  all over the world (the Netherlands, Germany, Belgium, the 
UK, the USA, Italy, Denmark, Australia, India and China, with South Africa, Ireland 
and Canada as prospective partners), which applies RLHC using the euroCAT 
project (www.eurocat.info)[15]. Figure 1.3 shows the infrastructure of the euroCAT 
project. This project overcomes some of the classical barriers to data sharing by 
using ‘distributed learning’ to train RLHC models on data locally without the data 
needing to leave its relative institute (please see the animation: (https://youtu.be/
nQpqMIuHyOk). 
For this project to work, data within the institutes needs to be translated to 
general, well-defined terms. Machine-readable data needs to be developed, 
where local terms can be matched to the general ones, for example the NCI 
Thesaurus. These general terms serve as an interface for each institute, enabling 
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information gathering and interpretation by a semantic gateway to the data. This 
also stimulates the harmonization between institutes on which data should be 
collected and how (disease specific ‘umbrella’ protocols)[16].
 
Figure 1.3: The graphical abstract for “Infrastructure and distributed learning methodology 
for privacy-preserving multi-centric rapid learning health care: euroCAT”[15].
Machine learning
Extracting knowledge from data is the third step in RLHC, and a common method 
used for this is machine learning[17]. Machine learning trains models on past data 
and uses it to make predictions regarding outcomes, such as tumor control and 
complication risks on data obtained from a new patient. Before models obtained 
with machine learning can be applied, they need to be validated, for which the 
TRIPOD (transparent reporting of a multivariable prediction model for individual 
prognosis or diagnosis) statement is a popular template[18]. The TRIPOD statement 
demands that the model is externally validated, so on dataset comparable to the 
training set, but from a different institute. There are a number of radiotherapy 
models available for different types of diseases, for example on https://www.





Figure 1.4: An example of a multifactorial Decision Support System that uses clinical 
information to make a three level comparison between proton and photon therapy for 
prostate cancer.
Decision support systems
The third phase of RLHC is the application of gained knowledge, which can be 
applied using DSS. DSS are typically software applications such as recursive partitioning 
analyses models, nomograms or websites such as https://www.ai4cancer.ai. A DSS 
is used to support the groups responsible for deciding on patient treatment, such as 
the physician, the tumor board and the patient, in making a knowledgeable decision 
regarding treatment options. Within the field of radiotherapy, it is acceptable to 
uses physics- and radiobiology-based models to predict complication risk and 
tumor control using tumor control probability (TCP) models[19] and normal tissue 
complication probability models (NTCP)[20]. DSS is an extension to this practice, 
integrating validated physics and radiobiology based models, together with patient 
and disease parameters into a multifactorial structure[21] (Figure 1.4).
The goal of a DSS is to use a combination of features (clinical, treatment, imaging, 
biomarkers, pathology, genetics etc.) and use it to make a robust prediction on 
patient outcome[22], as shown in Figure 1.5. The outcome predicted by a DSS can 
include tumor control, including local recurrence or rate of metastases, complication 
probability, overall survival or even cost-effectiveness. 
Clinical features
In several studies, clinical features have found to have a large influence on patient 
outcome[23, 24], and for a DSS to make individual predictions for patients, these 
features should be integrated into the system. Examples of clinical features are 
disease progression, organ function, age or sex of the patient, etc. The measurement 
of some of these features, such as performance status, is straightforward and can 
BIG DATA-BASED DECISION SUPPORT SYSTEMS FOR RADIOTHERAPY
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be done using methods such as questionnaires[25]. However, in order to reach a 
level of trustworthiness similar to that of randomized trials, the clinical parameters 
must be recorded in a meticulous manner. Standardized protocols should be used 
to this end, for example the ‘Umbrella’ protocol NCT01855191
https://www.cancerdata.org/protocols/eurocat-umbrella-protocol-nsclc. 
 
Figure 1.5: A multifactorial Decision Support System uses existing research evidences and 
resources to give a customized recommendation on patient treatment.
It is crucial that this is done after establishing a standardized protocol to ensure 
that the results are comparable between different centers and time points[26]. 
Additionally, perquisites for the measurements of certain features should be 
recorded, for example features evaluated only on patients showing certain 
symptoms, to prevent bias when interpreting the measurements. 




graded using validated systems, for example the common terminology criteria for 
adverse events (CTCAE)[27], which allows events to be reported by either patient 
or physician. A protocol must be established to report which system was used 
for observation and how events resulting from the treatment were managed. 
The reporting of the toxicity should be conducted in line with the Strengthening 
“The Reporting of Observational Studies in Epidemiology” (STROBE) statement 
for observational studies and genetic-association studies[28]. This statement is a 
protocol which lists all items that should be addressed during reporting to ensure 
standardized interpretation for these types of studies. 
Treatment features
Radiotherapy treatment features include both dose features and additional, 
none radiation treatments given to the patient, such as chemotherapy or hormonal 
therapy, which have shown to influence the outcome. Modern technologies 
such as intensity modulated radiotherapy (IMRT), brachytherapy, volumetric arc 
radiotherapy (VMAT) or particle-beam therapy, such as hadron therapy, allow for 
localized dose delivery around the target volume with maximum sparing of the organs 
at risk with very high dosimetric accuracy[29]. These techniques, in combination 
with increasing knowledge of normal tissue response to radiotherapy[30], is used 
to keep the delicate balance between TCP and NTCP. Figure 1.6 shows the dose 
distribution resulting from IMRT, VMAT, intensity modulated proton therapy (IMPT) 
and brachytherapy (BT) treatment planning on the prostate. 
To model the dose response in a DSS, the relevant features are obtained from 
the planned dose distributions. To ensure that these features are realistic, measures 
should be taken to deliver the prescribed dose as planned and these measures 
should be described[31]. One of the modelling challenges on this field is how best 
to combine the dose distribution for every sub-volume of a structure into features. 
Parameters such as mean dose, maximum dose, volume receiving more than a 
set amount of dose, or equivalent uniform dose (EUD) are easily quantified and 
are often used, which is acceptable for a large range of applications. However, to 
improve personalized decision making, spatial characteristics should be analyzed 
as well to differentiate in radio-sensitivity in different regions of organ or tumor[32].
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Figure 1.6: Dose distributions resulting from intensity modulated radiotherapy (IMRT), 
volumetric arc radiotherapy (VMAT), intensity modulated proton therapy (IMPT) and 
brachytherapy (BT) treatment planning on a patient with prostate cancer.
Cost-effectiveness
In the past, the endpoint of most DSS have been TCP and/or NTCP. However, due 
to the limited resources available in healthcare and considering the increasing costs 
of newer treatments, cost-effectiveness (CE) comparisons are becoming increasingly 
relevant[33]. This is especially important when considering treatments which are not 
significantly beneficial to all patients, but are notably more expensive or invasive 
than traditional treatments, such as hadron therapy[34]. A CE analyses is a good way 
to weigh the TCP, the NTCP and the treatment costs against each other. Additionally, 
a CE analyses could improve the insurance perspective regarding more expensive 






The goal of RLHC is to improve predictability of treatment outcomes to allow 
increase of effectiveness and efficiency of patient treatment. However, it is 
important to verify the improved predictability of multifactorial decision support 
systems compared to generally accepted, and often less complex, models[36]. 
Accepted RLHC models should repeatedly be reevaluated using robust data to test 
if the outcome is as expected and how this relates to evidence based guideline 
knowledge. 
Summary
Modern healthcare aspires to optimize personalized cancer therapy and faces 
many challenges in this respect. The increase in available treatment options and 
the diversity in patients prove incredibly problematic for individualized decision 
making. However, DSS developed using RLHC have the potential to bring us 
one step closer to realizing that goal. An essential step that needs to be taken 
is the standardization of data acquisition, including data concerning treatment, 
clinical features, imaging, genetics, and outcome. Also the clinical assessment 
of developed DSS is critical, as well as standardizing the development of robust 
prediction models. 
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The focus of this work was on the third phase of the rapid learning healthcare 
cycle: the development of clinical decision support systems (DSS). The primary aim 
of this thesis was the following:
“Bridging the gap between machine learning based models and the decision 
making process through the development of clinical decision support systems for 
prostate cancer patients”
We focused our efforts on prostate cancer patients, as this disease has a large 
variety of viable treatment options with similar cure rates, and a large demographic 
that could benefit from such a tool (~2,400 patients in the Netherlands receive 
active treatment for prostate cancer per year). We divided our primary aim into 
two sub-objectives:
Objective 1: To provide an overview of decision support systems in prostate 
cancer treatment 
Objective 2: To develop and challenge new clinical decision support systems that 
aid in the treatment selection of prostate cancer both a) within the 
field of radiotherapy and b) multidisciplinary.
Hypotheses
Relating to Objective 2, we tested the following hypotheses:
1. Image deformation can be used to create a CT scan of a patient with an 
implantable rectum spacer prior to implantation, allowing for dose comparisons.
2.  A clinical decision support system can be used to identify patients for whom 
an implantable rectum spacer is beneficial prior to treatment.
3.  The expected biochemical failure-free survival of patients can be improved 
when using an iso-toxic DSS to decide on the implantation of an implantable 
rectum spacer during external beam radiotherapy.
4. The expected quality of life and cost-effectiveness of patients can be improved 
when using a clinical decision support system to decide between external 
beam radiotherapy and prostatectomy for the treatment of prostate cancer.
Thesis outline
In this work we focus on the development of DSS for prostate cancer treatment, 
particularly external beam radiotherapy (EBRT). We split this thesis into 3 parts: 
Part I consist of the general introduction and a literature overview to work towards 
meeting Objective 1; Part II consists of the development and of new DSS which 
addresses Objective 2; Part III consists of a general discussion (Figure 2.2) .
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Part I
To demonstrate the significance of rapid learning health care, and the role of 
DSS in this practice, we provide a general introduction in Chapter 1.
The first step to meeting our primary aim and addressing Objective 1 was to gain 
insight in current literature concerning DSS for prostate cancer. In order to identify 
the gap in current decision support systems regarding prostate cancer treatment, 
an overview is made of current available tools, including diagnostic support tools, 
treatment DSS, and patient decision aids (PDA) in Chapter 3. 
Part II
Objective 2a was to develop a new DSS within the field of radiotherapy. During 
EBRT for prostate cancer the anterior rectal wall, which lays in close proximity to the 
prostate, has the risk to receive high dose levels, possibly leading to chronic rectal 
bleeding. In order to reduce the dose in this organ at risk, rectal spacers have been 
developed, such as the implantable rectum spacer (IRS) (Figure 2.1). Chapters 4-6 
cover the  development, refinement and challenge the robustness of  a proof of 
concept DSS for the placement of an IRS during EBRT treatment of prostate cancer. 
Chapter 4 describes the development of a virtual IRS (V-IRS) which uses image 
deformation to generate virtual CT image of a patient with IRS. This V-IRS is used as 
the basis for a new three-level DSS based on the V-IRS, comparing dose, NTCP and 
TCP on both the image without IRS and with V-IRS. The performance of this V-IRS 
is assessed by comparing to the CT images of real IRS’. Chapter 5 expands this DSS 
by making it iso-toxic, thus  calculating the maximum achievable TCP possible for a 
given patient based on toxicity restraints on the rectum, as well as by including two 
SNPs predictive for late rectal bleeding. In Chapter 6 we challenged the robustness 
of the V-IRS by testing the effect of the exact volume of the IRS on dose metrics and 
NTCP values calculated on the rectum. This study used a set of patients who had 
received a balloon spacer at the beginning of treatment, and for whom cone-beam 
CTs were collected in the course of treatment. During this time, the balloon spacer 
deflates, reducing the space gained by the IRS for each image. We compared the 
dose metrics in the rectum and the NTCP values for late rectal bleeding of the later 
images to the treatment planning image. 
24 CHAPTER 2
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Figure 2.1 – Graphic overview of prostate anatomy during radiotherapy and the effect of the 
implantable rectum spacer
Objective 2b  was to develop and challenge a new DSS on a multidisciplinary 
level. In Chapter 7 we developed a DSS for treatment using radical prostatectomy 
(RP) or EBRT. This was done by combining a set of predictive models for TCP and 
probability of late rectal bleeding, erectile dysfunction and urinary incontinence 
with an extensive cost-effectiveness analysis. In this chapter we tested our DSS 
using a synthetic patient dataset, which used a combination of published clinical 
parameters to create a representation of low-intermediate risk prostate cancer 
patients. The synthetic dataset was adjusted to recreate published clinical trials for 
the validation of the DSS. We also used this synthetic dataset to create a proof-of-
concept in vitro clinical trial. 
Part III
In the final section a critical discussion is presented of how well the objectives 
were met, and in how far the obtained knowledge through this research has filled 
the gap in the literature. As a supplement to this reflection, further research aspects 
are suggested that would further the development and integration of DSS for 
prostate cancer research. This section also discusses developments and challenges 
of individualized patient decision aids (iPDAs), which forms an important field 
parallel to DSS to further shared decision making.
2
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Figure 2.2 – Outline of the thesis
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Background: A multifactorial decision support system (DSS) is a tool designed to 
improve the clinical decision-making process, while using clinical inputs for an 
individual patient to generate case-specific advice. The study provides an overview 
of the literature to analyze current available DSS focused on prostate cancer (PCa), 
in order to better understand the availability of decision support tools as well as 
where the current literature is lacking.
Methods: We performed a MEDLINE literature search in July 2018. We divided the 
included studies into different sections: diagnostic, which support the diagnosis 
of PCa; treatment, which support the decision between treatment modalities 
or treatment plans; and patient, which focusses on informing the patient. We 
manually screened and excluded studies that did not contain a DSS concerning 
prostate cancer and study proposals.
Results: Our search resulted in twelve diagnostic DSS; six treatment DSS; two 
patient DSS; and eight papers that could improve DSS.
Conclusions:  Diagnosis DSS is well represented in the literature as well as 
treatment DSS considering external beam radiotherapy, however, there is a lack of 
DSS for other treatment modalities. The development of patient decision aids is a 
new field of study, and few successes have been made for PCa patients. These tools 
can improve personalized medicine, but need to overcome a number of difficulties 
to be successful and require more research.




Worldwide, prostate cancer (PCa) is the second most occurring type of cancer 
in men, and the most commonly diagnosed cancer for men living in developed 
countries, making it a very relevant topic for cancer research[1]. 
A variety of treatment options is available to treat PCa, such as externalbeam 
radiotherapy (EBRT) and radical prostatectomy[2-4], which have similar long-term 
survival outcomes. Other treatments, such as brachytherapy[5-8] are gaining 
popularity, and active surveillance is an increasingly viable option as well[9, 
10], due to the slow progression of some kinds of PCa. Retrospective studies 
comparing different treatment modalities tend to be conflicting and biased. 
Consensus on the best treatment choices for men with PCa remains absent 
because prospective trials for different treatments report different toxicities[4, 
11, 12]. Due to this, the treatment choice is largely dependent on both patient 
and physician subjective preferences, rather than knowledge-based decision-
making[13]. Additionally, treatment outcome is dependent on a large number of 
features, including treatment, patient, tumor, clinical, and genetic features[14]. 
These factors further complicate the integration of evidence-based decision 
making into clinical practice due to the limitations of human cognitive capacity, 
which can only take a relatively small number of factors into account on which 
to base a decision[15, 16]. In order to meet the aspiration of personalized medicine, 
the need for multifactorial decision support systems (DSS) is growing[17-23]. A DSS 
is a tool designed to improve the difficult medical decision-making process. It 
uses multifactorial inputs (treatment, patient, tumor, clinical, genetic, etc.) for 
a given patient to generate case-specific advice for patients, clinicians or other 
medical professionals. Due to the variety of treatment options for PCa, all equally 
efficacious for outcome, but having different secondary effects, this disease is an 
interesting subject for the use of DSS.
In addition to the need for DSS for treatment selection, similar systems can 
be used for the diagnosis of PCa, improving early detection as well as reducing 
over-diagnosis and unnecessary testing. These DSS can use imaging, clinical, 
biological, and other parameters to improve detection and risk classification of 
PCa in a minimally invasive method to maximize individual treatment.
This study provides an overview of the literature to analyze current available 
DSS focused on PCa, in order to better understand the availability of DSS as well 
as noting where the current literature is lacking. We aim to provide an update 
for clinicians about recent advances in DSS for personalized PCa oncology, which 






In order to identify all decision support systems with relations to treatment for 
PCa, we performed a MEDLINE/PubMed literature search in July 2018, restricted to 
English. Details of the strategy we used are shown in Figure 3.1.
Figure 3.1 – Flowchart of the results of the literature search in PubMed
Selection criteria
Prior to review full texts, we manually checked the abstracts and titles to select 
papers for this study. Duplicates, posters or abstracts that did not include a published 
work were excluded. Additionally, we excluded studies which clearly did not include 
a DSS for PCa. After full text review, we excluded any papers that described study 
proposals that did not describe a DSS in PCa. We selected appropriate studies by 
manually screening and considering the aforementioned criteria.




The studies we included were divided into sections according to the type of 
DSS: diagnostic DSS, which support the staging of PCa or support the decision for 
more invasive or expensive diagnostic tests; treatment DSS, which support the 
decision between treatment modalities or treatment plans; and patient DSS, which 
focusses on informing the patient.
We described each study using the number of patients, the decision that the 
system supports, and the system inputs and outcomes. We also commented on 
the general applicability, the reported performance of the system and some of 
the primary limitations. In order to assess the reporting quality of the studies, 
we tested each paper for their compliance to the TRIPOD (Transparent Reporting 
of studies on prediction models for Individual Prognosis Or Diagnosis) reporting 
guideline[24]. We reported this in a percentage calculated using the document: 
“Scoring adherence of prediction model study reports to the TRIPOD reporting 
guideline”, available on http://www.tripod-statement.org/.
Results
Included Studies
DSS for Diagnosis and Diagnostic Interventions
The studies that contained a diagnostic DSS are listed in Table 3.1. Two of the 
studies we found had as goal to support the use of a diagnostic tool: Lee et al. (2010) 
and Mukai et al. (2013). The application tested by Mukai et al. (2013) was meant to 
support the use of prostate specific antigen (PSA) tests for patients. The DSS was a 
web-based application that would aid in the decision to perform PSA tests for general 
practitioners (GPs) in Denmark. The study lead to the conclusion that it was possible 
to grant GPs in Denmark easy access to web-based DSS by replacing certain words 
in their medical records by hyperlinks. However it also showed that this DSS did not 
change PSA-testing behavior. Since this study neither developed nor validated this 
DSS, the compliance to the TRIPOD guidelines could not be tested.
Lee et al. (2010) attempted to support the use of a biopsy by predicting initial 
biopsy outcomes through three different models: support vector machine (SVM), 
artificial neural network (ANN) and multiple logistic regression. The study trained 
each of the models on 600 patients who had undergone transrectal ultrasonography 
(TRUS)-guided prostate biopsies, and tested them on 477 and compared the 
model performances. The parameters of the models were TRUS findings and 
clinical parameters, including age and PSA. The area under the receiver operating 
characteristic (ROC) curve (AUC) for the use of multiple logistic regression analysis, 
ANN, and the SVM were 0.768, 0.778, and 0.847, respectively, and pairwise 
comparison of the ROC curves showed that the SVM model had superior performance.




(2017) and Chang et al. (1999) all aimed to detect, diagnose or classify PCa using a 
variety of methods. Kim et al. (2011) performed a study similar to Lee et al. (2010), 
but with as aim to improve pathological staging, rather than reduce the number of 
biopsies. Two models were developed, SVM and ANN, for the prediction of advanced 
PCa and compared these based on performance. The models used TRUS-guided 
biopsy parameters and were tested on 532 patients divided into training and test 
groups. The SVM model performed significantly better (p=0.02) than the ANN model 
based on ROC curve, with an AUC 0.805 while that of the ANN model was 0.719. This 
study showed that these models could improve objective pathological staging of 
biopsy-proven PCa patients, and could be applied in combination with TRUS-guided 
biopsies once externally validated.
Another neural network was trained on laboratory results by Sadoughi et al. 
(2014) who then performed particle swarm optimization. The specific goal of this 
study was to aid in distinguishing between localized PCa and benign hyperplasia of 
the prostate. The model was internally validated on 60 patients, and the authors 
found an accuracy of 98.33%. The description of the methodology was limited, 
and the reporting conformed only 33% to the TRIPOD guidelines. The model could 
potentially improve detection of PCa and possibly reduce the number of biopsies, 
but external validation is necessary. 
Notable is Shah et al. (2012), who also used SVM, but in contrast to Lee et al. 
(2011), the model was not trained on biopsy results, but on pathological regions of 
a magnetic resonance imaging (MRI) scan of post prostatectomy prostates. The aim 
was not only to diagnose PCa, but to locate it specifically on MRI scans by modeling 
voxel specific risk analyses. The sensitivity and the specificity of the model with 
optimized SVM parameters was 90%, and the Kappa coefficient was 80%, where 
the raters were the DSS and the ground truth histology. The study only included 24 
patients, but since the model was trained on specific regions, the training was done 
on 225 cancer and 264 non-cancerous regions. This model could be applied in any 
hospital with a 3.0 T endorectal MP-MRI scanner, although it still requires validation
Van Leeuwen et al. (2017) developed a nomogram, rather than a deep learning 
algorithm, that included a larger number of parameters to diagnose significant PCa. 
The nomogram included Prostate Imaging Reporting and Data System (PIRADS), 
age, PSA, digital rectal examination (DRE), prostate volume, and prior biopsy. The 
model performed with an AUC of 0.864 on an external validation set, and the paper 
proposed an optimal strategy to reduce the number of biopsies needed with minimal 
risk of under-diagnosis. This paper conformed to the TRIPOD guidelines for 97%.
Chang et al. (1999) evaluated the usefulness and the performance of a DSS, the 
Prostate Cancer Expert System (PCES), which was validated on 43 patients with 
confirmed PCa. The PCES system, which utilized PSA, Gleason score, TRUS, and DRE 
was used to categorize the patients into localized or advanced PCa, and the same 
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test was applied to four attending physicians and four residents. The results showed 
that the PCES performed with a higher accuracy than all residents and physicians, 
though the difference was only higher for two physicians. It also showed that after 
consultation of the PCES, the staging accuracy of the residents improved to the level 
of the attending physicians.     
A number of prediction tools are currently being applied in the clinic to aid 
in the further diagnosis of the PCa disease, providing predictions on lymph node 
(LN) involvement, organ confinement (OC), seminal vesical (SV) involvement and 
extracapsular extension and risk of failure after treatment. The Partin tables[25, 26] 
are a set of nomograms to predict OC of PCa, initially introduced in 1993, and most 
recently updated in Tosoian et al. (2017)[27]. Based on these nomograms, Roach 
derived a set of formulas for the prediction of SV involvement in a paper published 
by Diaz et al. (1994)[28]. Roach et al. (1994)[29] also derived formulas that predicted 
LN involvement based on PSA and Gleason score, and Roach et al. (2000)[30] did the 
same for the risk of failure following radiotherapy (RT) and extracapsular extension 
in patients with localized PCa. 
Tosoian et al. (2017) validated and updated the Partin tables on a patient cohort 
of 4459 patients with as goal to predict the pathological outcome after radical 
prostatectomy. The performance of the model was tested for binary regression 
where the AUC was calculated when comparing organ confined (OC) PCa to other 
pathological outcomes. The model performed best when predicting OC versus LN 
involvement (AUC = 0.918) and versus seminal vesical (SV) involvement (AUC = 
0.856). The weakest performance was for OC versus extra-prostatic extension (AUC 
= 0.673).
Diaz et al. (1994) split patients into high risk and low risk groups of SV involvement 
using PSA and Gleason score, and tested this on 217 patients. The incidence rate of 
SV involvement in the low risk group was 7%, while the incidence rate in the high risk 
group was 37%, resulting in a chi-square of 23.17. 
Roach et al. (1994) performed a similar study on 282 patients, but divided the 
patients into low and high risk groups for LN involvement. This resulted in 6% 
incidence rate in the low risk group and a 40% incidence rate in the high risk group, 
resulting in a significant split (p <0.001). 
Roach et al. (2000) split 895 patients into low, intermediate and high risk groups 
for extracapsular extension. This resulted in an incident rate of 17.8%, 46.7% and 
66.7% incidence rate in low, intermediate and high risk groups respectively, which 
was a significant split (p <0.01).
D’Amico et al. (1998) suggested a widely accepted risk classification for prostate 
cancer to help predict biochemical outcome after five years after PCa treatment, 
stratifying them into low, intermediate and high risk PCa[31]. This study included 1872 




was used to calculate the relative risk between different groups of patients, based on 
risk level and treatment type. No validation was performed in this paper.
Memorial Sloan Kettering Cancer Centre (MSKCC) also has a set of nomograms 
publically available that is based on data from more than 10,000 patients. They 
have nomograms available to predict outcome after radical prostatectomy both 
pre- and post-treatment as well as after PSA elevation (see https://www.mskcc.org/
nomograms).
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Table 3.1 – Overview Diagnosis support systems
Study N Decision/Diagnose Inputs Outcomes TRIPOD




P of LN 
involvement
 79%
Diaz 1994[27] 217 Low or high risk of SV 
involvement
PSA, GS P of SV 
involvement 
69%





Chang 1999[31] 43 Localized vs Advanced 
PCa
PSA, GS, TRUC, 
DRE
P advanced PCa 
and P localized 
PCa
65%
Roach 2000[29] 895 Extracapsular extension PSA, GS Extracapsular 
extension risk
92%**
Lee 2010[32] 1077 Biopsy Clinical*, 
Imaging*, PSA
P PCa 86%
Kim 2011[33] 532 Advanced PCa TRUS, Clinical, 
PSA
P advanced PCa 79%
Shah 2012[34] 31 Location PCa MRI image Cancer 
probability map
83%
Mukai 2013[35] 30773 PSA test Clinical recommendation -***
Sadoughi 2014[36] 360 PCa PSA, Age P PCa 33%
van Leeuwen  
2017[37]
591 Significant PCa Clinical, PSA, 
PIRADS
P significant PCa 97%
Tosoian, 2017[26] 4459 Pathological Stage PSA, GS, 
Clinical stage
% likelihood of 
given stage
83%
Abbreviations. N: number of patients; P: probability; PCa: prostate cancer; PSA: prostate specific 
antigen; PIRADS: Prostate Imaging Reporting and Data System; TRUS: transrectal ultrasound 
scan; LN: Lymph Node; GS: Gleason Score; SV: seminal vesicles; TRIPOD: adherence to the TRIPOD 
statement; DRE: digital rectal examination
*Clinical, imaging and tumor parameters
**Abstract only
***No development or validation of DSS, so no TRIPOD evaluation possible
DSS Supporting Treatment Decisions
The studies that contained treatment DSS are listed in Table 3.2. The studies 
described by Walsh et al. (2018), Smith et al. (2016) and van Wijk et al. (2018) 
compare different RT treatment plans performed on the same patient and the DSS 
selects the best plan with most favorable outcome. This type of personalized DSS 
is very suitable for the comparison of RT modalities, as the treatment plans are a 
predictor for the delivered dose, with consequent treatment outcome. Walsh et al. 
(2018) used a combination of existing models for tumor control probability (TCP) 
and normal tissue complication probability (NTCP) to compare different treatment 




corrections for displacements during treatment, which aided in the prediction of 
delivered dose. As this was a modelling study, no validation was done. However, the 
concept could be used as a basis for RT plan selection between different modalities 
and could aid in the optimization of TCP and NTCP. Smith et al. (2016) utilized 
an advanced Bayesian network to optimize intensity modulated radiotherapy 
(IMRT) treatment plans based on outcome in terms of progression free survival 
and toxicity. The models were validated against independent clinical trials for the 
metastasis free survival and overall survival, and resulted in uncertainties of 2.5% 
and 2% respectively. This method could potentially be implemented into any IMRT 
planning system and has the potential to improve the quality of treatment plans, 
resulting in optimized outcomes.
A device called the implantable rectum spacer (IRS) has been developed to spare 
the rectum during IMRT by increasing the distance between the anterior rectum 
wall and the prostate[39, 40]. Van Wijk et al. (2018) made use of image deformation 
based on a virtual IRS[41, 42]: she published models to predict the sparing effect of 
an IRS before implanting the IRS. The model was tested in a proof of concept study 
with 16 patients, comparing the DSS outcome for the virtual IRS to the real IRS in 
the patients, and the median discrepancies in outcome was 1.8%. Once validation 
has taken place, this DSS could be applied into any RT planning system, and has the 
potential to personalize treatment choice. 
Two studies were found that supported the decisions involving follow-up 
treatment. (Reed et al. 2014) analyzed the cost-effectiveness (CE) of the use of a 
nucleic acid detection immunoassay (NADiA) ProsVueTM to support the decision for 
adjuvant radiotherapy (ART). This model showed that primarily for the intermediate 
risk patients, NADiA ProsVue had an incremental cost-effectiveness ratio (ICER) 
lower than $50,000,- in 83.6% of the simulations. This analysis in its current state 
is not applicable outside the USA. Salem et al. (2018) validated a computer-led 
decision support system aimed to give additional advice in follow-up treatment 
strategy. This system uses the clinical profile of the patient in combination with 
blood test results to propose a follow-up strategy. Validation was done on 200 
patients by comparing the computer generated strategy to the advice given by 
trained urologists. In all cases, the agreement between the experts and the system 
was better than moderate (kappa >0.6). The paper argued that such a system could 
significantly reduce costs in follow-up care in the United Kingdom, and believed the 
system can be used by any healthcare worker, regardless of urology background.
Hodges et al. (2012) developed a CE model to analyze the benefit of IMRT with 
respect to stereotactic body radiotherapy (SBRT). Though this study compared these 
two treatments, this study analyzed on cohort level and not case-specific, as is expected 
of personalized medicine. The CE analysis was done based solely based on probabilistic 
simulations, thus not taking into account variations in cost, transition rates, or utility 
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values. A sensitivity analysis was performed, revealing that in 66% of the iterations 
SBRT was cost-effective over IMRT. 
Vanneste et al. (2015) constructed a CE model to compare IMRT + IRS versus 
IMRT without IRS. He developed a decision-analytic Markov model to examine the 
effect of late rectal toxicity and compare the costs and quality-adjusted life years 
(QALYs). An ICER of €55,880 per QALY was gained. For a ceiling ratio of €80,000, 
IMRT+S had a 77% probability of being cost-effective.
Table 3.2 – Overview of Treatment support systems
Study N Decision Inputs Outcomes TRIPOD
Hodges 
2012[43]
Model SBRT, IMRT Utility, 
transitions
QALY, Costs, ICER 80%







QALY, Cost, ICER 81%
Smith 2016[46] Model RT plan Utility, 
transitions
TCP, NTCP, QALY 87%
van Wijk 
2018[47]

















Abbreviations. N: number of patients; IMRT: intensity modulated radiotherapy; V-mat: volumetric-
modulated arc therapy; PSPT: passively scattered protontherapy; IMPT: image modulated proton 
therapy; TCP: tumor control probability; NTCP: normal tissue complication probability; DVH: 
dose-volumehistogram; QALY: quality adjusted life year; IRS: implantable rectum spacer; ART: 
adjuvant radiotherapy; ICER: incremental cost-effectiveness ratio; TRIPOD:adherence to the TRIPOD 
statement.
*Clinical parameters.
DSS Focusing on Providing Patient Information
This section describes the studies that attempted to improve shared decision-
making. This type of DSS fosters patient involvement in therapeutic decisions, and 
emphasizes the provision of information needed to make such decisions (Table 3.3). 
Berry et al. (2013) described the testing of a personal patient-profile (P3P) intervention 
for PCa patients. P3P is a web-based program to help men prepare for shared decision 
making about the management of early stage prostate cancer. The study hypothesized 
that when P3P was used in combination with a consultation with different clinicians to 
prepare for decision making, patients were more satisfied with their treatment choice 
and experienced less regret, but testing did not result in significant improvement. 




and priorities, while when only using consultations, these preferences can be 
misinterpreted by clinicians. The paper suggested similar studies to be performed in 
the future on larger cohorts.
Nguyen et al. (2009) performed an extensive literature research for predictive 
outcome models for 15 different treatment options for PCa, including active 
surveillance, combinations of radical prostatectomy, RT, hormonal therapy and high 
intensity focused ultrasound. They attempted to create a comprehensive overview 
of the different outcome combinations, such as survival, metastasis, and various 
toxicities. This overview was designed to be comprehensive for patients so that they 
could use their own priorities and preferences to make an informed decision. Though 
they concluded that there is a great need for additional models, this paper provided a 
framework and is a step towards evidence-based personalized medicine. Additionally, 
this framework could be a useful tool for clinical decision making by medical personnel 
when adapted for these users.
Table 3.3 – Summary of patient support systems
Study N Decision Inputs Outcomes TRIPOD
Nguyen 2009[50] Literature Treatment Various Various 86%
Berry 2013[51] 494 Treatment P3P Decision satisfaction 82%
Abbreviations. N: number of patients; P3P: personal patient-profile for prostate cancer.
Excluded studies
Two studies, Stacey et al. (2016)[52] and Jayadevappa et al. (2015)[53] were excluded 
because they contained study proposals. Both these studies will attempt to test patient 
decision aids. Another study, McRae et al. (2016)[54] was excluded because it was not 
about prostate cancer. 
Eight studies in total were excluded as they did not describe a DSS, but instead 
provided tools that could be used in the development of a DSS. Though these studies 
can be used to further personalize PCa treatment, these tools cannot be applied in the 
clinic in their current form. A short overview of these papers is given in Table 3.4. 
Two studies, Daemen et al. (2009) and Beyan et al. (2014) attempted to use 
genetic information to improve cancer prediction outcomes. Beyan specifically worked 
to incorporate single nucleotide polymorphisms (SNPs) into the national health 
information system of Turkey. 
Zumsteg et al. (2013)[55], Gnanapragasam et al. (2016)[56] and Epstein et al. (2016)
[57] provided new definitions for risk group stratification, increasing upon the current 
low, intermediate and high risk groups. They found clear separation in progression free 
survival in their new risk groups, making these a potential tool for diagnostic DSS. Gries 
et al. (2017)[58] provided a method to interpolate the utility values for all combinations 
of 18 different health states, which could be a valuable tool for DSS to quantify QALYs. 
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Kuru et al. (2013)[59]showed that a PIRADS score on multiparametric magnetic resonance 
imaging (mpMRI) is prognostic for PCa.
Finally Kent et al. (2015)[60] performed a literature search and attempted to create a 
diagnostic tool which would predict the life expectancy in PCa patients. They concluded 
that no existing model was suitable for incorporation into a DSS.
Table 3.4 – Overview of excluded studies that described tools to improve DSS
Study N Tool Inputs Outcomes
Daemen 2009[61] 55 Genetic integration DNA, CNV Cancer outcome
Kuru 2013[59] 50 Diagnostics mpMRI PIRADS
Zumsteg 2013[55] 1024 Risk stratification Risk factors, Gleason 
score, biopsy
Risk group
Beyan 2014[62] Model Genetic integration SNPs Various





10139 Risk stratification PSA, stage, Gleason 
score
Risk group
Epstein 2016[57] 26325 Risk stratification PSA, stage, Gleason grade




Abbreviations. N: Number of patients; CNV: copy number variation; SNP: single nucleotide 
polymorphism; PSA: prostate specific antigen; mpMRI:multiparametric magnetic resonance 
imaging; PIRADS: Prostate Imaging Reporting and Data system.
Discussion
Primary findings
In response to the increasing number of PCa treatment options, the development 
of DSS has become a growing topic of interest to provide an aid in difficult medical 
decisions. Diagnosis and staging DSS have also been a growing topic of interest, as well 
as a number of tools to improve cancer detection, predictions of treatment outcome 
and outcome stratification. However, there is still a need for new DSS in treatment 
decision aids and validation of diagnostic DSS. Additionally, the field of patient 
informed decision-making is still in its infancy, but essential for the growth towards 
individualized medicine. 
For the diagnostic tools, there are a number of viable tools available for the diagnosis 
of local PCa that have been validated on large cohorts[33, 34, 36, 38, 63]. Additionally, a study 
has been performed for detection of PCa on the voxel level for MRI images[35]. This type 
of diagnostic DSS could additionally assist in treatment planning or treatment selection. 
One study explores diagnosis of PCa with LN metastasis[64], but this field remains 
largely uncharted, similar to the computer automated detection of biochemical failure 




For treatment DSS, the proportion between the number of treatment options 
and the decision support tools remains somewhat skewed. Nguyen et al. (2009)[50] 
suggested 15 different combinations of treatment options, and this did not include 
the use of rectal displacement devices[65, 66] or proton therapy. The treatment DSS 
that were found by the current study primarily involved RT, including treatment 
plan selection[46], proton compared to photon therapy[49], SBRT compared to 
IMRT[43], and the use of an implantable rectum spacer in EBRT[47]. Nguyen et al. 
(2009) attempted to create a general overview of prediction tools to create a 
clear overview for patients, and found most prediction tools to be focused on RT 
and radical prostatectomy. Less prediction tools are available for brachytherapy, 
which is a very viable treatment option for PCa. One study is Alitto et al. (2017)[67] 
describes an Umbrella Protocol for the standardized development of new DSS. This 
protocol could help in improving the application of new DSS in clinics.
Development of patient decision aids is challenging, as cultural and language 
barriers are much more present in this field of research. Nguyen et al. (2009) 
developed a comprehensive treatment overview for patients, but found that the 
predictive tools available were limited, leaving an incomplete overview. Berry et 
al. (2013)[51] hypothesized that patient satisfaction was increased after treatment 
when they were actively involved in the decision-making process, as well as 
comorbidities like anxiety, depression and fatigue was reduced, and proceeded to 
test this using the P3P intervention. He has found, however, that this method has 
not increased self-reported preparation for the intervention.
DSS Design
The last decade deep learning algorithms have gained popularity in the 
development of DSS for the classification of cancers, and the same is true 
within the field of PCa. Kim et al. (2011) and Lee et al. (2010) tackled a similar 
problem with both an ANN and an SVM, but the dataset of Kim et al. (2011) was 
approximately double in size. This increased patient cohort resulted in a higher 
AUC performance for both models, which confirms that deep learning algorithms 
rely heavily on large datasets. Also, no external validation was done, so currently 
these models are not generally applicable. An approach to make these models 
both more accurate and applicable for clinical use would be to use distributed 
learning, where the models are trained on centers all over the world, without the 
data having to leave the clinics. Shah et al. (2012) used an SVM for a more complex 
problem than just classification by doing voxel based analyses for the localization 
of PCa. The drawback of this model is that for training, a large amount of imaging 
data must be available, as well as 3D pathology, but the advantage is that the usage 
of sub-regions in the prostate allows for data augmentation.
Notable is that a number of nomograms initially developed more than two 
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decades ago are currently still in use, though updated using newer datasets. The 
continued application of simple, easy to interpret models is something to keep 
in mind in the development of new DSS. Though artificial intelligence has the 
potential to improve diagnosis of PCa, transparency plays a large role in clinical 
application. It also shows that predictive parameters for PCa are very consistent, 
with persistent usage of Gleason score, PSA, Clinical stage and age. Any new DSS 
being developed should be tested against the performance of these parameters 
to avoid tackling a simple problem using computationally heavy machine learning.
When looking at the available treatment DSS, we see that most of these are 
focused around RT. This is likely due to the patient specific treatment planning 
done in RT, which result in highly detailed dose maps before the start of treatment. 
This is ideal for DSS, as different treatment plans can be directly compared, and 
the different outcomes can be predicted using dose response curves. Other types 
of treatment, such as prostatectomy or watchful waiting rely much more heavily 
on clinical parameters and tumor parameters for predictions of their outcome or 
on subjective physician decisions. This makes it harder to compare outcomes of 
different treatments for the same patient. The development of new DSS comparing 
completely different treatment types with each other for the same patient would 
be very beneficial for filling this gap in the current literature.
Study Limitations
This study focused on DSS in PCa, and the scope did not include any other 
cancer types. It is possible that general DSS, applicable for more than one cancer 
type were therefore overlooked. The search was also focused on DSS, and thus 
did not include any predictive models that could aid in decision-making. The 
terms describing DSS may not have been used in interesting studies that could 
have been included in this overview. Patient decision aids was also not a search 
term, which may be the cause of the limited number of DSS for patients included 
in this overview. The search performed was only MEDLINE/PubMed linked, so 
studies not available on this medium were overlooked.
Inherent to literature overviews is that negative findings are not always 
reported, so failed attempts at creating DSS are often uncommon in overviews 
and literature reviews, and this may cause a biased view on the subject.
We assessed the reporting quality of each included study using the TRIPOD 
statement for quantification and comparison. Although the TRIPOD statement 
has been endorsed by a large number of medical journals and editorial 
organizations, it is not an universal gold standard. The checklist used for the 
assessment has limitations, such as the severe point punishment for the lack of 
specific keywords in title or abstract. This could reduce the score of a well-written 




into a single number, and the specific reporting issues were not named, such as 
improper analyses, lack of validation or reporting of study specifics. However, 
it is a useful tool to show the strength of a report, as when adherence to the 
TRIPOD statement was high, the paper was clearly written, and all proper steps 
were taken for the development of quality DSS tools.
Conclusion
A number of DSS for the primary diagnosis and staging of localized PCa are available. 
Treatment DSS were mostly focused on EBRT, for which several tools are available. 
However, a lack of DSS for other treatment modalities suggests that the development 
of new tools are necessary to compare objectively different treatment modalities. The 
development of patient decision aids is a new field of research, and few successes have 
been made for PCa patients. Though the idea of informed decision making by patients 
is in line with the goal of personalized medicine, the development of these tools needs 
to overcome a number of barriers to be successful, like comprehensiveness, language 
barriers, patient cooperation, physician cooperation, etc. More research needs to be 
performed to better empower clinical decisions in the diagnosis and treatment process.
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Background: Previous studies have shown that the implantable rectum spacer (IRS) 
is not beneficial for all patients. A virtual IRS (V-IRS) was constructed to help identify 
the patients for whom it is cost-effective to implant an IRS, and its viability as a tool 
to tailor the decision of an IRS implantation to be beneficial for the specified patient 
was assessed. Please watch animation:
(https://www.youtube.com/watch?v=tDlagSXMKqw) 
Methods: The V-IRS was tested on 16 patients: 8 with a rectal balloon implant (RBI) 
and 8 with a hydrogel spacer. A V-IRS was developed using 7 computed tomography 
(CT) scans of patients with a RBI. To examine the V-IRS, CT scans before and after 
the implantation of an IRS were used. IMRT plans were made based on CT scans 
before the IRS, after IRS and with the V-IRS, prescribing 70 Gray (Gy) to the planning 
target volume. Toxicity was accessed using externally validated normal tissue 
complication probability (NTCP) models, and the Cost-effectiveness was analyzed 
using a published Markov model.
Results: The rectum volume receiving 75 Gy (V75) were improved by both the 
IRS and the V-IRS with on average 4.2% and 4.3% respectively. The largest NTCP 
reduction resulting from the IRS and the V-IRS was 4.0% and 3.9% respectively. The 
RBI was cost-effective for 1 out of 8 patient, and the hydrogel was effective for 2 out 
of 8 patients, and close to effective for a third patient. The classification accuracy of 
the model, regarding cost-effectiveness, was 100%.
Conclusions: The V-IRS approach in combination with a toxicity prediction model 
and a cost-effectiveness analyses is a promising basis for a decision support tool for 
the implantation of either a hydrogel spacer or a rectum balloon implant.




For patients with prostate cancer, intensity modulated radiotherapy (IMRT) is 
one of the curative treatment options. Dose-escalation has revealed to improve 
tumor control and overall survival  in intermediate and high-risk prostate cancer[1-3]. 
However, this also leads to increased risk of gastro-intestinal (GI) toxicity which 
negatively impacts the quality of life (QoL)[4, 5]. The proximity between the prostate 
and the anterior rectal wall causes part of the high radiation-dose region (>90%) to 
overlap with the rectum, the primary organ at risk (Figure 4.1A). 
Figure 4.1 – Flowchart (A) The prostate (blue) and rectum (brown) before placement of an 
Internal Rectum Spacer and (B) after the placement of the Spacer. The contour is the iso-
dose at 90% of the target dose.
To spare the rectum, two commercially available implantable rectum spacers 
(IRS) have been developed: one type based on polyethylene glycol hydrogels 
(SpaceOAR™ System, Augmenix Inc.)[6] and the other is a biodegradable saline-filled 
rectal balloon implant (BioProtect Ltd, Israel)[7, 8]. These devices have been designed 
to increase the distance between the anterior rectal wall and the prostate, and 
pushing the rectal wall out of the high-dose region (Figure 4.1B). Several studies 
have shown that this technique results in lower dose within the rectum, resulting in 
lower toxicity levels[9, 10]. However, the IRS has not shown significant improvements 
for all patients, and is a costly and invasive procedure[11-13]. 
To identify the patients that are expected to benefit most from an IRS, we 
developed a novel method to explore a priori the benefit of the IRS. The method 
simulates an IRS through the use of deformation fields and predicts the geometric 
result of an IRS before the start of treatment: a so-called virtual implantable rectum 
spacer (V-IRS). This results in a comparison between computed tomography (CT) 




without IRS. To this end, a comparison of dose gain distributions, predicted normal 
tissue complication probabilities (NTCP) and a cost-effectiveness (CE) analysis 
between these two treatment plans can be performed (Figure 4.2). The developed 
method is based on the multifactorial decision support system developed in[14] and 
may be used to support the decision on the implantation of an IRS for individual 
patients[15, 16]. In this study, we evaluated the V-IRS’ performance in helping the 
decision support to implant an IRS or not for patients with prostate cancer. We 
did this by comparing the V-IRS to the real IRS on the three different levels: dose, 
NTCP, and CE. 
Figure 4.2 – An overview of the decision support system for which the virtual internal 
rectum spacer (IRS) would be a basis. The image shows the input to be a treatment plan for 
a patient without the IRS, a treatment plan for a patient with the virtual IRS and relevant 
clinical information. The input data are then split into two different pipelines: one for 
without IRS and one for with IRS, and a three level analyses is performed. The two pipelines 
come together in a third pipeline, where comparison is made which can help support the 
decision to place a spacer or not. NTCP = normal tissue complication probability.
Material and methods
Patient characteristics
This study included 23 patients with localized prostate cancer who have signed 
informed consent. We placed a rectal balloon implant (RBI) in 15 of these patients 
and 8 patients had a hydrogel IRS implanted. All patients were included after 
approval by the local ethics committee.
Image acquisition and organ delineation
Each patient was scanned in supine position using standard CT imaging. The patients 
with a hydrogel IRS all underwent two CT scans: one prior to the IRS implantation, and 
one several days after implantation. The slice thickness of these scans was 5mm, with 
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a pixel size of approx. 1 mm. Of the 15 patients who received a RBI, 8 were scanned 
prior to implantation as well as several days after, and 7 only after implantation. The 
slice thickness for these scans was 3 mm with a pixel size of 1 mm.  
The clinical target volume (CTV) in the patients who received a RBI was defined as 
the prostate only, and for the patients with a hydrogel it was defined as the prostate 
with seminal vesicles, according the risk of involvement of the seminal vesicles.
The planning target volume (PTV) was obtained by expanding the CTV by 6 mm 
in all directions to account for geometrical uncertainties (daily setup variability and 
internal organ motion). 
V-IRS
To predict the geometrical changes which occur after implantation of an IRS, a 
virtual CT image was created using image deformation.
The precise shape of an IRS after implementation varied from patient to patient, 
which is why a model of an IRS was used as the basis for the deformation. The 
model of the RBI was obtained using the CT scans of 7 of the patients with RBI. The 
method used is visualized in Supplementary Figure 1. 
The model IRS was inserted into the CT image by applying a deformation 
field, shown in Supplementary Figure 2, to a CT image of a patient prior to the 
implantation of an IRS. Several assumptions were made during the development of 
the deformation field. First, the deformation was assumed to only take place along 
the direction in which the IRS inflates. Though a small amount of deformation 
took place along the other axes, this effect was assumed minimal compared to 
the inflation direction. Second, the deformation was assumed to affect up to 2 cm 
of tissue. After this, the deformation fades due to compression. Last, due to the 
stiffness of the prostate and the rectum, the organs didn’t align perfectly around 
the IRS. This effect was simulated using a parabolic distribution. The field was 
applied to the CT image and contours using the REGGUI software for MATLAB®[17], 
placing the center of the field between the middle of the prostate and the rectum. 
A comparison between the shape of the real IRS and organs is compared to the 
shape of the V-IRS and organs in Supplementary Figure 3. 
Dose distribution
A certified technician applied a treatment plan on the CT scan prior to IRS 
implementation, with IRS, and on the virtual image. All treatment plans were designed 
for dose delivery with a volumetric modulated arc technique with 10 MV photon beams 
(Eclipse Version ICD-10, Varian Medical Systems Inc., Palo Alto, USA). The treatment 
plans included 28 fractions of 2.5 Gray (Gy), resulting in a total dose of 70 Gy[18]. The 
equivalent 2 Gy dose (EQD2) for this type of plan is 77 Gy[19], for an α/β ratio of 3 Gy 




The Dose Volume Histogram (DVH) of the dose within the rectum was used for 
dose comparison between the plan without IRS to the plan with IRS. To test the 
V-IRS, three treatment plans were made for each patient; one on the scan before 
IRS insertion, one on the scan with the IRS, and one on the scan with the V-IRS. To 
check that all plans were comparable, the equivalent uniform dose (EUD) in the 
CTV was calculated for each plan. 
Toxicity model
To indicate whether the IRS results in significant improvement in GI toxicity for a 
given patient, the DVH alone is not sufficient. Clinical differences between patients 
result in variations in predicted toxicity even when the dose distribution is similar. 
In order to predict the GI toxicity resulting from the treatment plan in combination 
with certain clinical parameters, a validated NTCP model was used (Table 4.1). The 
chosen model is a multivariate logistic regression model that uses the mean rectal 
dose, the percentage of the volume of the rectum receiving more than 75 Gy (V75) 
and several clinical parameters as predictors for late rectal bleeding[21, 22].  The 
concordance indices for this model were 0.62 and is the same NTCP model used 
in[11]. The IRS is expected to improve the NTCP predicted by this model, because 
the IRS increases the distance between the rectum and the prostate, thus reducing 
the V75 in the rectum. 
Table 4.1 – Overview of the NTCP models used.
G2-G3 acute rectal bleeding (N = 1,132) Coefficient SE
Constant -2.489 0.5243
Use of anticoagulants (0/1) -0.4702 0.2034
Diabetes (0/1) 0.2445 0.2543
Hemorrhoids (0/1) 0.4066 0.1796
Irradiation of pelvic nodes (0/1) 0.4455 0.2821
Hormonal therapy (0/1) -0.4252 0.2079
Mean rectal dose (Gy) 0.0339 0.0096
G2-G3 late rectal bleeding (N = 718) Coefficient SE
Constant -3.5082 0.7000
G2-G3 acute rectal bleeding (%) 0.0258 0.0173
Prior abdominal surgery 0.7465 0.4175
V75 in rectum (%) 0.0571 0.0215
G2-G3: grade 2-grade 3 standard RTOG/EORTC scores, RTOG: Radiation therapy oncology group, 
EORTC: European organization for research and treatment of cancer, Gy: Gray, V75: volume 
percentage receiving more than 75 Gy, SE: standard error




The system is expanded with a published Markov model that analyses the CE 
of the implantation of the IRS by comparing the gain from the IRS in quality of life 
with the increased costs associated with the IRS[13].  The Markov model calculates 
the incremental net monetary benefit (iNMB) between the two treatment options: 
IMRT with IRS (IMRT+IRS) and IMRT without IRS (IMRT-IRS). The NMB is obtained 
by multiplying the number of quality adjusted life years (QALY) with a willingness 
to pay (WTP) threshold and subtracting the treatment costs. The iNMB is obtained 
by subtracting the NMB of IMRT-IRS from the NMB of IMRT+IRS. If the iNMB is 
positive, the implantation of an IRS is considered cost-effective. In this study a 
WTP threshold of €80,000 is used, which is the informal ceiling ratio for a high 
burden of disease in the Netherlands[23]. The WTP varies strongly per country 
(£20,000-£30,000 in the UK and $50,000-$100,000 in the USA), and is a variable 
input parameter in the model. Whether or not the IRS was effective or not in a 
given patient strongly depends on the decrease in NTCP resulting from the IRS. A 
reduced NTCP results in more QALY’s, but also lower follow-up costs resulting from 
toxicity. 
Statistics
We used two-tailed Wilcoxon signed rank tests to determine whether the 
differences between the plans without IRS and the plans with IRS were significant. 
P-values of less than 0.05 were considered significant.
Results
Rectum Balloon Implant results
The implantation of a RBI resulted in a minor reduction of the mean rectal dose: 
1.5 Gy[-14.9-12.4] average (p = 0.383) for the RBI and 5 Gy[2.3-8.4] for the V-IRS (p 
= 0.008) (Table 4.2). Large differences were observed in rectal volumes in IMRT+IRS 
and IMRT+V-IRS: in one patient the rectal volume before RBI implantation was 
215.5 cm3, and 33.1 cm3 after RBI implantation.  The EUD in the CTV for all these 
plans was between 79 and 80.5 Gy. 
The mean reduction in V75 was 3.2% [0.4-8.6] (p = 0.008) resulting from the RBI 
and 3.2% [1.0-7.8] from the V-IRS. The largest difference between the V75 of the 




Figure 4.3 – The decrease in normal tissue complication probability (iNTCP) as a result of the 
implantable rectum spacer (IRS). The results for the rectum balloon implants (RBI) are shown 
in A, and those for the Hydrogel spacer in B. These decreases are compared to those caused 
by the virtual IRS (V-IRS).
Figure 4.4 – The incremental net monetary benefits for each of the patients with a 
Rectum balloon implant in A, and with a Hydrogel Spacer in B. If the iNMB is negative, the 
implantation of an IRS is not cost-effective.
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The NTCP reduction resulting from the RBI was on average 1.0% [-0.6-3.9], and 
1.1% [0.3-3.5] resulting from the V-IRS. The decrease in NTCP resulting from the 
RBI and from the V-IRS is shown in Figure 4.3A.  Note that the NTCP for patient 7 
was lower than before the IRS was implanted. This resulted in an average iNMB 
of -€1158 and -€1032 for the RBI and the V-IRS respectively, showing that the 
implantation of an IRS is not cost-effective when performed on all 8 patients. The 
iNMB’s for each of the patients that received a RBI are shown in Figure 4.4A. For 
all these patients, the V-IRS predicts correctly whether or not the implantation 
of an IRS is cost-effective. For one patient among these eight the implantation is 
expected to be cost-effective. 
Hydrogel results
The mean rectal dose was reduced by 5.6 Gy [-7.8-7.0] after the implantation of 
a hydrogel IRS (p = 0.055), and by 6.3 Gy [1.8-4.0] with the V-IRS (p = 0.008) (Table 
4.2). For this set of patients, large differences in rectal volume were found as well, 
one with 263 cm3 before the implantation of the hydrogel IRS and 156 cm3 after. 
The implantation of the hydrogel IRS resulted in a mean V75 reduction of 5.2% 
[-1.7-9.8] (p = 0.0156), and the V-IRS predicted a reduction of 5.4% [0.9-9.8] (p = 
0.008). The largest difference between the V75 of the plans on the CT’s after the 
implantation of a hydrogel and those with a V-IRS was 3.7%. The EUD in the CTV for 
all these plans was between 79.5 and 81 Gy.
The NTCP was 1.8% [-1-3.8] lower, on average, after the implantation of a 
hydrogel IRS than before, and 1.9% [0.4-3.9] lower with V-IRS. The decrease in NTCP 
resulting from the Hydrogel and from the V-IRS is shown in Figure 4.3B. Note that 
the NTCP for patient 8 was lower than before the IRS was implanted. The resulting 
iNMB was -€669 and -€567 for the hydrogel IRS and the V-IRS, respectively, showing 
that the implantation of the hydrogel is also not cost-effective when applied to all 
patients. Figure 4.4B shows the iNMB’s for each of the patients with a hydrogel 
spacer. For this set of patients the V-IRS classifies the cost-effectiveness correctly 
when compared to the real IRS. Patient 4 and 5 appear to be cost-effective, though 




Table 4.2 – Overview of results for the Rectum Balloon implants (RBI) and the virtual 
implantable rectum spacer (V-IRS).
Before RBI After RBI V-IRS






























Before Hydrogel After Hydrogel V-IRS






























RBI: Rectal Balloon implant, V-IRS: Virtual Implantable Rectum Spacer, EQD2: Equivalent 2 Gy Dose, 
V75: Volume percentage receiving at least 75 Gy, NTCP: Normal tissue complication probability, 
iNMB: incremental Net Monetary Benefit.
* Two-tailed Wilcoxon signed rank test: significant difference in dose at 5% from the plan before 
hydrogel




In this study, we have developed a V-IRS which can be used to support the 
decision for the implantation of an IRS for a specified patient or not. 
Our method has two main strengths. The first is that a CT of a patient with 
an IRS can be generated and made available for treatment planning purposes 
without the real implantation of the IRS itself. This means that the benefit of the 
IRS for the specified patient can be estimated without having to put the patient 
through the discomfort of the operation, and without the additional costs of the 
placement of the IRS. The second is that instead of only looking at the improved 
dose reduction by implanting the IRS, the NTCP reduction and the CE are also taken 
into consideration. This allows for a decision based not only on dose reduction, 
but also on the health gain and the costs associated with the health gain.  
The V-IRS gives a good approximation of NTCP and of the cost-effectiveness 
when compared to an IRS for both commercial systems: the RBI and the hydrogel 
IRS. The differences between the health gain predicted by the V-IRS and achieved 
by the RBI were small for 7 of the 8 patients. For the hydrogel these differences 
were larger, especially when the NTCP was smaller than 2.5%. However, at higher 
NTCP values, the V-IRS made more accurate predictions. On CE level, the V-IRS 
performed well: each time the real IRS was expected not to be cost-effective, 
the V-IRS had the same conclusion, and vice versa. The differences in iNMB 
between the V-IRS and the RBI were small, showing that the V-IRS is an excellent 
approximation of the RBI. The differences in iNMB between the hydrogel IRS and 
the V-IRS were larger, but not enough to cause a classification error. 
The V-IRS was based on the RBI, which, as a closed system, inflates to a 
predetermined shape, which is not the case for the hydrogel IRS. This could cause 
errors in the predicted iNMB for the hydrogel spacer, but due to the variability 
of the shape of the hydrogel, a V-IRS based on a hydrogel is not likely to be more 
predictive than the one used in this study. However, the volume of the hydrogel 
was often lower than the V-IRS, possibly overestimating its effectiveness. This 
could be solved by decreasing the V-IRS volume when applied to hydrogels. 
The results presented in this study showed that the patients who were to 
be implanted with a hydrogel spacer had higher NTCP’s than the patients to be 
implanted with a RBI. This was because all patients in the hydrogel spacer group 
had the seminal vesicles included in the CTV, while the patients with in the RBI 
group didn’t. This is kept consistent with the V-IRS, and did not visibly influence 
its performance.
One of the main limitations of the study was the small amount of patients 
included. Though they were sufficient for a first proof of concept, a more 





Further, the deformation field used to create the images with the V-IRS was 
arbitrarily chosen, and did not succeed in accurately predicting the deformation 
caused by the IRS. These differences in precise shape did not impact the 
performance on NTCP level because at very low dose levels the NTCP is impacted 
more strongly by clinical factors than dose, so as long as the spacing caused by the 
IRS was sufficient, the predictions were precise enough for classification. However, 
better deformation predictions would lead to more accurate classifications. Image 
registration could be used to develop a deformation field once a larger amount of 
patients becomes available which could be updated every time a new patient is 
treated. 
Next, the mean rectal dose has been shown to be a predictor for acute rectal 
bleeding, which, on its turn, is a predictor for late rectal bleeding (consequential 
late effect). Although the mean rectal dose is dependent on the overlap between 
the rectal wall and the high-dose region, it is mainly affected by the rectum volume, 
which varies strongly[24, 25]. This change in rectal volume cannot be predicted by the 
model, and might influence the decision on whether or not to place an IRS. For 2 
patients, patient 7 with a RBI, and patient 8 with a hydrogel, this even led to an 
increase in predicted NTCP. Future works should include models that use the dose 
surface histogram (DSH), rather than the DVH in the rectum, as this is much less 
affected by the rectal volume[26]. 
During this study the only NTCP taken into account was for late rectal bleeding. 
Late fecal incontinence, erectile dysfunction, and urinary symptoms are not 
calculated, but do have an effect on the patients QoL. An appropriate expansion 
to the system would be to include NTCP models for these types of toxicities. The 
possible complications after placement of the IRS (pain, rectal perforation) were 
not taken into account, as the risk of these factors is low (<5%)[27], and are not 
yet fully described. Furthermore, the nomograms on which the NTCP model is 
based are from 2002-2004, where now outdated dose delivery techniques were 
conformal. The performance of a decision support system based on a V-IRS is 
partially dependent on the accuracy of the NTCP models. This must be taken into 
account during further development of the system, by using newer models when 
these become available.  
The current model is isodosimetric which shows the toxicity for both the CT 
images before the IRS and after the IRS assuming both receive the same dose within 
the target volume. Future studies should include an analyses of an isotoxic version 
of the model, which would analyze how much dose escalation is possible while still 
maintaining low NTCP values for each of the different situations. Including genetic 
markers into the NTCP model would also improve the decision support on whether 
or not to place an IRS in a prostate cancer patient[28]. 




The implantation of an IRS is not cost-effective for all patients, so individual 
patient assessment is needed. The V-IRS approach in combination with a NTCP 
model and a CE analysis can serve as the basis for a decision support system for the 
implantation of either a hydrogel IRS or a rectum balloon implant.
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Supplementary Figure S4.1 - Seven delineations of Implantable rectum spacers (IRS) were 
used to create a probability map for the shape of the rectal balloon implant. At value 1, all 
IRS’s overlap, at value 0, no delineations of IRS’s were found at all. The threshold for the 
model IRS was set at 0.6 and is indicated by the black contour.
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Supplementary Figure S4.2 – The deformation field assumed  only deformation along the 
axis through both the prostate and the rectum. After 2 cm the deformation field is 0. The 
spacer is assumed to have deformation effect in a hyperbolic distribution along the other 
axes. The top left image shows the prostate and rectum before deformation. The top right 




Supplementary Figure S4.3– An overlap of the structures one of the images with the real 
implantable rectum spacer (IRS) and with the virtual IRS. On the left side the structures of 
the real image are that of a rectum balloon implant, on the right side the real structures are 
of a hydrogel spacer.
Supplementary Table S4.1: An overview of the constraints set during treatment planning 
(given dose)
Structure Constraints
Planning target volume V70 > 95% V77 < 3%
Rectum volume V70 = 0%
Anal canal volume V74 = 0% Mean dose < 40 gy
Anorectum volume V54 < 50% V65 <20%
Bladder volume V70 = 0%
Gy: gray, vxx: percentage of volume receiving more than xx gy
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Supplementary Table S4.2: Overview of the distances between the rectum and the prostate 
at mid-prostate level and the PTV overlap with the rectum after placement of an RBI or 
hydrogel spacer and after application of the V-IRS.
Property RBI V-IRS P-Value
Median Distance (cm)













PTV Overlap With Rectum (cm3)






Property Hydrogel V-IRS P-Value





















RBI: Rectum Balloon Implant, V-IRS: Virtual Implantable Rectum Spacer,  PTV: Planning Target 
Volume
*the median of the median distance between the rectum and the prostate over all patients
** the median of the minimum distance between the rectum and the prostate over all patients
Supplementary Table S4.3: An overview of the values used in the Markov CE model for the 
cost-effectiveness of the IRS
Utilities Value SE
Prostate cancer without treatment-related toxicity 0.9 0.05
Prostate cancer with severe late GI toxicity (grade>=2) 0.727 0.04
Costs Value CI
Yearly costs prostate cancer without toxicity €323 €215-€430
Yearly costs late grade 2 GI toxicity €481 €160-€482
Yearly costs late grade 3 GI toxicity €4,051 €1,876-€5,832
Proportion grade 2 (of all grade>=2) 0.75 0.652-0.848
Cost IRS treatment €1,700 €1,300-€2,100




Supplementary Table S4.4: An overview of the iNMB of the RBI and the hydrogel spacer after 
rescaling of the treatment plan to a target dose of 80 Gy in 32 fractions.
RBI V-IRS

























RBI: Rectal Balloon implant, V-IRS: Virtual Implantable Rectum Spacer, iNMB: incremental Net 
Monetary Benefit.
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Introduction: Previous studies revealed that dose escalated radiotherapy for 
prostate cancer patients leads to higher tumour control probabilities (TCP) but also 
to higher rectal toxicities. An isotoxic model was developed to maximize the given 
dose while controlling the toxicity level. This was applied to analyse the effect of 
an implantable rectum spacer (IRS) and extended with a genetic test of normal 
tissue radio-sensitivity. A virtual IRS (V-IRS) was tested using this method. We 
hypothesized that the patients with increased risk of toxicity would benefit more 
from an IRS.
Materials and Methods: 16 localised prostate cancer patients implanted with an 
IRS were included in the study. Treatment planning was performed on Computed 
Tomography (CT) images before and after the placement of the IRS and with a 
V-IRS. The normal tissue complication probability (NTCP) was calculated using 
a QUANTEC reviewed model for Grade>=2 late rectal bleeding and the number 
of fractions of the plans were adjusted until the NTCP value was under 5%. 
The resulting treatment plans were used to calculate the TCP before and after 
placement of an IRS. This was extended by adding the effect of two published 
genetic single nucleotide polymorphisms (SNPs) for late rectal bleeding.
Results: The median TCP resulting from the optimized plans in patients before 
the IRS was 75.1% [32.6-90.5%]. With IRS, the median TCP is significantly higher: 
98.9% [80.8-99.9%] (P<0.01). The difference in TCP between the V-IRS and the real 
IRS was 1.8% [0.0-18.0%].  Placing an IRS in the patients with SNPs improved the 
TCP from 49.0% [16.1-80.8%] and 48.9% [16.0-72.8%] to 96.3% [67.0-99.5%] and 
90.1% [49.0-99.5%] (P<0.01) respectively for either SNP. 
Conclusion: This study was a proof-of-concept for an isotoxic model with genetic 
biomarkers with a V-IRS as a multifactorial decision support system for the decision 
of a placement of an IRS.




Intensity modulated radiotherapy (IMRT) is one of the primary curative 
treatments for patients with prostate cancer. Studies have revealed that dose 
escalation leads to better biochemical progression free survival[1, 2]. However, the 
proximity between the anterior rectal wall and the prostate allows for limited dose 
escalation without resulting in severe gastro-intestinal (GI) toxicity[3-5]. 
The implantable rectum spacer (IRS) is a device developed to spare the rectum 
by increasing the distance between the anterior rectal wall and the prostate, thus 
reducing the overlap between the rectal wall and the high dose region[6-10]. Recent 
studies have shown that this device significantly reduces the dose in the rectum, 
thus reducing the risk of complications, for approximately 20% of the patients[5]. 
For these patients, the IRS would allow for same radiation dose and cure rate with 
decreased rectal toxicity rates. There is increasing evidence supporting the role 
of several genetic variants in the development of radiation-induced toxicity to 
distinguish the patients having increased risk factors for severe rectal and urinary 
toxicity[11, 12]. We hypothesize that the patients with increased risk of radiation-
induced rectal toxicity would benefit more from an IRS. Furthermore, the use of 
IRS in prostate cancer patients allows for more dose escalation, with consequently 
improving their prospective therapeutic ratio.
In this proof-of-concept study we developed a method to determine the 
amount of possible dose escalation with the resulting tumour control probability 
(TCP) without exceeding the set of boundaries for the complication risks: the so-
called “isotoxic dose escalation” approach[13-15]. This method is applied to compare 
the possible dose escalation on patients with plans available before and after the 
placement of an IRS. This model is combined with a so-called ‘virtual IRS’ (V-IRS)
[16]. This method uses image deformation to obtain CT images of patients with a 
predicted IRS position without having to place one (watch the animation: https://
www.youtube.com/watch?v=tDlagSXMKqw). Furthermore, this method helps 
identify the patients for whom significantly higher TCP is possible by placing an IRS. 
To further individualize the predictions done for patients, the patients radio-
sensitivity needs to be taken into account. Studies have shown that the difference in 
radio-sensitivity between patients are likely due to common genetic variants, such 
as single nucleotide polymorphisms (SNPs). We applied the developed method to 




For this study, 16 patients with localized prostate cancer who had signed an 




different commercial types of IRS’s are used: 8 had received a rectum balloon 
implant (RBI) (BioProtect Ltd, Israel)[6] and 8 had a hydrogel spacer (HGS) 
(SpaceOARTM System, Augmenix Inc., Waltham, MA) placed. The hydrogel and 
RBI patients included in this study were consecutively selected in 2011 and 2015, 
respectively. Both studies were approved by their local ethics committees[7]. The 
RBI patients were included in a clinical trial between 2015 and 2016 (registration 
number: 14-38-03/09-internal-6335)[10]. As this is a consecutive case study, it is 
assumed these patients are representative of average prostate cancer patients.
Imaging and treatment planning
Standard Computed tomography (CT) imaging was performed twice on all 
patients while they were in supine position: once before and once after placement 
of an IRS. These images had a slice thickness of 5 mm for the patients with a HGS, 
and 3 mm for those with a RBI. The pixel size was 1 mm for all images
The clinical target volume (CTV) was defined as the prostate for 8 patients, and 
the prostate including seminal vesicles for the rest and the planning target volume 
(PTV) was obtained by extending the CTV with 6 mm in all directions to account 
for uncertainties in planning an treatment delivery. The rectum volumes were 
delineated as a solid organ, including the rectum as well as the anal canal. The 
same experienced radiation oncologist (BV) did all delineations.
Plans were performed by a certified technician on all CT images, yielding two 
treatment plans for each patient (one without IRS, one with IRS). The treatment 
plans were designed for dose delivery with a knowledge-based volumetric 
modulated arc technique with 10 MV photon beams (Eclipse Version ICD-10, Varian 
Medical Systems Inc., Palo Alto, USA). Dose delivery was planned to be done in 28 
fractions of 2.5 Gray (Gy)[17]. Dose constraints held during treatment planning are 
shown in Supplementary Table S5.2.
Isotoxic model
Dose calculations
Treatment planning was performed in fractions of 2.5 Gy instead of 2 Gy, which 
is the case for the treatment plans on which the NTCP model was based. For this 
reason, the equivalent 2 Gy dose (EQD2) in the rectum resulting from the treatment 
plan is calculated and used as input for the model. This is done using the Withers 
equation[18]:
 (5.1)
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Here D is the total dose, d is the fraction dose and α⁄β represent the fractionation 
sensitivity of the organ. For late rectal toxicity, the α⁄β ratio has been estimated to 
be 3 Gy[19].
NTCP model
The NTCP model used is the Lyman-Kutcher-Burman (LKB) model[20] that was 
reviewed by the QUANTEC group (quantitative analysis of normal tissue effects 
in the clinic). The LKB model is a dose response curve that uses the generalized 
equivalent uniform dose (gEUD) as a dose parameter, which is obtained using the 
DVH, and a parameter n, which determines which part of the DVH is statistically 
most important. The curve is dependent on the dose required for an NTCP of 
50% (D50) and the steepness of the curve (m). The QUANTEC-recommended 
parameters are TD50 = 76.9, n = 0.09 and m = 0.13 for grade>=2 late rectal toxicity. 
The NTCP model used is a Lyman-Kutcher-Burman (LKB) model that was 
reviewed by the QUANTEC group (quantitative analysis of normal tissue effects in 





where gEUD stands for generalized equivalent uniform dose, i is the number of the 
DVH bin, vi is the volume of the bin and di is the dose. The QUANTEC-recommended 
parameters are TD50 = 76.9, n = 0.09 and m = 0.13 for grade>=2 late rectal toxicity. 
Single Nucleotide Polymorphisms 
This NTCP model was expanded as a proof-of-concept with genetic markers of 
rectal toxicity, for which we used published results of a meta-analysis of GWASs 
(Genome Wide Association Study) for genetic markers of late toxicity, in prostate 
cancer patients treated with radiotherapy[12]. The two SNPs most associated 
with rectal bleeding, that approach meta-analysis significance, were selected for 
the initial proof-of-concept: rs141044160 (SNP 1) with an odds ratio of 2.68 (P 
= 2.26*10−6) and rs7432328 (SNP 2), with an odds ratio of 3.36 (P = 3.32*10−6). 
The SNPs were incorporated into the dose response curve using a published 
mathematical method[21]. In this method, clinical parameters are incorporated into 
a dose response by separating the curve for the overall population into two curves: 




This is done using the odds ratio and the proportion between the population with 
and without the risk factor. The proportion of the population with the SNP risk 
allele can be calculated using the minor allele frequency (MAF). For this study, we 
demonstrated the effects of the SNPs on the NTCP model by applying it on the 
patient cohort, assuming they were carriers for either SNP risk allele.
In order to incorporate a SNP into the LKB model, the dose response curve 
was split into two different dose response curves: one for the population with the 
SNP and one without. The dosimetric factor used by the LKB is the generalized 
equivalent univorm dose (gEUD), and the parameters which determine the shape 
of the dose response curve are the TD50, which is the gEUD needed for a 50% 
response, and m, which is inversely proportional to the gradient at TD50. In order 
to split the LKB curve into two, we need to determine the new TD50 and the new 
m for both curves. For this, we need to know the relationship of the response of 
the curve without SNP and with SNP, p0 and p1 respectively, to the original curve p.
The prevalence factor of the SNP can be calculated using the minor allele 
frequency as shown in equation (5.5):
(5.5)
Where s is the prevalence. Because the total probability of toxicity needs to 
remain the same over the whole populations, the relationship of the two new 
curves to the original can be described as shown in equation (5.6):
 (5.6)
The odds ratio (OR) can be described as function of p0 and p1 as shown in 
equation (5.7):
(5.7)
Which allows us to describe equation (5.6) as shown in equation (5.8):
(5.8)
Since the OR of each SNP is reported, as well as the MAF, we can now use the 
method reported in Appelt&Vogelius (2012) to find the correct values for TD50 
and m corresponding to the low and high risk curves.
TCP model
The used TCP model[22] was built to predict the clinical response to external beam 
radiotherapy in patients with low, intermediate and high risk prostate cancer, and is 
available on http://predictcancer.org/. This model utilizes realistic radio biologically 
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input parameters and works for a wide range of treatment strategies[23]. 
The model is described using equation (5.9):
(5.9)
where k represents groups of patients with separate radiosensitivity, N0 is 
the initial clonogen sum and S(D) is the surviving fraction of a population of cells 
irradiated by a total uniform dose D.
The inputs to the TCP model are the number of fractions, the fraction dose, the 
treatment modality and the risk group of the patient. The prostate-specific antigen 
(PSA), TNM and Gleason score are the input factors to the classification of the risk 
group: low, medium or high[24].  To evaluate the result of dose escalation, only the 
fraction dose is varied in this study to test the amount of dose escalation possible 
without exceeding NTCP limits. 
Isotoxic method
The proposed model uses an optimized treatment plan for a patient, calculates 
the DVH in the organs at risk and scales this DVH by changing the fraction dose 
used during treatment planning. The fraction dose is varied in order to obtain a 
maximum TCP value without exceeding the cut-off value set for the NTCP value, 
which, for this paper, is arbitrarily chosen to be 5% (Figure 5.1). The fraction dose 
for a plan with 28 fractions advised by the model can vary between 1.5 and 3.5 
Gy. These limits are chosen because a plan with 28 fractions with less than 1.5 
Gy, resulting TCP was modelled to always be lower than 25%, and more than 3.5 
fractions was to always result in a TCP higher than 95%. In reality 1.5 Gy in 28 
fractions would not be for curative treatment, but in this study these plans are 
calculated for theoretical comparison. 
The method only takes into account rectal toxicity, but as the bladder is also 
an organ at risk, we added a constraint to the bladder dose[25], as is shown in 
Supplementary Figure S5.1.
To use the method to select patients for whom the placement of an IRS is 
beneficial, a minimum increase in TCP should be chosen. For this study, two cut-
off values were used for the increase in TCP as a result of the placement of an IRS: 




Figure 5.1. A flowchart of the isotoxic model. The model loads a treatment plan made by an 
expert and increases or decreases the fraction dose. Each time fraction dose is increased or 
decreased, the normal tissue complication probability (NTCP) is recalculated until a set cut-
off value is reached. The tumour control probability (TCP) is hen calculated
Virtual Spacer
In order to use the isotoxic model to predict the improvement of the IRS in a 
specified patient, CT images of a patient are needed before the placement of the 
IRS. To this end, a previously developed V-IRS was used[16]. This V-IRS uses a model 
IRS derived from 7 delineations of a RBI and uses image deformation to insert the 
model into a CT image of a patient without an IRS, thus creating a virtual image of 
the patient with an IRS. This virtual image is then subjected to treatment planning, 
and the isotoxic model is used to calculate the highest possible TCP without 
exceeding the NTCP limit. In this study we test the V-IRS by comparing the results 
of the isotoxic model to those of the actual IRS.
Statistics
We used two-tailed Wilcoxon signed rank tests to determine whether the 
increase in optimal TCP for the plans without IRS and with IRS was significant. The 
test was also applied to test if the difference between the NTCP values before 




Giving more dose per fraction increases both the TCP and the NTCP predictions 
for a given patient (Figure 5.2). The original plans (before applying the isotoxic 
method) consisted of 28 fractions of 2.5 Gy, which, for this set of patients 
corresponds to a median TCP of 80.8% with a range of [51.8-92.0%]. The median 
fraction dose allowed by the model without exceeding the NTCP constraint before 
the placement of an IRS was 2.5 Gy [2.4-2.7 Gy] (Table 5.1), and corresponds 
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to 75.1% [32.6-90.5%] TCP. The TCP for the patients when given a conformal 
treatment plan of 2 Gy in 35 fractions corresponds to a TCP of 60.8% [26.3-80.9%]. 
Figure 2 shows that to obtain a median TCP of at least 90%, the dose needs to be 
escalated further to 2.7 Gy per fraction for a treatment plan with 28 fractions, 
which was possible for 2 of the 16 patients while holding to the pre-set accepted 
toxicity rates. For 5 of the patients 2.6 Gy per fraction could be given, and for the 



































IRS: Implantable Rectum Spacer, V-IRS: virtual IRS, EUD: equivalent uniform dose in rectum with 
n=0.09, TCP: Tumor Control Probability, NTCP: Normal Tissue Complication Probability, RB: rectal 
bleeding
Figure 5.2. The median tumour control probability (TCP) and the median normal tissue 
complication probability (NTCP) is plotted against the fraction dose for the patients without 
implantable rectum spacer (IRS) and with IRS.
IRS gain 
The placement of an IRS resulted in an increase in advised fraction dose of 0.4 
Gy [-0.1-0.9 Gy] on average for all patients. Note that the minimum increase is 
negative, which means this is a decrease. This results in an absolute increase in TCP 
of 21.1% [-8.9-57.9%] which is statistically significant (P <0.01) (Figure 5.3). Patient 
specific outcomes have been plotted in a similar manner in Supplementary Figure 
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S5.2.  In only one patient the TCP after the placement of an IRS is lower than before 
placement. For this patient, the rectum volume had decreased after the placement 
of an IRS (from 268.9 cm3 to 156.1 cm3). 
If an increase in TCP of 25% is taken as a threshold for the decision to place an 
IRS, then 7 of the 16 patients would be selected by the model for the placement 
of an IRS. Two patients even had an increased TCP of 50% resulting from the IRS.
The difference in the NTCP resulting from the optimized plan for the patients 
without IRS and with IRS is 0.15% and is not significant (P = 0.47). We performed 
an analyses for different NTCP limits in Supplementary Figure S5.3.
Figure 5.3. The median tumour control probability (TCP) and range, as well as the median 
normal tissue complication probability (NTCP) and range, for the patients without 
implantable rectum spacer (IRS), with IRS and with the virtual IRS (V-IRS) is shown.
Performance V-IRS
The difference in fractionation result between the V-IRS and the real IRS was a 
median of 0.3 Gy [0-0.8 Gy], which translates to a median TCP difference of 1.8% 
[0.0-18.0%]. The difference between the optimized TCP for the real IRS and the V-IRS 
was not significant (P = 0.2). There were two patients for whom the difference in TCP 
between the V-IRS plan and the IRS plan was 18%, and in both patients the rectum 
volume had changed significantly (57.9% and 58.1% volume decrease in the image 
after the IRS).
When considering a minimum increase in TCP of 25% for the placement of an 
IRS, then 6 of the 16 patients would be selected by the model using the V-IRS, in 




was underestimated compared to the real IRS in one patient, with an increase of 
13.7% versus 27.7%. The two patients who had an increased TCP of 50% resulting 
from the real IRS, had the same increase predicted by the V-IRS.
SNP results
Figure 5.4 shows the TCP and the NTCP as function of the fraction dose, and it 
can be observed that though the TCP is the same as for the patients without SNPs, 
the NTCP curve is much steeper for both SNPs. 
The median NTCP for the original plan (28 fractions of 2.5 Gy) was 11.2% [2.2-
19.6%] and 13.1% [2.7-22.5%] for SNP 1 and SNP 2 respectively, which is reduced 
significantly (P<0.01) when using the isotoxic method. The results show (Table 
5.2) that if the patients are carriers of the chosen SNPs, the TCP while restraining 
the NTCP would be 49.0% for SNP 1, and 48.9% for SNP 2. The placement of an 
IRS resulted in significantly better TCP values (P<0.01), with a median of 96.3% 
[67.0-99.5%] and 90.1% [49.0-99.5%] for SNP 1 and SNP 2 respectively, which was 
significantly higher than without IRS (P<0.01) for both SNPs. Four other SNPs were 
found to be near significant for late rectal bleeding; results for these SNPs are shown 
in Supplementary Figure S5.4. We performed a sensitivity analyses on a range of 
odds ratios to show the possible effects of different SNPs for late rectal bleeding in 
Supplementary Figure S5.5.
  
Figure 5.4. The median tumour control probability (TCP) and the median normal tissue 
complication probability (NTCP) is plotted against the fraction dose for the patients with SNPs 
(a: rs141044160 and b: rs7432328) without implantable rectum spacer (IRS) and with IRS.
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Table 5.2 – Overview Diagnosis support systems
SNP 1 Before IRS Median 
[range]
























































IRS: Implantable Rectum Spacer, V-IRS: virtual IRS, EUD: equivalent uniform dose in rectum with 
n=0.09, TCP: Tumor Control Probability, NTCP: Normal Tissue Complication Probability, SNP: Single-
Nucleotide Polymorphism, SNP 1: rs141044160, SNP 2: rs7432328
Discussion
In this study, we have developed an isotoxic method integrating genetic markers 
of rectal radio-sensitivity combined with a V-IRS which can be used to support the 
decision for the implantation of an IRS for a specified patient or not. The method 
applies image deformation to a CT image of a patient without IRS, and creates a 
virtual CT image with IRS. The method calculates the maximum dose per fraction 
that can be given without exceeding an upfront determined limit for the NTCP 
value for late rectal bleeding. 
The results show that a higher prescribed dose should be given to improve TCP, 
and can be safely administered when combined with an IRS. This method can be 
used as the basis of a multifactorial DSS[26], which can be used as a meta-treatment 
planning system[27] to decide in which patients to place an IRS, as well as advise 
on how much dose escalation is possible to apply for a specified patient[28, 29]. This 
method also allows for shared decision making, taking into account the patients 
priorities, such as cure rate or risk of toxicity.
Our method has two main strengths. Firstly, the method uses NTCP prediction 




toxicities under control. Applying this method in the clinic would allow dose 
escalation to be used more safely and improve outcomes for patients[30]. Secondly, 
treatment planning with an IRS can be applied to a CT of a patient without the real 
implantation of the IRS itself. This means that the increase in TCP with the IRS for 
the specified patient can be estimated without having to put the patient through the 
discomfort of the implantation, and without the additional costs of the placement of 
the IRS, before it has been established that an IRS will be beneficial.  
The results showed that the system would advise further dose escalation even 
without the placement of an IRS, which would result in better outcomes for these 
patients. The system foresees a gain in TCP for 7 of the 16 patients, showing the 
model can be used as to identify patients for whom an IRS is beneficial. Using the 
V-IRS, 6 of the 7 patients for whom the spacer would be significantly effective could 
be identified. The patient not identified had very different rectal fillings before and 
after IRS placement. This demonstrates that this DSS has the potential to identify 
patients who benefit most from an IRS. This improves the cost-effectiveness of the 
IRS by only placing it in patients who would benefit from it, while also improving 
their survival and quality of life. 
During this study, SNPs were incorporated into the NTCP model and tested on 
the patient cohort, assuming all were heterogeneous for either SNP. Because the 
toxicity risk of a carrier is larger than for a non-carrier, these patients could normally 
be considered for alternative treatments, such as surgery. However, the method 
presented here has the potential to identify patients with this SNP who could be 
treated safely with radiotherapy after placement of an IRS. This would be beneficial, 
since placing an IRS is less invasive and has a very low to no impact on the quality 
of life, especially in comparison with surgery[8]. This would also be beneficial for 
patients who don’t want an operation or who are not eligible for surgery.
One of the main limitations of the study was the small amount of patients 
included. Though they were sufficient for a first proof-of-concept, a more elaborate 
study including a larger amount of patients is required for internal validation of the 
method, and additional data sets are required for external validation.
Furthermore, the LKB model uses the entire DVH as a predictor for late rectal 
bleeding, which is partly effected by the rectal volume, a factor which varies strongly 
over time[31]. The model cannot predict these changes in rectal volume, and for some 
patients this may influence the outcome. For two patients, this difference in volume 
was as much as 150 cm3, and for one patient this resulted in a large overestimation 
of the NTCP by the V-IRS. For another patient the decrease in rectal volume even 
resulted in an increased NTCP after the placement of the IRS. A possible solution 
to this problem is to submit patients with very full rectums to rescanning, or for 
patients to be given a laxative prior to scanning. For future validation of the V-IRS, 
only CT scans with similar rectal filling before and after IRS placement should be 
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used, as only then a fair comparison can be made. Finally, concerning optimising 
the treatment planning technique: it is possible to reduce intermediate dose levels 
(30−50 Gy) in the rectum region by an arc-therapy with an avoidance-region near 
the rectum. 
Another possible error in both the TCP and the NTCP model is the α/β ratio, 
which varies between prostate, rectum and bladder. In order to fully understand the 
effect possible errors in the α/β ratio have on the calculated outcome, a sensitivity 
analyses should be done. However, considering the uncertainty in estimates for α/β 
ratio’s results for these kind of analysis should always be interpreted carefully.
The V-IRS used in this study was based on a RBI, a closed system which has a 
predictable shape, while 8 of the patients were implanted with a HGS, which has 
a highly variable shape[32]. However, patients with a large increase in TCP resulting 
from a hydrogel spacer can still be identified using the V-IRS, and therefore it still 
has potential as the basis of the DSS, even for the hydrogel spacer. The V-IRS has 
been published in a proof-of-concept study but requires validation. The V-IRS 
performance is promising, however after validation it is expected to improve and 
consequently leading to better outcome results.
The integration of the SNPs is theoretical in this study, as none of the patients 
were sequenced and tested for the SNPs, and as the MAF is low (0.05 and 0.06), it 
is not likely any of them would be carriers. An improved method would be to build 
an NTCP model on a large patient cohort for whom sequencing has been done 
and for whom outcome data has been collected. Also, though SNPs have been 
identified that are significant for rectal toxicity in general, currently no SNPs have 
been found to be significant for late rectal bleeding specifically[12]. To date, six SNPs 
have been associated with rectal bleeding (11), of which two were used in this 
study. These SNPs approaching statistical significance in a meta-analysis (P <5*10-
6). Further validation in larger studies are needed before incorporate these SNPs in 
NTCP models.  Once significant SNPs are identified, these can be incorporated into 
NTCP models. 
The NTCP model is dependent on the DVH in the rectum; however, during 
treatment this DVH might vary depending on day-to-day variability of rectum filling. 
This could influence the accuracy of the NTCP model. In order to fully demonstrate 
the effect this has on the NTCP prediction, the real administered rectal dose should 
be computed. Also, the NTCP model used in this study only uses the DVH as a 
predictor for late rectal bleeding, however, studies have shown that several clinical 
parameters (diabetes, abdominal surgery, etc.) are also strong predictors. In future 
work, we intend to include NTCP models using clinical predictors into the model as 
well as validated SNPs. We also want to validate the method of combining published 
SNPs with NTCP models on a dataset for which sequencing was done, and for which 




Including different endpoints for the toxicity models, such as incontinence, 
erectile dysfunction and urinary toxicity would serve to further improve patient 
specific decision making. Another good expansion of the model would be to add a 
cost-effectiveness analyses, which would enhance the cost-effectiveness of the IRS, 
a topic that is becoming increasingly important due to ever-expanding expenses in 
health care[33, 34]. Another development would be to focus on hypofractionation as 
well. Possibilities for extreme hypofractionation, such as stereotactic radiotherapy, 
single fraction high dose rate brachytherapy or single shot proton therapy could 
be explored. This would serve to further increase patient prospects as well as cost-
effectiveness. 
Before application in the clinic is possible, the DSS model needs to be further 
developed while taking into accounts the limits of treatment planning and application. 
When the model advices lower dose prescription than the original treatment plan, 
the V-MAT system might not be able to calculate the treatment plan. Analyses should 
be done on how easily prescription dose can be adjusted, and whether variation in 
fraction dose and/or number of fractions would be most effective. 
The isotoxic model integrating genetic markers for rectal toxicity developed in 
this study can be used to evaluate a treatment plan, and test how much dose can 
be given without causing excessive damage to the rectum. Thus sparing the organs 
at risk at a chosen described level while optimizing the TCP. In combination with the 
V-IRS, this method can serve as the basis for a DSS for the implantation of an IRS.
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Supplementary Table S5.1: An overview of the patient characteristics.
Characteristic Subgroup Number of patients (%)
Risk group Low 2 (12.5%)
Intermediate 7 (43.75%)
High 7 (43.75%)
IRS Balloon 8 (50%)
Hydrogel 8 (50%)
IRS: Implantable rectum Spacer
Supplementary Table S5.2: An overview of the constraints set during treatment planning 
(given dose)
Structures Constraints
Planning Target Volume V70 > 95% V77 < 3%
Rectum Volume V70 = 0%
Anal Canal Volume V74 = 0% Mean dose < 40 Gy
Anorectum Volume V54 < 50% V65 <20%
Bladder Volume V70 = 0%
Gy: Gray, Vxx: percentage of volume receiving more than xx Gy
Supplementary Figure S5.1: The Vxx% is the percentage of the bladder volume receiving 
at least xx Gray (Gy). This figure shows the V80%, V75%, V70% and V65% for each of the 
patients included in the study after the dose was optimized by the isotoxic model. For all 
treatment plans, the bladder dose remains within the given limits.
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Supplementary Figure S5.2 the normal tissue complication probability (NTCP) predictions 
as function of the fraction dose for each individual patient before and after the placement 
of an implantable rectum spacer (IRS). The first 8 patients received a rectum balloon 




Supplementary Figure S5.3: The normal tissue complication probability (NTCP) predictions 
as function of the fraction dose for each individual patient before and after the placement 
of an implantable rectum spacer (IRS). The first 8 patients received a rectum balloon 
implant (RBI) and the second 8 received a hydrogel spacer. The dashed lines are before IRS 
placement, the solid lines after.
Supplementary Figure S5.4: The median tumour control probability (TCP) and range, 
as well as the median normal tissue complication probability (NTCP) and range, for the 
patients without implantable rectum spacer (IRS), with IRS and with the virtual IRS (V-IRS). 
Per group, the NTCP limit of the iso-toxic model is set to be 2.5, 5 and 10%.
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Supplementary Figure S5.5: To demonstrate the effect of the odds ratios (ORs) single 
nucleotide polymorphisms (SNPs), the OR’s of the SNPs were artificially varied between 
0.5 and 10, and the resulting normal tissue complication probability (NTCP) was calculated 
for the different fraction doses. Since the tumour control probability (TCP) is not effected 
by the SNPs, this remains the same. The top plot shows the results without implantable 
rectum spacer (IRS), the bottom one with. The Minor Allele Frequency for all these ORs was 
assumed to be 0.05.
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Purpose: To assess the effect of a shrinking rectal balloon implant (RBI) on 
the anorectal dose and complication risk during the course of moderately 
hypofractionated prostate radiotherapy. 
Methods: In 15 patients with localized prostate cancer, an RBI was implanted. 
A weekly kilovolt cone-beam computed tomography (CBCT) scan was acquired 
to measure the dynamics of RBI volume and prostate–rectum separation. The 
absolute anorectal volume encompassed by the 2 Gy equieffective 75 Gy isodose 
(V75Gy) was recalculated as well as the mean anorectal dose. The increase in 
estimated risk of grade 2–3 late rectal bleeding (LRB) between the start and end of 
treatment was predicted using nomograms. The observed acute and late toxicities 
were evaluated.
Results: A significant shrinkage of RBI volumes was observed, with an average 
volume of 70.4% of baseline at the end of the treatment. Although the prostate-
rectum separation significantly decreased over time, it remained at least 1 cm. 
No significant increase in V75Gy of the anorectum was observed, except in one 
patient whose RBI had completely deflated in the third week of treatment. No 
correlation between mean anorectal dose and balloon deflation was found. The 
increase in predicted LRB risk was not significant, except in the one patient whose 
RBI completely deflated. The observed toxicities confirmed these findings.
Conclusions: Despite significant decrease in RBI volume the high-dose rectal 
volume and the predicted LRB risk were unaffected due to a persistent spacing 
between the prostate and the anterior rectal wall.




External beam radiation therapy (EBRT) is an effective curative treatment 
option for patients with localized adenocarcinoma of the prostate compared to 
surgery[1]. Increasing radiation dose is associated by increased control however this 
is correlated with an increased potential risk of gastro-intestinal (GI) toxicity, with 
possibly a decrease in the quality of life[2-4]. Despite the development of advanced 
treatment techniques like intensity-modulated radiation therapy, volumetric arc 
therapy, and image-guided radiotherapy, sparing of the rectal wall is a prerequisite 
for safe delivery of high doses to the prostate. This makes the rectum the dominant 
dose-limiting organ at risk in prostate EBRT. To spare the rectum, artificial spacing 
material has been used for insertion into the retro-prostatic space. Implantable 
rectum spacers (IRS) separate the anterior rectal wall from the prostate by creating 
an artificial distance between these organs. As such they reduce the dose exposure 
to the rectum, consequently decreasing the risk of GI toxicity. Different types of 
IRS exist, all of which are implanted through a transperineal approach. Hyaluronic 
acid[5] and collagen implants[6] are physiologically compounds made of substances 
that are naturally present in the human body. Potential side effects for transmission 
of infectious agents or immunological reactions have been reported[7]. Therefore, 
commercially available spacers based on polyethylene glycol (PEG) hydrogels[8] and 
biodegradable saline-filled rectal balloon implants (RBI)[9] have been developed. 
Recently Wolf and co-workers compared PEG and RBI spacer technologies in 59 
prostate cancer patients undergoing radiation treatment and concluded that the RBI 
was superior in reducing rectum dose, whereas the PEG-hydrogel spacer had a better 
volume consistency with respect to the duration of treatment[10]. They reported an 
early and sudden RBI volume decline in 4 out of 16 patients, and an average volume 
loss of >50 % in the remaining 12 patients during the full course of treatment over 8 
weeks of a normofractionated radiotherapy regimen comprising 41 fractions. 
The aim of our study was to evaluate the RBI volume stability and the dosimetric 
effect of RBI volume shrinkage on the anorectum and to estimate the 3-year 
risk of grade 2-3 late rectal bleeding (LRB) during the course of a moderately 
hypofractionated EBRT regimen comprising 28 fractions. We tested the hypotheses 
that despite of an expected RBI volume decrease over time there is no significant 
increase in the absolute anorectal volume encompassed by the 2 Gy equieffective 
dose of 75 Gy (V75Gy) and in the mean anorectal dose, both of which are considered 
relevant parameters for predicting LRB. We also tested the hypothesis that there 
is no correlation between RBI deflation and mean anorectal dose. Additionally we 
hypothesized that the predicted increase in risk of LRB resulting from the volume 
decrease of the RBI is insignificant. Furthermore, we postulated that this predicted 




of at least 1 cm during the whole course of treatment. Finally, we reported the 
observed acute and -as far as possiblelate toxicities.
Materials and methods
Patient selection
After approval by the institutional review board (number 14-38-03/09- 
internal-6335) 15 consecutive prostate cancer patients were prospectively included 
in this study between June 2015 and March 2016. Patients with a histologically 
confirmed, localized adenocarcinoma of the prostate were enrolled in this study to 
receive an RBI (BioProtect Ltd, Israel). All patients had signed an informed consent. 
The patient and tumor characteristics are summarized in Table 6.1. Patients who 
had been classified as intermediaterisk were prescribed additional neo-adjuvant 
hormonal therapy for 6 months[11]. The high-risk patients were offered an additional 
1.5 years hormonal therapy in extent of the 6 months neo-adjuvant therapy 
after EBRT. All patients underwent magnetic resonance imaging (MRI) to exclude 
extraprostatic spread. Dorsal extra-prostatic disease extension (stage T3a/4) was an 
exclusion criteria, as well as distant metastatic disease, inflammatory bowel disease 
and previous pelvic EBRT.
Table 6.1 – Patient (N=15) and tumor characteristics
Parameter name Value
Age (years; median [range]) 72 [63−77]
Prognostic risk group*: no. of patients)
      Low-risk 1 (7%)
      Intermediate-risk 5 (33%)
      High-risk 9 (60%)
* Low-risk: no risk factors: PSA <10 ng/ml; Gleason score <7; cT-stage <2b; 
Intermediate-risk: PSA 10–20 ng/ml and/or Gleason score =7 or cT-stage = 2b/c; 
High-risk: PSA >20 ng/ml or Gleason score >7 or cT-stage >2b/c.
RBI implantation procedure
An RBI was implanted in these patients between the prostate and the anterior 
rectal wall 7-10 days prior to the start of EBRT. The injection technique has been 
described in detail previously[12]. A short general anesthesia is preferred at our 
department. However, the implantation procedure can be also performed under 
local or spinal anesthesia. Firstly, 4 fiducial markers (PolyMark™, CIVCO, Orange 
City, USA) were implanted intraprostatically for daily position verification. The 
RBI was implanted transperineally under bi-plane transrectal ultrasonography 
guidance. A bubble-free (sterile) saline solution was used to fill and inflate the 
RBI. The saline solution was mixed with approximately 1.5 cm3 iodinated contrast 
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medium to enhance the visualization of the RBI on computed tomography (CT) 
scans. The injected volume was varied, depending on the volume of the prostate. 
Because the RBI should not be filled to achieve a prostate-rectum separation larger 
than 30 mm we adapted the volume of the RBI to the volume of the prostate: small 
prostates (<35 cc) do not need the maximum RBI volume to guarantee a prostate-
rectum separation of at least 1 cm, which is considered as a conclusive spread[13].
Figure 6.1. Color-wash isodose distribution projected on an axial CT slice before (a) and after 
RBI implantation (b) in the same patient with the planning target volume in red. Without RBI 
(a), the high-dose region >80% (green isodose) overlaps with the entire ventral part of the 
rectum (black line), whereas with the RBI in situ (b) the rectum is exposed to a dose <65% 
(blue isodose)
Treatment planning
Each patient underwent a CT scan and MRI scan 5-7 days after RBI implantation 
in supine position with a slice thickness of 3 mm for treatment planning and target 
volume delineation purposes, respectively. One hour prior to image acquisition 
patients were instructed to first empty their bladder, then drink 300 ml of water to 
have a full bladder, and empty their bowel. No use of laxative was recommended. 
The CT and MRI scans (balanced turbo field-echo-sequence with isotropic 0.5 mm 
in-plane resolution) were co-registered based on the fiducial markers.
Delineation of the prostate (CTV = clinical target volume) was performed on 
the T2-weighted MRI scan, while the RBI and the organs at risk were delineated on 
the CT scan (Figure 6.1). In case the CT and MR images showed different prostate 
shapes and volumes (e.g. due to differences in rectal filling), the MR imaging was 
repeated. The first planning target volume (PTV1) was constructed according to the 
institutional protocol by expanding the CTV with 10, 7 and 6 mm in cranial-caudal, 
anterior-posterior, and left–right direction respectively. A second PTV (PTV2) was 




and bladder. All treatment plans were designed for dose delivery with a volumetric 
modulated arc technique (VMAT) using 10 MV photon beams (Eclipse Version ICD-
10, Varian Medical Systems Inc., Palo Alto, USA). The prescribed dose to PTV1 and 
PTV2 was 65.8 and 70 Gy, in 28 fractions of 2.35 and 2.5 Gy, respectively[14]. With 
α/β = 3 Gy for late rectal toxicity, the maximum 2 Gy equieffective dose (EQD23) in 
the anorectum for this type of plan is 77 Gy[15]. No density override for the iodine-
containing RBI was performed, because it was assumed that the contrast medium 
that was present in the RBI at the time of CT scanning and treatment planning 
remained present during treatment delivery. The overall treatment time was 7 
weeks, at 4 fractions a week. The dose-volume constraints fulfilled the institutional 
protocol, which is based on the QUANTEC guidelines[16]. All patients underwent 
daily X-ray based position verification and repositioning based on the intraprostatic 
fiducial markers.
RBI volume and distance dynamics 
To assess the volume stability of the RBI over time, a weekly kilovolt conebeam 
computed tomography (CBCT) scan was acquired in treatment position prior to 
irradiation, respectively at fractions 1, 7, 11, 15, 19, 23, and 27. The resulting 105 
CBCT scans were imported into the treatment planning system for delineation 
and subsequent 3D volumetry of the RBI. Furthermore, the minimum distance 
between the prostate and the anterior rectal wall was measured at mid-prostate 
level in anterior-posterior direction. Two observers independently delineated the 
RBI (RG and BV) and the anorectum (DH and BV). The anorectal structure consists 
of the rectum and the analcanal. The rectum was delineated from the top of the 
anal-canal up to the recto-sigmoid flexure. The anal-canal was considered as the 
distal 3 cm of the anorectum. Six to nine months after RBI implantation an MRI 
scan was acquired to evaluate the biodegradability of the RBI.
Anorectal dose estimation
To assess the dosimetric consequences of RBI shrinkage on the anorectum, 
the planned dose distribution of the three patients with the largest observed RBI 
volume reduction was recalculated on the weekly acquired CBCT images, while 
keeping all planning parameters (e.g. beam arrangement, field size, fluence maps, 
monitor units) the same as for the initial, CT-based treatment plan. The DVH for 
the anorectum obtained from the treatment plan was converted into EQD23 using 
the Withers formula[17]:
 (6.1)
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where α/β = 3 Gy for late rectal toxicity, D is the total dose, and d is the dose per 
fraction. All dose(-volume) parameters were obtained from the EQD23-converted 
DVH. The absolute V75Gy of the anorectum was compared between the CT and 
CBCT plans: in the 3 cases with the largest RBI volume decrease the weekly CBCT 
images were compared. For the remaining patients, only the CBCT images of the 
last week (CBCT27) were used for comparison of the anorectal V75Gy against the 
CT-based plan. The EQD23-converted mean anorectal dose was calculated for the 
planning CT and the final CBCT for all patients.
Complication risk estimation
To assess the effect of the RBI volume decrease on the 3-year risk of grade 2-3 
LRB, a set of previously published multifactorial nomograms were used[18]. These 
nomograms use clinical parameters (use of anticoagulants, hormonal therapy, or 
anti-hypertensives; pelvic node irradiation; presence of diabetes or haemorrhoids; 
and a history of pre-RT abdominal surgery), in addition to dosimetric parameters 
(mean rectal dose and the percentage of the anorectum volume receiving at least 
an EQD23 of 75 Gy) to predict the risk of late rectal bleeding. The nomograms were 
applied to the initial treatment plans and the plans performed on the final CBCT 
images for each patient. The results were used to estimate the largest change in 
predicted complication risk due to shrinkage of the RBI.
Observed Toxicity Assessment
The complications were recorded in terms of Common Terminology Criteria for 
Adverse Events (Version 4.03). Acute gastro-intestinal (GI) and genitourinary (GU) 
toxicities were scored in the 2nd, 4th, 6th week of treatment and 3 months after 
its completion. Late toxicities were scored in the 6th, 9th, and – in case if possible 
– 12th, 18th months after treatment completion.
Statistical analysis
The statistical analyses were carried out using the Statistics Toolbox of MATLAB 
(Version 10.2, The MathWorks, Natick, USA) software. The pairedsamples Wilcoxon 
signed rank test was applied to test for a significant decrease in volume of the RBI 
on weekly acquired CBCT scans, and for a significant decrease in distance between 
prostate and rectum. This test was also applied to test for a significant increase in 
predicted complication risk between the first and last fraction. All statistical tests 









Planning CT 20.0 [12.9 − 22.6] 2.3 [1.9 − 2.9]
CBCT 1 19.6 [12.8 − 21.7] 2.2 [1.8 − 2.8]
CBCT 7 16.0 [12.8 − 20.7] 2.0 [1.7 − 2.5]
CBCT 11 15.8 [11.7 − 20.7] 1.9 [1.6 − 2.4]
CBCT 15 15.6 [11.7 − 20.6] 1.9 [1.5 − 2.4]
CBCT 19 14.5 [11.3 – 20.0] 1.9 [1.3 − 2.4]
CBCT 23 14.0 [9.6 − 19.8] 1.7 [1.1 − 2.3]
CBCT 27 11.9 [6.3 − 19.8] 1.4 [1.1 − 2.3]
Abbreviations: RBI = rectal balloon implant; CBCT = cone-beam computed tomography
Results
RBI volume and distance stability
The median injected and delineated RBI volumes were 17.0 cm3 [range: 9−17 
cm3] and 20.0 cm3 [range: 12.9−22.6 cm3], respectively. Volume differences are 
explained by the fact that the delineated RBI structure comprises both the injected 
saline solution and the RBI envelope. Two patients were excluded from the stability 
analysis, because in one patient CBCT scans were missing due to a protocol 
violation and in another patient the RBI had disappeared on CBCT in the third 
week of treatment as no contrast medium could be detected. For the remaining 
13 patients, the descriptive statistics of the RBI volume dynamics are summarized 
in Table 6.2 and depicted in Figure 2. The median RBI volumes at fractions 1, 15 
and 27 were 19.6 [range: 12.8 – 21.7], 15.6 [range: 11.7 – 20.6], and 11.9 cm3 
[range: 6.3 – 19.8], respectively. The weekly decrease in absolute RBI volume was 
significant for all time points, with an average volume loss of 29.6% at fraction 27 
relative to baseline. The largest relative volume decrease occurred during the first 
week (i.e. between fraction 1 and 7), and after fraction 19 (Figure 6.2). The median 
volume loss relative to baseline was 25% [range: 5.7 – 54.9%]. The descriptive 
statistics of the prostate-rectum distance dynamics are also summarized in Table 
6.2. Although the weekly decrease of minimum prostate-rectum distance was 
significant for all time points, this distance remained greater than 1 cm at all times.




Figure 6.2. A box and whisker plot of the delineated rectal balloon implant (RBI) volumes 
during a full treatment course of 28 fractions in 13 patients (grey dashed lines) observed by 
weekly cone-beam computed tomography (CT) images
RBI resorption
Six to nine months after completion of EBRT a residual rest of the RBI envelope 
was visible on T2-weighted MRI in only 1 out of 15 (7%) patients; no contrast 
medium or saline solution could be observed. Neither space-occupying effects 
nor complications (infections, perforations, fibrosis) were observed in any of the 
patients.
Table 6.3 – Descriptive statistics or treatment plans based on the planning CT scan and the 





Rectal volume (cc) 88.7 [56.1–187.4] 68.65 [45.3–200.8]
Mean rectal dose (Gy) 26.2 [10.9–34.6] 33.9 [19.3–38.7]
V75Gy (cc) 0.1 [0.0–1.6] 0.7 [0.0–5.9]
Complication risk (%) 4.1 [3.8–11.9] 4.5 [3.9–11.6]
CT computed tomography, CBCT cone-beam computed tomography, V75Gy volume receiving 





Figure 6.3. Relative volume dynamics of rectal balloon implant during a full treatment 
course of 28 fractions in 13 patients (grey dashed lines) observed by weekly cone-beam 
computed tomography (CT) images. The mean values (dark blue) with the standard 
deviations (light blue) are presented
Anorectal dosimetry
In the patient whose RBI had disappeared on the CBCT scan in the third week 
of treatment, the V75Gy of the anorectum significantly increased from 0 to 4.3 
and 5.9 cm3 at fraction 1, 11 and 27, respectively (Pat. 9, Figure 6.3). In the other 
two patients  (nrs. 5 and 12) exhibiting the largest RBI volume decrease (45% and 
52% of the original volume, respectively) a significant increase in absolute V75Gy 
of the anorectum was only observed in the CBCT scan of fraction 23 (Pat. 5 and 12, 
Figure 6.3). Furthermore, the RBI deflation did not lead to significant increase in 
V75Gy (p = 0.577). Among the remaining patients there was only one patient who 
showed an increase of V75Gy from 0 cm3 on the CT plan to 3.6 cm3 on the CBCT27 
plan (Table 6.3). In 2 out of 11 patients the V75Gy remained 0 for both the CT and 
CBCT27 scans. In 6 patients even a slight decrease of V75Gy was determined. The 
increase in V75Gy for all patients except the one of whom the RBI disappeared was 
not significant (P = 0.57). The increase in mean anorectal dose was significant (P = 
0.02), however, no correlation was found between the mean anorectal dose and 
the volume of the RBI (P = 0.3). The correlation between the anorectal volume and 
the anorectal mean dose was significant (P = 0.005). 
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Figure 6.4. Dynamics of estimated absolute anorectal volume encompassed by the biological 
equivalent 75 Gy isodose during a full treatment course of 3 patients (numbers 5, 9, 12) 
exhibiting the largest volume decrease of the implanted rectal balloon. Patient 9 had the 
complete rectal balloon implant (RBI) shrinkage on cone-beam computed tomography 
(CBCT) of fraction 11: the V75Gy increased significantly. In the other two patients (5 and 12) 
a significant increase in absolute V75Gy of the anorectum was observed in only one CBCT 
scan (fraction 23) over the total treatment course.
Risk of late rectal bleeding
In the patient whose RBI had completely deflated in the third week of treatment 
(patient 9), the risk of LRB was predicted to increase from 4.0% to 9.8%. For the two 
patients with the largest observed RBI shrinkage (patient 5 and 12) the predicted 
increase in LRB risk was 0% and 0.2%, respectively (Figure 6.4). The largest increase 
in complication risk predicted for the remaining patients was 3.4%, resulting from 
a RBI volume decrease of 32%. The difference between the predicted risk of LRB 
at the start of treatment and the end of treatment, excluding the patient with the 




Figure 6.5. Increase in predicted probability (percentage points) of late rectal bleeding 
between the planning computed tomography (CT) and the last cone-beam CT (CBCT) scan 
(fraction 27) for each of the patients
Observed toxicities
No acute grade 3 or 4 toxicities were reported during treatment or 3 months 
after completion. Overall, 5 patients (33%) experienced no toxicity at all, 6 patients 
(40%) had grade 1 GU toxicities, and 4 patients (27%) had grade 2 GU toxicities. 
During the course of therapy, in 4 patients (27%) grade 1 GI toxicity was observed, 
but no grade 2 or more acute GI toxicities.
No late grade 3 GI toxicity has been reported. Late grade 2 GI toxicity was 
observed in 1 patient: the rectal bleeding started at 9 months after radiation. This 
was the patient whos RBI had completely deflated in the third week of treatment. 
Grade 1 GI and GU late toxicities were reported in 2 patients. 
Discussion
This study provides the first evaluation of RBI volume stability that is based on 
weekly CBCT measurements during the full course of EBRT.  As previously reported 
in literature, an RBI volume decrease was expected over time. We analyzed the 
dosimetric consequences of this phenomenon and predicted the increase in risk 
of 3-years grade 2-3 late rectal bleeding resulting from a shrinking RBI to assess 
its potential clinical impact. Moreover, the observed acute and early late toxicities 
were adjusted.
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GI toxicity is the major treatment-related side effect in prostate cancer 
radiotherapy: the rates of acute and chronic Grade ≥2 rectal toxicity has increased 
by dose-escalated EBRT (up to a dose of 78 Gy) compared with lower doses (e.g., 
68 Gy) from 3% to 20% and from 5% to 21%, respectively[20-24]. Therefore, it is 
advantageous to push the rectal wall out of high-dose regions by implantation of an 
IRS device[25, 26]. So far, most studies in literature have reported on the use of a PEG-
hydrogel as an IRS[27-31]. The RBI has some practical advantages[9]. First of all post-
implant correction of the RBI position is possible; if the RBI is dispositioned, it can 
be easily deflated and replaced, whereas liquid spacers (PEG-hydrogels, hyaluronic 
acid, human collagen) do not permit any correction once being injected[9,12]. In 
addition, a chemical reaction is required to occur in PEG-hydrogels, which limits 
the implantation time. Furthermore, since the RBI inflates to a predetermined and 
predictable shape, the learning curve to obtain an adequate implant is less steep 
than for PEG-hydrogels. Additionally, due to the defined shape and homogenous 
hypodense signal, the RBI has an excellent CT visibility, which is most advantageous 
for treatment planning and CBCT-based evaluations. Besides, some amount of 
iodine contrast can be added to the saline to enhance the visualization of the RBI 
on CT and CBCT scans (Figure 6.1). Moreover, because the RBI is a closed system, 
there is no risk of air or hydrogel injection into vessels. 
Nevertheless, also disadvantages of the RBI have been reported. Recently Wolf 
and colleagues described an early deflation effect[10]. They reported an average 
volume loss of >50% during a full treatment course of 37–41 fractions (8 weeks). 
The volumes they estimated were mainly based on measurements of the diameters 
of the RBI on two orthogonal X-ray images and calculations by the volume formula 
for an ellipsoid cylinder. The measurements were only performed on CBCT scans of 
fraction 20 and 38. Data on the dynamics of the prostate-rectum separation over 
time is missing in their study. Wolf and colleagues only recalculated one treatment 
plan on a CBCT scan for a single patient whose RBI showed a significant volume loss 
of 58%, and reported an increase of 9.2 cm3 for the rectum volume encompassed 
by the 95% isodose.  We measured 3D volume changes on weekly CBCT scans and 
observed that a prostate-rectum separation of at least 1 cm is maintained during the 
full treatment course, except in the patient where the RBI deflated. The persistent 
spread of at least 1 cm means that also for other RT techniques like 3D conventional 
EBRT, intensity-modulated radiotherapy, or proton therapy, the sustained spread is 
considered as enough for protecting the anorectal structures[13].
By evaluating the dose on the anorectal structure, we observed that the V75Gy 
of the anorectum steadily increased only in one patient whose RBI disappeared 
completely in the third week of treatment. In the 2 remaining patients where the 
RBI shrank most, the V75Gy changed significantly in only 2 CBCT scans during the 




a difference in rectal filling (inclusion of gas bubbles and/or stool). The distance 
between the prostate and anorectum was still enlarged due to the presence of the 
RBI. However, the distance between the prostate and anorectum at the level of 
the cranial part of the rectum (above the RBI) could decrease incrementally. This 
is especially the case when the rectal filling is increased dramatically, and when 
seminal vesicles are irradiated. In this situation, the cranial part of the rectum 
above the RBI anorectum could receive a higher dose. Further, the RBI could exert 
pressure on the rectum and thereby decrease the rectal volume being exposed to 
an intermediate and a high dose and increase the volume being exposed to low 
doses, with unknown clinical consequences. To reduce the low- and intermediate 
dose levels, a different treatment planning technique using either an arc technique 
with an avoidance region near the rectum or using strictly anterior and lateral 
beams would be required.
By applying multifactorial nomograms on the initial treatment plan and on 
the final treatment plan, the predicted increase in risk of late rectal bleeding 
was analyzed. This showed that for the patient with the deflated RBI, the risk 
considerably increased, emphasizing the effect of the device. For the patient 
whos RBI had completely deflated a significant increase in the risk of late rectal 
bleeding was predicted by the nomogram. This was confirmed by the late rectal 
bleeding event at 9 months after treatment. For the remaining patients there was 
no significant increase in predicted complication risk, suggesting that the decrease 
in RBI volume has little impact on the effectiveness of the RBI. Some fluctuations in 
predicted toxicity risk can be seen, but these are likely also due to the rectal filling. 
Indeed, besides the distance between the rectal wall and the prostate, the rectum 
size could be a possible predictor of GI toxicity[32-35].
A previous study reported a sudden complete deflation of the RBI in 4 out of 16 
patients three weeks after implantation[10]. In our series, one patient experienced 
such a sudden complete deflation three weeks after implantation. A possible 
explanation was a non-optimal positioning: the RBI was positioned more caudally 
than the others, with the tip of the RBI in the pelvic muscle. Because of this 
positioning an excessive force was required to inflate the RBI, which could have 
damaged the sealing mechanism. Another possible explanation of early deflation 
could be an excessive filling of the RBI (i.e., prostate-rectum separation larger than 
30 mm) with bursting and consequent loss of function: each RBI is handmade, and 
one has to be sure not to exceed the maximum volume allowed that is indicated 
on the label of the product.
A limitation of this study is the limited number of patients included. As this 
was a feasibility study, only 15 patients were included. Furthermore, there was 
no prior consensus on the level and window settings of the CBCT scans, which 
might have influenced the volumetric results. In addition, the CBCT scans were 
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acquired at different time points and hence revealed different bladder and rectum 
filling, hence adding extra uncertainty to the comparison performed. Further, the 
nomograms used are not validated for patients treated with a RBI. More research 
is needed in larger patient cohorts to obtain more evidence. Finally, we evaluated 
weekly time points, and not daily, which latter could be more representative for 
the whole treatment.
The RBI was successfully implanted in all 15 patients. The mean RBI volumes 
revealed an average volume of 70.4% of baseline at the end of treatment. Despite 
the weekly RBI shrinkage to be significant, neither significant increase in absolute 
V75Gy of the anorectum nor in predicted LRB risk were observed over the full 
treatment course of our moderately hypofractionated EBRT regimen. Although the 
minimum prostate–rectum distance showed a significant decrease, it was at least 
1 cm during the full treatment course, indicating that such spacing is sufficient 
to reduce the anorectal V75Gy of a treatment plan delivered by a volumetric 
modulated arc technique. In patients experiencing a complete deflation of the RBI, 
the absolute V75Gy of the anorectum is expected to increase significantly, and so 
is the predicted risk of late rectal bleeding, and the observed toxicity. We advise 
to acquire imaging by CBCT scans at regular times during the course of treatment 
to assess deflation dynamics of the RBI. Only when the prostate-rectum distance is 
decreasing under 1 cm a treatment plan adaptation is recommended. 
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Background: Studies have found that survival after radical prostatectomy (RP) and 
external beam radiotherapy (EBRT) as primary treatment for prostate cancer (PCa) 
is similar, but the risks of toxicities are not. The aim of this study was to build a 
decision support system (DSS) using a decision-analytic model (individual state-
transition model) based on predictive models (TRIPOD 2-4) for estimating tumor 
control and toxicity probabilities for both RP and EBRT for low to intermediate risk 
localized PCa. 
Methods: We performed analyses on a synthetically generated dataset of 1000 
patients with realistic clinical parameters, externally validated our approach by 
comparing our results with those from randomized clinical trials, and subsequently 
set up an in silico clinical trial for elderly patients. We assessed the cost-effectiveness 
(CE) of the DSS for treatment selection by comparing it to randomized treatment 
allotment as a proxy for current clinical practice.
Results: Using the DSS to decide upon treatment (RP or EBRT) for the synthetic 
dataset, 47.8% were selected for RP and 52.2% for EBRT. Upon comparison to 
published results, differences with the simulations of late toxicity and biochemical 
failure never exceeded 2%. The in silico trial showed that for elderly patients, toxicity 
has more influence on the decision than TCP, and the predicted QoL depends on 
the initial erectile function. The DSS is estimated to result in cost savings (€323 
(95% CI €213-€433)) and more quality adjusted life years (QALYs; 0.11 years, CI: 
0.00-0.22) than randomized treatment selection.
Conclusions: This modelling study shows that DSS based treatment decisions will 
result in a clinically relevant increase in the patients’ quality of life and could be 
used for in silico trials.




Prostate cancer (PCa) is the second most commonly diagnosed cancer for 
men, ac-counting for 13.5% of new cancers diagnosed in 2018 in the Netherlands, 
of which 40% are low- to intermediate-risk localized PCa[1,2]. PCa is a topic of 
heightened research interest, with new biomarkers and treatment modalities being 
tested at a high rate[3]. The leading choices for managing clinically localized PCa 
are external beam radiotherapy (EBRT), radical prostatectomy (RP), brachytherapy, 
and active surveillance[4]. For low- and intermediate-risk PCa, active surveillance 
is often proposed (in ~70% and ~30% of cases, respectively), and of the active 
treatment options, RP and EBRT are recommended most often (~50% and ~45%), 
according to the Netherlands Cancer Registry. However, no consensus has been 
reached as to which is superior in terms of effectiveness and/or toxicity, both due 
to the varying spectrum of toxicities as well as the difference in incidence. The 
treatment decision is often based on doctor preference and, to a much lesser 
extent, on patient preferences and patient-specific characteristics or expected 
outcomes such as (biochemical recurrence-free) survival or toxicity[5]. Typically, 
cost-effectiveness is not taken into account in the treatment decision. Since no 
calculations are performed based on patient-specific outcomes, one could argue 
that this treatment selection method is random when considered from an outcome 
perspective.
Previous work has compared EBRT to RP in terms of long-term survival as well 
as different toxicities. Chen et al. performed a meta-analysis of the efficacy of EBRT 
versus RP[6]. They reported no statistical difference in cancer-specific survival for 
low- and intermediate-risk patients. Potosky et al.[7] and Donovan et al.[8] showed 
that urinary incontinence and reduced sexual function were more common for 
RP, but bowel toxicity was more likely after EBRT. Currently, there are no studies 
available that help assess the individual benefits of EBRT versus RP based on patient 
characteristics[9–11], even though it has been suggested that parameters such as 
age, BMI, tumor grade, and pretreatment prostate-specific antigen (PSA) levels do 
influence both recurrence-free survival and toxicity[12].
The importance of personalized medicine has become progressively evident, 
and treatment selection for PCa is no exception[13]. An important step towards 
personalized PCa treatment would be a clinical decision support system (DSS), 
introduced in 2013[14], that aids in the decision between RP and EBRT. Additionally, 
when considering the limited resources available for cancer care, it is becoming 
increasingly important to consider the cost–benefit ratio when comparing 
treatments to guide the decision-making process[15]. The integration of a clinical 
DSS could aid in this, as it has already for proton therapy[16].
In addition, the possibility of very cost-effective in silico trials (individualized 




promise to improve clinical research through better design, more transparent and 
detailed information about possible results, and greater explanatory power in 
interpreting side effects, as well facilitating the exploration of interactions with the 
individuals’ biology and the long-term or rare effects.
Our hypothesis is that the DSS can accurately replicate the results from published 
studies and can be used for in silico trials. We also hypothesize that the use of a 
DSS for treatment selection results in better tumor control, less toxicity, increased 
patient quality of life (QoL), and improved cost–benefit ratio when compared with 
current clinical practice based on tumor boards or medical specialist opinion.
The aim of this study is to build such a DSS using predictive models for 
estimating tumor control and toxicity probabilities for both RP and EBRT for low- 
to intermediate-risk localized PCa patients and validate this by comparing it to 
published clinical trials. We also set up an in silico trial using this model-based 
approach to assess the outcome for elderly patients. Additionally, we compared 
the cost-effectiveness (CE) of applying this DSS to random treatment decisions as 





The target population consisted of overall tumor stage T1-T2 PCa patients who 
were eligible for active treatment (i.e., EBRT and RP). The DSS was developed 
by constructing an individual state-transition model to estimate the effects and 
associated costs of treatment with RP vs. EBRT for each patient. Based on patient-
specific parameters (e.g., age) and treatment type (EBRT or RP), probabilities of 
developing long-term toxicities, including rectal bleeding, urinary incontinence, 
and impotence or a combination, are calculated. After treatment, patients have 
a risk of progressing to the recurrence state, which is de-pendent on patient-
specific parameters (e.g., Gleason score), after which they can develop metastatic 
disease and subsequently progress to PCa-related death. Furthermore, from any 
health state, it is possible to die of causes unrelated to cancer (Figure 7.1). The 
DSS then pro-vides a comparison of tumor control probability (TCP), probability of 
chronic erectile dysfunction (ED), chronic urinary incontinence (UI), and late rectal 
bleeding (RB), as well as a comparison of expected costs and quality-adjusted life 
years (QALYs). Detailed explanation of the transition probabilities are shown in 
Supplementary Information S7.1.
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Figure 7.1. Setup of the clinical decision support system and a summary of the Markov 
model. Ovals represent different health states, arrows represent transitions between 
health states. IMRT: intensity modulated radiotherapy, RP: radical prostatectomy, CE: cost-
effectiveness, QALY: quality adjusted life year, TCP: tumor control probability, ED: erectile 




Several assumptions are made in this model, the four most relevant being: (i) 
All RP patients start with ED and UI (at the first cycle); (ii) when a patient has 
developed bio-chemical failure, the utility value is described by a single number 
rather than separate disutility for ED, UI, and RB; (iii) we assume that after 
progression, the patient cannot re-turn to the cancer-free health state; (iv) the 
transition probability from recurrence to meta-static disease is the same for all 
patients for both treatments. Moreover, a cycle time of one month and a time 
horizon of 20 years were used; these were chosen since the survival of low–
intermediate prostate cancer is high, while increasing the time horizon beyond 20 
years would unnecessarily increase model uncertainty.
In order to quantify the relative importance of various health outcomes using a 
common measurement unit, utility is used as a metric to assign weights to health 
states on a scale ranging from 0 (for dead) to 1.0 (for perfect health). Health-state-
specific utilities, also incorporating treatment-related toxicities (and all possible 
combinations), were retrieved from Stewart et al.[17]. QALYs are obtained by 
multiplying these utility values by the time spent in the corresponding health state.
In order to account for the baseline utility of men living in the Netherlands, 
we used a published model that had calculated the age-dependent health-related 
quality of life (HRQoL) for different countries and applied it as a multiplicative 
factor to health-state-specific utilities[18].
The costs were calculated from the perspective of the healthcare system, so 
other societal costs, such as productivity losses and patient and family costs, were 
excluded. For detailed descriptions of the utility and cost data, see Supplementary 
Information S7.2.
Predictive models
The transition probabilities were estimated per individual in order to make 
this DSS patient-specific and ready for precision medicine applications. The 
individual probabilities of progression after treatment and the risk of developing 
toxicities were calculated using a selection of regression models or nomograms 
from the published literature (Table 7.1), adherent to the TRIPOD statement[19]. 
For nomograms, the coefficients or intercepts were derived (if not reported) by 
reading the nomogram and using interpolation and fitting.
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Table 7.1 An overview of the literature models used for the state transition probabilities. 
Rectal bleeding does not typically occur after RP, so the transition was set to zero for this 
treatment type.
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AUC = 0.77 
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AUC = 0.87 
for EBRT







TRIPOD: Transparent reporting of a multivariable prediction model for individual prognosis 
or diagnosis; EBRT: external beam radiotherapy; RP: radical prostatectomy; n: number; ADT: 
androgen deprivation therapy; PSA: prostate specific antigen; BED: biologically effective dose; BFFS: 
biochemical failure-free survival; R2: coefficient of determination; Gy: gray; BMI: body mass index; 
C-index: concordance statistic; RFS: regression free survival; UI: urinary incontinence; ASA: American 
Society of Anesthesiologists; V75: volume receiving at least 75 Gy; RB: rectal bleeding
*Due to incomplete information, some model coefficients had to be derived from the nomogram.
**Recurrence was defined as biochemical failure, initiation of secondary therapy, distant metastases 






Since no complete patient cohort for which all required input parameters 
were known was identified, we generated a synthetic patient dataset. A patient is 
described by a set of parameters, which we randomly assigned by drawing values 
from a distribution. We chose the distributions based on the patient cohorts on 
which the models had been developed (Supplementary Table S7.9). We assumed 
that the clinical parameters were independent of one another and generated a 
synthetic patient dataset including 1000 patients so that the mean and associated 
error of the generated clinical parameters matched that of the original datasets.
Validation of NTCP and TCP models
In order to validate the combination of our NTCP and TCP models, we compared 
the simulation results to the published results. The reliability of the model and the 
measure in which the synthetic dataset reflects real patient datasets were assessed 
by generating the synthetic patients so that they matched the reported clinical 
parameters from actual trials, such as age, Gleason score, PSA values, and T-stage. 
Nonreported clinical parameters were kept the same as the original synthetic 
dataset. Dosimetric parameters were scaled according to the 2 Gy equivalent dose. 
The relevant outcomes, such as biochemical free survival or toxicity, were then 
compared between the simulation and the clinical trial. For the EBRT α/β ratio (a 
measure of the fractionation sensitivity of the tissue) of PCa, we used a value of 
1.5 Gy[26].
In order to assess the credibility of the predicted biochemical free survival, the 
model was compared to the results of a randomized clinical trial, reported by Hamdy 
(2016), that compared EBRT to RP[27]; to assess the effect of hypofractionation, we 
compared bio-chemical free survival to the CHHiP trial[28]. In order to validate the 
model’s predictions of toxicity, we compared the model results to Donovan et al. 
(2016), who published patient-reported outcomes after EBRT or RT[8].
In silico trial 
A DSS such as this, in combination with the synthetic patient dataset, could 
function as an in silico clinical trial, a precursor to actual clinical trials, in order to 
improve study design or explanatory power. We demonstrated this by generating 
a patient dataset with patients aged 75-80 to test the outcomes of different 
treatments for elderly patients, an of-ten-underrepresented group in clinical 
trials, but a group that might still be eligible for both treatments. We adjusted 
pretreatment erectile function to an average of 15% to reduce the impact of ED on 
the outcome.




In order to determine the potential benefit of a DSS for PCa, we performed CE 
anal-yses that compared two different treatment allotment strategies. In the first, 
each patient in the synthetic dataset was allotted the treatment for which the DSS 
calculated the highest number of QALYs. For the second, each patient was allotted 
a randomized treatment as a proxy for current clinical practice.
To determine which treatment allotment strategy was cost-effective, the 
incremental net monetary benefit (iNMB) was calculated. This is described by the 
following Equation 7.1:
Where CostsDSS and Costsrandom are the mean costs per patient if treatment 
decisions are based on a DSS or randomized treatment allotment strategy 
respectively, and QALYDSS and QALYrandom are the mean number of QALYs per 
patient. WTP is the willingness to pay per QALY. If the iNMB is positive, the DSS 
was considered cost-effective. In the Netherlands, a WTP threshold of €80,000 is 
agreed upon for high burden diseases[29]. We applied discount rates of 1.5% for the 
QALYs, and 4% for the costs, which is standard practice within the Netherlands[30]. 
Results
Synthetic data characteristics 
When applying the DSS on a synthetically generated patient dataset of 1000 
patients with clinical parameters similar to those on which the predictive models 
were built, 47.8% of the patients had a higher number of QALYs for RP and 52.2% 
for EBRT. The patients for whom EBRT was chosen had a higher mean age (64 
versus 59 years), higher mean prostate specific antigen (PSA) values (8.3 versus 6.8 
ng/ml), and a higher percentage of T2 stage (49% versus 24%), as shown in Table 




Table 7.2 Patient characteristics of the synthetic patient dataset
Parameter name EBRT mean (SD) RP mean (SD) P
Age (years) 63.8 (10.7) 58.8 (9.1) <<0.001
PSA (ng/mL) 8.3 (3.5) 6.8 (3.5) <<0.001
T-stage 2 (%) 48.7 24.4 <<0.001
P. Gleason grade 4 (%) 27.1 3.3 <<0.001
S. Gleason grade 4 (%) 14.7 20.9 0.01
ADT given (%) 79.8 0 <<0.001
PSA: prostate specific antigen; T-stage: tumor stage;  P.: primary;  S.: secondary;   ADT: androgen 
deprivation therapy
Validation 
We compared the outcome reported in three separate papers against the same 
out-come simulated by our DSS on a synthetic patient dataset; the results are 
reported in Table 7.3. More details on the parameter values used are shown in 
Supplementary Table S7.11, and results are shown in Figure 7.2. The progression-
free survival reported by Hamdy (2016) was very similar to our simulation results, as 
was the Kaplan–Meier curves obtained from the GUROC (Genitourinary Radiation 
Oncologists of Canada)[31] Prostate Cancer Risk Stratification (ProCaRS) database[32], 
and the National Prostate Cancer Register of Sweden (NPCR)[21,33]. Dearnaley (2016) 
published the results of the CHHiP trial and compared the results of different 
fractionation plans[28]. When comparing these results to what was simulated by our 
DSS, the simulation was close to the published results, but the difference increased 
with stronger hypofractionation. Donovan (2016) was used for toxicity comparisons 
and showed that the DSS simulated late toxicity best but was less accurate for 
acute toxicity. The relative differences between the simulations and the studies 
for the different treatment modalities were similar, and the conclusions coincided. 
The most notable discrepancy is for acute ED for EBRT, which was underestimated 
by the simulations because we assumed no acute ED after EBRT treatment.




Figure 7.2. Progression free survival and probability of toxicity of the model compared to 
published data. Progression free survival data was obtained from the GUROC (Genitourinary 
Radiation Oncologists of Canada) Prostate Cancer Risk Stratification (ProCaRS) database, 
and the National Prostate Cancer Register of Sweden (NPCR). Data on toxicity was obtained 
from Donovan 2016 et al.
In silico trial 
We performed an in silico trial on the synthetic dataset by increasing the age of all 
patients to between 75 and 80 but leaving all other clinical parameters as they were. 
We found that TCP for RP was marginally higher than for EBRT (HR: 1.007), and the risk 
of chronic UI was much higher for RP (HR: 10) as well as ED (HR: 1.59); consequently, 
EBRT did result in more QALYs and lower costs than RP. The DSS selected EBRT for 96% 
of the patients. We repeated this analysis while assuming that 85% of the patients 
had ED before the start of treatment. This resulted in a smaller difference in ED, thus 
decreasing the dif-ference in QALYs between RP and EBRT (Table 7.4) and resulting in 




Table 7.3 Patient characteristics of the synthetic patient dataset
Study Treatment [N] Outcome Published 
study (%) 
Simulation (%) Difference (%)
Hamdy 2016 EBRT [545] 5 year BDFS 88.5 89.0 0.5
RP [553] 5 year BDFS 88.1 87.0 1.1
CHHiP EBRT 74 Gy 
[1065]
5 year BDFS 88.3 88.4 0.1
EBRT 60 Gy 
[1074]
5 year BDFS 90.6 89.9 0.7
EBRT 57 Gy 
[1077]
5 year BDFS 85.9 87.9 2.0
Donovan 
2016
EBRT [545] 6 month UI























RP [553] 6 month UI















N: number of patients; EBRT: external beam radiotherapy; RP: radical prostatectomy; BDFS: 
biological disease-free survival; UI: urinary incontinence; ED: erectile dysfunction; RB: rectal 
bleeding; Gy: gray; GS: Gleason score
Table 7.4 In Silico trial results












5 year TCP [%] 84 (7) 84 (4) 84 (4) 84 (7) 84 (4) 85 (5)
2 year ED [%] 93 (6) 61 (19) 61 (20) 100 (0) 98 (2) 98 (2)
1 year UI [%] 70 (16) 7 (4) 8 (10) 70 (16) 7 (4) 22 (26)









4.30 (0.83) 4.32 (0.84)
Costs (1000 €) 15.2 (1.1) 12.6 (1.0) 12.7 (1.1) 15.2 (1.1) 12.7 (1.0) 13.3 (1.5)
RP: Radical prostatectomy; EBRT: external beam radiotherapy; DSS: decision support system; PTED: 
85% pretreatment erectile dysfunction; SD: 1 standard deviation; TCP: tumor control probability; ED: 
Erectile dysfunction; UI: Urinary incontinence; RB: rectal bleeding QALY: quality adjusted life years
Cost-effectiveness analysis 
When comparing the DSS treatment selection to a randomized treatment 
allotment strategy, the DSS resulted in an average cost saving (discounted) of EUR 
317 per patient and an increase in the number of discounted QALYs of 0.11 years. 
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With an incidence rate of 12,500 patients a year in the Netherlands, with 40% 
being low- to intermediate-risk PCa patients and 50% receiving active treatment, 
this DSS could affect ~2400 patients a year. Since the costs decreased while the 
QALYs increased, the DSS was the dominant strategy in this “base case” scenario, 
with an iNMB (Equation (7.1)) of EUR 8798 per patient. The TCP is higher for the 
DSS than for randomized treatment allotment, and the probability of all toxicities 
decreases with the use of this DSS (Table 7.5).
Table 7.5 Probability of different outcomes




DSS mean (SD) P
5 year TCP [%] 83 (8) 84 (4) 0.003 83 (7) 85 (5) <<0.001
2 year Erectile 
dysfunction [%]
83 (13) 59 (2) <<0.001 71 (14) 67 (20) <<0.001
1 year Urinary 
incontinence [%] 
27 (18) 7 (4) <<0.001 16 (9) 13 (15) <<0.001
3 year Rectal 
bleeding [%]
0 (0) 5 (4) <<0.001 2 (2) 1 (3) 0.61
RP: Radical prostatectomy; EBRT: external beam radiotherapy; DSS: decision support system; SD: 




Figure 7.3. The cost-effectiveness plane when comparing the DSS to the randomized 
strategy. Each blue point represents the incremental costs and quality adjusted life years 
(QALYs) for DSS vs randomized treatment allocation of a single simulation over all 1000 
patients. The yellow dot shows the deterministic simulation, and the dashed lines show 
confidence intervals of the simulations.
A probabilistic sensitivity analysis, performed with 5,000 Monte-Carlo 
simulations, resulted in a cohort with a mean increase in discounted QALYs of 0.11 
(95% CI 0.00-0.22), and a mean decrease in costs of €323 (95% CI €213-€433) 
(Figure 3) for DSS compared with randomized treatment allocation. For 98.6% of 
the simulations, using a DSS was cost-effective when compared to a randomized 
strategy (dominant for 98.2% of the simulations). For a detailed cost-effectiveness 
analysis of the model, see Supplementary Information S7.3.
Discussion 
In this study, we developed a clinical DSS for the treatment of PCa patients 
with either EBRT or RP and tested this on a synthetic patient dataset. We validated 
the DSS against published clinical studies and set up an in silico trial for patients 
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between 75 and 80, eligible for both RP and EBRT. We also assessed the CE of 
a treatment allotment strategy based on the DSS compared to a randomized 
treatment allotment strategy. Our first hypothesis was that we could accurately 
replicate results from published studies, which we aimed to confirm by generating 
synthetic datasets with clinical parameters similar to published trials. The DSS 
largely replicated the published results accurately. The relative differences between 
the treatment modalities and fractionation plans were replicated by the model, 
and the conclusions of the DSS and the studies agreed. We also performed an in 
silico trial, exclusively including elderly patients first without, then with, prior ED, 
using the DSS and found that for the first group, EBRT was preferred, and, for the 
second, RP performed better in terms of QALYs. Additionally, we hypothesized that 
a treatment se-lection strategy based on the DSS would improve tumor control, 
reduce toxicity, and im-prove CE as opposed to randomized treatment selection. 
Our CE analyses suggest that not only do the costs of treatment decrease with 
the application of a DSS, but the number of QALYs also increases, making the 
integration of a DSS dominantly cost-effective com-pared to current clinical 
practice. The expected cost savings within the Netherlands when using a DSS could 
be as high as EUR 3.8 million ‬over five years, assuming 2400 patients are affected 
every year. Additionally, the number of patients with recurrence after treatment 
could be reduced slightly by 2%.
These results imply that when deciding between RP and EBRT for a given patient, 
making the right choice can improve overall QoL and that this decision should not 
be random. The DSS offers the possibility of combining a large number of clinical 
parameters to predict NTCP and TCP and quantify these risks into a single metric for 
different treatment options. This has the potential to improve the decision-making 
process, along with other factors such as incorporating patient preferences. The 
development of a DSS fits well into the current trend that strives for personalized 
medicine, and the results presented in this study confirm the added benefit of such 
a tool[34]. The application of the DSS for in silico trials has great potential benefits; 
it not only improves the design of clinical trials through precursory simulations 
but also has the benefit of being able to apply different treatments to the same 
“patient”, which allows for a more objective comparison. Another advantage 
of the DSS is that it is detailed and can be further extended with other disease 
management options such as brachytherapy or active surveillance. The framework 
of the DSS is also flexible, making it easy to replace individual models or update 
them as new clinical trial results are published. It can also be used as the basis for 
an individualized patient decision aid (iPDA).
This study has several limitations. The first one is that this is a model-based 
study, using models that were trained and validated on different cohorts. The 




patients included, and whether or not they used clinical parameters and a TRIPOD 
level. We also attempted to make sure we only selected models trained on patients 
with similar treatment modalities and similar clinical parameters; however, not all 
clinical parameters were reported. In addition, the correlation between clinical 
parameters was not reported, and when generating the synthetic dataset, no 
correlations were assumed. It should also be noted that the clinical parameters 
found in the clinical trials used as a basis for the synthetic dataset may not be 
representative of the whole patient population. Different outcomes of the models 
were validated in different studies, so the DSS as a whole has not been validated on 
a single patient population. However, the acquisition of a dataset where not only 
all the clinical parameters but also long-term follow-up data for TCP and toxicity 
for both treatment arms are reported might not be feasible. Moreover, the NTCP 
models used doctor-reported out-comes as endpoints, while the validation was 
done on patient-reported outcomes. How-ever, the promising benchmark results 
indicate that the models have significant value in simulating reality. These results 
were generated using an α/β ratio of 1.5; should this value be proven inaccurate, 
these results will have to be reassessed.
In the CE analysis, we used randomized treatment allotment as a proxy for 
clinical practice; however, we were not able to compare the performance of the 
CE model to actual clinical practice. This is because there is no hard baseline and 
actual clinical practice can vary strongly between countries and even hospitals. 
However, in Supplementary Information S7.3, we do compare the performance 
of the CE model to simple clinical parameters, which, in clinical practice, could 
help determine treatment choice. In its current state, the DSS does not take 
into account patient preferences but uses average utility values obtained from a 
population. However, the risks of different types of toxicities are what often drive 
treatment decision-making, and patient preferences should be taken into account. 
Future versions of the DSS should allow patients’ input to affect the utility values 
of different toxicities and be integrated into iPDAs to allow for shared decision-
making[35,36]. This is especially true for the 15% of patients for whom the expected 
difference in QALYs is very low (<0.05 years).
A limitation of the reported CE analysis is that both the DSS and the CE model 
were based on the same state-transition model (committing a potential petitio 
principii fallacy). The differences between the two were that the DSS was based 
on the undiscounted deterministic run, while the CE model used discount rates 
for both QALYs and costs and was based on probabilistic simulations. The costs 
used in this study were based on the health costs in the Netherlands. One of the 
assumptions in the model was that if the patient had biochemical failure after 
primary treatment, no secondary treatment would take place, though, often, this 
is not the case. The health-state recurrence now has the same costs as a regular 
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follow-up, but with secondary treatment, these costs would be higher. However, 
when applying the model with higher costs for recurrence, matching them with 
the costs for metastatic disease, the cost-effectiveness was not impacted, so this 
assumption has no direct impact on our conclusions. For the application of the 
tool in other countries, the costs will be most complex to adapt. However, utility 
values are simpler to adjust to different countries, so it might be possible only 
to transfer the section of the tool that calculates QALYs, which already provides 
valuable information that can support decision making. However, it should be 
aspired to include the monetary calculations, as these play an increasingly large 
role in healthcare decision making.
Short-term future work includes merging this DSS with previously developed 
DSSs, including one where the effectiveness of an implantable rectum spacer is 
accessed on the patient level[37,38] as well as a DSS that compares photon to proton 
therapy. We also plan to expand the NTCP models by including single nucleotide 
polymorphisms and tumor somatic mutations to incorporate genetic information 
into the decision-making process[39].
Conclusion 
This study lays the groundwork for a detailed, personalized treatment DSS that 
aids in the choice between EBRT and RP for low to intermediate risk PCa patients. 
This DSS could be used for in silico clinical trials when applied to a synthetic dataset, 
which would be a valuable precursor to clinical trials. The results suggest that the 
full development and clinical application of this DSS would improve the quality of 
patient care as well as cost-effectiveness and would be an important step towards 
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Supplementary Information S7.1: Calculation of transition probabilities
Within the Markov model used for the decision support system (DSS), the health 
state “disease free” consists a number of sub-heath states, namely no toxicity, or any 
combination of three different toxicities: rectal bleeding, urinary incontinence and 
erectile dysfunction. From the models we have available the probability that a patient 
has one of three different toxicities after a certain amount of time, however we need 
to transfer this into transition probabilities within our model. To explain how these 
were calculated please refer to the diagram in Supplementary Figure S7.1 below.
Supplementary Figure S7.1: The transition probability diagram of the “Healthy” life state. 
T = all three toxicities; H = no toxicities; T1 = erectile dysfunction; T2 = rectal bleeding; 
T3 = urinary incontinence; T12 = erectile dysfunction and rectal bleeding; T13 = erectile 
dysfunction and urinary incontinence; T23 = rectal bleeding and urinary incontinence
This diagram represents patients treated with prostatectomy, as they have a 
probability to recover from toxicity, but they will never get a toxicity if they don’t 
have it initially. We now need to calculate the separate transition probabilities using 
the probability of a patient recovering from a certain toxicity. First, we convert the 
probability calculated from the nomograms to the probability per cycle.
P1     = probability of recovering from Erectile dysfunction per cycle
P2     = probability of recovering from Rectal bleeding per cycle




First, we will calculate the probability of going from all toxicities to any other 
health state, as shown in Supplementary Figure S7.2 below.
Supplementary Figure S7.2: A diagram showing the transition from all toxicities health state 
to all other health states
The probability of recovering from all three toxicities in one cycle can be 
obtained using the following relation:
The probability of recovering from two different toxicities can be calculated by 
multiplying the probability of recovering from either toxicity, subtracted by the 
probability of recovering from all three toxicities.
The probability of recovering from only one toxicity is equal to the total 
probability of recovering of that toxicity subtracted by the probability of recovering 
from that toxicity in combination with any other toxicity.
Next we want to calculate the state transition probabilities from a combination 
of two toxicities to healthy or to a single toxicity, as shown in Supplementary Figure 
S7.3 below.
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Supplementary Figure S7.3: A diagram showing the state transitions from any combination 
between two toxicities to the no toxicity health state and a single toxicity heath state
The transition probability of any combination of two toxicities two healthy is 
multiplication of the total probability of recovering of either toxicity:
The probability of recovering from one of the two toxicities is the total probability 
of recovering from that toxicity subtracted by the probability of recovering from 
both toxicities.
Finally, the most straightforward transition probability is the probability of 
recovering from a single toxicity, which is equal to the total probability of recovering 




Supplementary Figure S7.4: The diagram showing the transition from a single toxicity health 
states to the no toxicity heath state.
Therefore: 
For external beam radiotherapy, patients start without toxicity and develop late 
toxicity, so the equations are the opposite.
Supplementary Information S7.2: Utility values and costs for Markov model
An overview of the utility values, obtained from Steward et al. are shown in 
Supplementary Table S7.1.
Supplementary Table S7.1: Utility values used in the Markov model
State Expected value SD









Metastatic disease 0.25 0.11
ED: erectile dysfunction; UI: Urinary incontinence; RB: rectal bleeding; SD: standard deviation
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An overview of the costs are shown in Supplementary Table S7.2.
Supplementary Table S7.2: Costs used in the Markov model
Description Mean costs (€) SD (€)
Open prostatectomy 9780 978
Radiotherapy 8275 827.5
Mean costs per year (€) SD (€)
Follow-up (year 1-2) 511 30
Follow-up (year >2) 255 21
Add. costs erectile dysfunction 60 9
Add. costs urinary incontinence 303 21
Add. costs rectal bleeding 95 10
Recurrence 2535 212
Metastatic disease 2288 252
Castrate resistant metastasis 6493 313
SD = standard deviation
These values were obtained using the care product codes of the relevant 
treatments. We used the costs published on https://www.opendisdata.nl, and we 
used a standard deviation of 10% of the total costs of the treatment (Supplementary 
Table S7.3).
Supplementary Table S7.3: Treatment costs
Total costs Care product code
Radiotherapy € 8275 990061072, 990061014
Open Prostatectomy € 9780 20109012
Costs of treatments less than € 850 were extracted using the care product 
code and the tariff tool developed by CZ (https://www.cz.nl/service-en-contact/
zoek-tarieven). For post-treatment costs we assumed 4 consultations and prostate 
specific antigen (PSA) tests per anno in the first two years, and 2 per anno after 
that (Supplementary Table S7.4).
Supplementary Table S7.4: Post-treatment costs
Quantity p.a Price/unit Total costs Product code
Year 1-2 >2 1-2 >2
Consultation 4 2 € 122 (15) € 488 (30) € 244 (21) 20109088
PSA test 4 2 € 5,8 € 23,2 € 11,6 72621




Costs of medication was taken from a website, https://www.
farmacotherapeutischkompas.nl, that reports the costs of pharmaceutical 
healthcare. At the suspicion of biochemical failure or metastatic disease, a 
PSMA scan can be made. If recurrence has taken place, the patient can receive 
secondary localized treatment, or hormonal therapy. Once the patient progresses 
to castrate resistant metastatic disease, the patient is treated with chemotherapy 
(Supplementary Table S7.5).
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Supplementary Table S7.5: Costs metastatic disease
Quantity p. a Price/unit (SD) Total costs (SD) Product code
Consultation 4 € 122 (15)  € 488 (21) 20109088
LHRH agonist 
leuprorelin
4 € 450 (125)  € 1800 (250) 20109010
Docetaxel 6 € 721 (120)  € 4326 (294) 20109050 
Prednisolon 6 € 18  € 108
PSMA-scan 0,35 € 1060 (123)  € 371 (73) 120501
Zoledronic acid 4 € 422 (40)  € 1688 (80)
Total € 8781 (401)
SD: standard deviation; p.a; per anno
For the management of late erectile dysfunction, we assumed that half the 
patients use medication, 10% of the patients use cavernous injections and 5% use 
a vacuum pump. We estimated that medication or injections would be used on 
average once a month, and that the vacuum pump lasts two years (Supplementary 
Table S7.6).
Supplementary Table S7.6: Costs of the management of erectile dysfunction
Quantity p. a Price/unit Total costs
Sildenafil 6 € 6,83 (2) € 41 (5)
Cavernous injection 1,2 € 11,06 (3) € 13 (3)
Vacuum pump 0,025 € 235 (35) € 6 (6,5)
Total € 60 (9)
For the management of late urinary incontinence, we estimate that 
approximately three quarters of patients use physiotherapy, with 8 sessions per 
year. We estimate that 90% of the patients with urinary incontinence use pads 3 
times a day. We assume that 5% requires diapers once a day, and all patients who 
use diapers or pads require net trousers. It is estimated that 2,5% require drainage 
bags, of which they will require bed bags and leg bags (Supplementary Table S7.7). 
For the prices of medical products such as pads, net trousers and leg bags, we 
collected costs from different websites such as www.mediqcombicare.nl, www.




Supplementary Table S7.7: Costs of the management of urinary incontinence
Quantity p. a Price/unit Total costs
Physiotherapy 1 € 35 (0,6) € 35 (0,6)
Balloon catheter 0,05 € 12 (0,3) € 0,6 (0,07)
Pads 394 € 0,36 (1) € 142 (20)
Diapers  18 € 0,65 (0,08) € 11,7 (0,3)
Net trousers  0,95 € 1,25 (0,1) € 1,2 (0,1)
Bed bag, sterile  3 € 20 (0,7) € 60 (1,2)
Leg bag, sterile  1,3 € 40 (1) € 52 (1,1)
Total € 302,5 (21)
Rectal bleeding is mostly treated with low cost treatments such as medication, 
but a low percentage has severe rectal bleeding and needs to be treated with 
infrared coagulation or a coloscopy (Supplementary Table S7.8).
Supplementary Table S7.8: Costs of the management of rectal bleeding
Quantity p. a Price/unit Total costs Product code
Salofalk/ Arestal 36,5 € 1,13 (1) € 41 (6)  
Sclerosis, infrared 
coagulation
0,05 € 167 (3,8) € 8 (0,8)  35135
Intervention-coloscopy 0,05 € 469 (7) € 23,5 (1,6)  34697
Sigmoidoscopy 0,05 € 445 (34) € 22 (8)  34686
Total € 94,5 (10)
Supplementary Table S7.9: Distribution for the generation of synthetic dataset
Parameter name Distribution type Ref
Age (years) Normal µ = 60 σ = 10 [1-5]
PSA (ng/mL) Beta α = 4.17 β = 51.5 [1-5]
BMI (kg/m2) Normal µ = 28 σ = 3 [3-5]
T-stage Step T1 = 66% T2 = 34% [1,3-5]
neg. biopsy cores (N) Normal µ = 4.5 σ = 1.9 [2]
pos. biopsy cores (N) Half normal Location = 1 Scale = 2.46 [2]
P. Gleason grade Beta 4 = 14% 3 = 86% [1,3,4]
S. Gleason grade Step 4 = 19% 3 = 71% [2]
ADT given Step no = 22% yes = 78% [1,7]
ADT length Beta α = 0.125 β = 1.25 [1]
ASA score Step I/II = 18% III/IV = 82% [1,3]
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Nerve sparing Step no = 81% yes = 19% [4]
Abdominal surgery Step no = 90.3% yes = 9.7% [6]
HRQOL (%) Beta α = 1.5 β = 6 [5]
Membranous urethra length (mm) Normal µ = 12 σ = 3 [4]
Mean Trigone dose (Gy) Normal µ = 68 σ = 6 [3]
V75 rectum (%) Gamma location = 1 scale = 4 [6]
Ref: reference;  PSA: prostate specific antigen;    BMI: body mass index; T-stage: Tumor stage;  N 
neg.: number of negative;   N pos.: number of positive; P.: Primary;  S.: Secondary;   ADT: androgen 
deprivation therapy;   ASA: American Society of Anesthesiologists;   PN: Pelvic nodes;   HRQOL: 
sexual health-related quality of life;   V75: percentage receiving at least 75 Gray;    Gy = Gray
1. Warner A, Pickles T, Crook J, et al (2015) Development of ProCaRS Clinical Nomograms for Biochemical 
Failure-free Survival Following Either Low-Dose Rate Brachytherapy or Conventionally Fractionated 
External Beam Radiation Therapy for Localized Prostate Cancer. Cureus 7:e276
2. Bjartell A, Bottai M, Persson J, et al (2016) Prediction of clinical progression after radical prostatectomy 
in a nationwide population-based cohort. Scandinavian Journal of Urology 50:255–259
3. Schaake W, van der Schaaf A, van Dijk LV, et al (2018) Development of a prediction model for late 
urinary incontinence, hematuria, pain and voiding frequency among irradiated prostate cancer 
patients. PLoS One 13:e0197757
4. Matsushita K, Kent MT, Vickers AJ, et al (2015) Preoperative predictive model of recovery of urinary 
continence after radical prostatectomy. BJU Int 116:577–583
5. Alemozaffar M, Regan MM, Cooperberg MR, et al (2011) Prediction of erectile function following 
treatment for prostate cancer. JAMA 306:1205–1214
6. Valdagni R, Kattan MW, Rancati T, et al (2012) Is it time to tailor the prediction of radio-induced 
toxicity in prostate cancer patients? Building the first set of nomograms for late rectal syndrome. Int 




Supplementary Table S7.10: distribution of clinical parameters in synthetic dataset
Parameter name EBRT (SD) RP (SD) P
Age (years) 63.8 (10.7) 58.8 (9.1) <<0.001
PSA (ng/mL) 8.3 (3.5) 6.8 (3.5) <<0.001
BMI (kg/m2) 27.9 (2.9) 28.0 (3.0) 0.81
T-stage 2 (%) 48.7 24.4 <<0.001
neg. biopsy cores (N) 3.7 (1.8) 4.8 (1.8) <<0.001
pos. biopsy cores (N) 3.5 (1.7) 2.7 (1.4) <<0.001
P. Gleason grade 4 (%) 27.1 3.3 <<0.001
S. Gleason grade 4 (%) 14.7 20.9 0.01
ADT given (%) 79.8 0 <<0.001
ADT length (months) 19.0 (27.5) 0 <<0.001
ASA score >II (%) 86.2 78.9 0.003
Nerve sparing (%) 12.4 27.5 0.001
Abdominal surgery (%) 6.4 11.6 0.005
HRQOL (%) 82.9 (12.3) 76.9 (14.6) <<0.001
Membranous urethra length (mm) 11.8 (3.0) 12.1 (2.8) 0.04
Mean Trigone dose (Gy) 67.2 (6.0) 68.4 (5.7) 0.001
V75 rectum (%) 3.8 (3.9) 4.5 (4.6) 0.008
EBRT: external beam radiotherapy;   RP: radical prostatectomy;    SD: standard deviation;    PSA: 
prostate specific antigen;    BMI: body mass index; T-stage: Tumor stage;  N neg.: number of 
negative;   N pos.: number of positive; P.: Primary;  S.: Secondary;   ADT: androgen deprivation 
therapy;   ASA: American Society of Anesthesiologists;   PN: Pelvic nodes;   HRQOL: sexual health-
related quality of life;   V75: percentage receiving at least 75 Gray;    Gy = Gray
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Supplementary Table S7.11: Benchmark study including clinical parameters reported
Study Treatment [N] Parameters Outcome Value Model
Hamdy 
2016
EBRT [545] Age  (years) 
GS 7
T2PSA <10 






5 year BDFS 88.5% 89.0%
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5 year BDFS 86.8% 87.9%
Donovan 
2016
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N: number of patients; EBRT: external beam radiotherapy; RP: radical prostatectomy; BDFS: 
biological disease free survival; UI: urinary incontinence; ED: erectile dysfunction; RB: rectal 
bleeding; Gy: gray; GS: gleason score; PSA: prostate specific antigen in ng/ml; ADT: androgen 
deprivation therapy
Supplementary Information S7.3: Sensitivity and scenario analysis Cost-
effectiveness analysis
Univariate one-way sensitivity analyses were performed to examine the impact 




parameters are graphically represented in a tornado plot (Supplementary 
Figure S7.5). In the diagram we varied each parameter between the 2.5 and 
97.5 percentiles and calculated the resulting iNMB of the DSS compared to the 
randomized treatment allotment strategy. The most impactful parameter is the 
utility value of erectile dysfunction, but over the range of these parameters the 
iNMB of the DSS was still positive, and thus cost-effective when compared to the 
randomized strategy.
Supplementary Figure S7.5: This figure shows the impact of individual parameters on 
the incremental net monetary benefit of a decision support system versus randomized 
treatment. The vertical line represents the deterministic run. ED = erectile dysfunction; OR 
= odds ratio; BED = biologically effective dose; RB = rectal bleeding; HRQoL = health related 
quality of life
To test the robustness of the model results, we varied some key assumptions in 
the model, of which the results are shown in Supplementary Table S7.12. Over the 
different scenarios the DSS kept a high probability of being cost-effective.
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Supplementary Table S7.12: The results of the different scenario analyses




QALY diff (years) 
[95% CI]
P CE (%)
Discount rate 0% 1.5 [-2.9-5.9] -478 [-657--324] 0.15 [-0.01-0.29] 99.2
5% 1.5 [-2.9-5.9] -296 [-396--196] 0.09 [0.01-0.18] 99.8
10% 1.5 [-2.9-5.9] -200 [-265--135] 0.07 [0.00-0.13] 98.6
Dose plan1 2.5x28 1.8 [-3.6 -7.3] -614 [-1376--148] 0.09 [-0.22-0.41] 79.4
2x35 2.0 [-2.2-6.2] -147[-832-538] 0.19 [-0.19-0.56] 88.0
2x37 1.5 [-2.9-5.9] -308 [-425--192] 0.13 [0.01-0.25] 99.4
Time horizon 5 1.5 [-2.9-5.9] -78 [-106-50] 0.03 [-0.01-0.07] 97.2
10 1.5 [-2.9-5.9] -173[-229--117] 0.07 [-0.00-0.15] 99.2
15 1.5 [-2.9-5.9] -260 [-347--172] 0.09 [0.00-0.18] 99.0
50 1.5 [-2.9-5.9] -418 [-561--274] 0.17 [-0.00-0.35] 98.6
Costs DSS 20 1.5 [-2.9-5.9] -304 [-414--194] 0.12 [0.01-0.23] 99.6
100 1.5 [-2.9-5.9] -224 [-334--114] 0.17 [-0.0-0.33] 98.6
250 1.5 [-2.9-5.9] -74 [-184-26] 0.17 [-0.0-0.33] 99.4
500 1.5 [-2.9-5.9] 176 [66-286] 0.17 [-0.0-0.33] 99.4
CI = confidence interval; P = probability; EBRT = external beam radiotherapy; DSS = decision support 
system
1 Fraction dose x the number of fractions
Supplementary Figure S7.6: the cost-effectiveness acceptability curve (CEAC) comparing the 
randomized treatment allotment strategy to the full decision support system (DSS), and a 




To test the usefulness of our advanced DSS, we tested a simplified DSS using 
only three clinical parameters: age, t-stage, and PSA. The simplified DSS had a large 
probability (85.1%) of being cost-effective compared to the randomized treatment 
allotment strategy. However, compared to the original DSS, the simplified DSS 
only had a 16.3% chance of being cost-effective. We expanded the simplified DSS 
with three extra parameters, including primary Gleason score, diabetes and prior 
abdominal surgery, and found that this simplified DSS had a 89.1% probability of 
being cost-effective compared to the randomized strategy, so 4% better than the 3 
parameter DSS. However, this 6 parameter DSS still only outperforms the full DSS 











The focus of this thesis was on the development of clinical decision support 
systems (DSS) for the treatment selection for low-intermediate prostate cancer 
patients, a group of patients for whom a variety of treatments provide comparable 
outcomes in terms of (progression-free) survival but which vary in possible 
treatment related side-effects. The development of DSS is an important part of 
rapid learning healthcare, a process described in Chapter 1, and is a crucial step to 
bringing machine learning based models that predict outcome into clinical practice.
The overall aim of this thesis, as defined in Chapter 2, is as follows:
“Bridging the gap between machine learning based models and the decision 
making process through the development of clinical decision support systems for 
prostate cancer patients ”
This aim was subdivided into two objectives:
Objective 1: To provide an overview of decision support systems in prostate 
cancer treatment  
Objective 2: To develop and challenge new clinical decision support systems 
that aid in the treatment selection of prostate cancer both a) within 
the field of radiotherapy and b) multidisciplinary.
We defined a number of primary hypotheses for this work:
1. Image deformation can be used to create a CT scan of a patient with an implantable 
rectum spacer prior to implantation, allowing for dose comparisons.
2. A clinical decision support system can be used to identify patients for whom an 
implantable rectum spacer is beneficial prior to treatment.
3. The expected biochemical failure-free survival of patients can be improved when using 
an iso-toxic DSS to decide on the implantation of an implantable rectum spacer during 
external beam radiotherapy.
4. The expected quality of life and cost-effectiveness of patients can be improved when 
using a clinical decision support system to decide between external beam radiotherapy 
and prostatectomy for the treatment of prostate cancer.
In the sections below we will present a motivated view of the methods used 
in this thesis and how they worked towards meeting our objectives as well as our 
primary findings and how they reflect on our hypotheses. This will be followed 







In Chapter 3, we provide an overview of available literature concerning DSS for 
prostate cancer, which works towards addressing Objective 1. The DSS were split 
into three different types: diagnostic DSS, which were meant to support diagnosis 
of prostate cancer; treatment DSS, which were meant to aid in treatment selection; 
and patient decision aids (PDA), which were meant to aid decision making by the 
patient. In this chapter we found that DSS that support diagnosis and staging of 
prostate cancer were the most available type and had often been validated on large 
cohorts. Diagnostic DSS were found for assessing a variety of factors, including 
lymph node involvement, seminal vesical involvement, risk group, cancer stage, or 
extracapsular extension. DSS for treatment selection were less varied all focused 
around different types of external beam radiotherapy (EBRT), including proton 
versus photon therapy, stereotactic body radiotherapy versus intensity modulated 
radiotherapy and the use of rectum spacing devices during EBRT. As for PDA, this 
was shown to still be a very immature field of study with many challenges to be 
overcome, such as cultural and language barriers. However, the studies found do 
show that patients actively involved in the decision-making process experienced 
increased satisfaction and reduced anxiety and depression. 
Implantable rectum spacer
Over the years, the benefit of dose-escalation during external beam 
radiotherapy (EBRT) for prostate cancer has become more and more evident, 
resulting in higher cure-rates[1, 2], however, the dose to the anorectum is one of the 
primary limiting factors in this development, as this can result in long term damage 
leading to bleeding and increased frequency[1]. Rectum separation devices, such 
as the implantable rectum spacer (IRS), protect the rectum from high dose levels 
by creating a distance between the anterior rectal wall and radiated prostate[2]. 
However, since the placement of an IRS does not come without additional costs[3], 
possible risks and discomfort to the patient, and it has been proven not all patients 
stand to benefit from such a procedure[4], a DSS to select patients for whom this 
would have clinical benefit is an important development. Building, expanding 
and challenging such a DSS was the focus of Chapter 4, 5 and 6, and addressed 
Objective 2a.
Virtual spacer
One of the challenges faced when developing a DSS for an IRS is that, in contrary 
to other EBRT DSS, it is not as straightforward to compare treatment plans, since 
a CT scan of a patient with IRS will not be available prior to treatment. Hypothesis 




patient with an IRS prior to implantation, allowing for dose comparisons. This was 
done in Chapter 4 by developing a virtual IRS (V-IRS) in the form of a vector field 
obtained from a set of CT scans of patients with rectal balloon implants. This vector 
field could then be applied to a CT scan, thus obtaining a synthetic CT scan of a 
patient with an IRS, a V-IRS. 
Hypothesis 2  was that a DSS can be used to identify patients for whom an 
IRS is beneficial prior to treatment. We used the V-IRS as the basis for such a 
DSS comparing dose, probability of developing late rectal bleeding and cost-
effectiveness based on two RT treatment plans: one with and one without a spacer. 
We assessed the performance of the V-IRS by comparing the DSS outcomes to the 
outcomes when using a real CT scan of an IRS. The results showed that the V-IRS 
could not exactly replicate the real IRS results, but performed well in treatment 
classification: e.g. the real IRS and the V-IRS agreed in optimal treatment selection. 
The study presented in this chapter has several limitations. The first one is that 
the model was only tested in a proof of concept study including 16 patients, and 
though the results were promising, the V-IRS and the DSS should be validated on a 
larger cohort. The advantage of this initial test was, however, that it included both 
hydrogel based IRS’ and balloon implants, proving that the model had potential 
on both closed system IRS  (balloon implant) and on liquid IRS (hydrogel). Another 
limitation is that the model for late rectal bleeding is dated, trained on older EBRT 
dose and delivery technologies. The used regression model also becomes less 
accurate when the probability of late rectal bleeding becomes lower than 4%, 
which becomes problematic when applying it to the IRS, as in some cased the dose 
to the rectum is sufficiently reduced so that the risk of late rectal bleeding would 
be negligible. A significant barrier for the implementation of this DSS in clinical 
practice is the treatment planning step; in the study published in this chapter 
manual treatment planning was done for the CT without IRS, with V-IRS and with 
IRS, and in clinical practice this would result in a minimum of 2 treatment plans, 
and a maximum of 3. This does not facilitate a streamlined clinical workflow. 
Expanding the DSS
With the ever growing number of biomarkers predictive for treatment outcome 
being published, the chasm between scientific literature and clinical practice seems 
to be growing. Though the biomarkers could provide insight into patient specific 
treatment outcome, the number and the variety of them issues a new challenge. 
In Chapter 5, we proposed a method of bridging this chasm by incorporating 
published biomarkers, namely single nucleotide polymorphisms (SNPs) predictive 
for rectal toxicity into a Lyman Kutcher Burke (LKB) model[5], without having to 
retrain the model. This was done using a mathematical approach that utilized the 




method is that biomarkers could be combined into existing models without having 
to retrain these models from scratch. This circumvents the limitation of needing 
clinical trials for whom these biomarkers as well as all the other parameters of 
the existing model have been documented, as this might not be feasible. This 
could aid in preventing valuable published biomarkers from being underutilized 
in clinical practice[7, 8].
The assessment of this method was only limited in this chapter, however, as 
only SNPs were integrated into an LKB model, and the challenge of incorporating 
biomarkers into other commonly used types of models, such as Cox regression 
models or Random Forrest models were not tested. Also the success of this 
method was not tested through validation on clinical data, and only the potential 
benefit was discussed and possible applications were indicated.
The DSS described in Chapter 4 was an iso-dose model, where both treatment 
plans were made with the same target dose to the target volume, and the effect 
on rectal dose and toxicity was further compared. In Chapter 5 we adapted the IRS 
DSS to be iso-toxic, where we optimized the target dose to result in an acceptable 
risk of rectal toxicity. We did this by performing treatment planning, and then 
scaling the dose volume histograms (DVHs) of the prostate, the anorectum and 
the bladder to mimic increasing or decreasing target dose until the expected risk 
of late rectal bleeding was within the target limit, or until bladder dose restraints 
were exceeded. The DSS was also expanded to include tumor control probability 
(TCP), but the cost-effectiveness comparison was excluded from the scope of this 
chapter. 
One of the primary limitations of this method were that the full treatment plan 
was not remade after initial treatment planning, and only the DVH was scaled. 
This assumes that when increasing the target dose, the shape of the DVH to 
organs at risk does not significantly change, and only the magnitude varies. The 
cost-effectiveness comparison being dropped somewhat undermines the value of 
the original DSS as well. 
Challenging the V-IRS
In Chapter 6 we challenged the robustness of the V-IRS by assessing the impact 
of rectal spacer dynamics on rectum dose and complication risk. It was shown that 
the exact shape of the IRS is not crucial in terms of expected toxicity, implicating 
that as long as there is sufficient distance between the anorectum and the prostate, 
the V-IRS and real IRS would find similar reductions in risk of toxicity. 
The primary limitations of this study were that the aim was not to assess 
the robustness of the V-IRS, but rather to assess the impact of natural balloon 
shrinkage over the treatment period. This had as a consequence that the changes 




structural assessment of the impact of shape, size and placement location of the 
IRS was done.
Prostatectomy versus radiotherapy 
For the treatment of low to intermediate risk prostate cancer patients, the two 
primary choices for active treatment are EBRT and radical prostatectomy (RP). 
Studies have shown that these treatments have similar outcomes in terms of cure-
rate, but differ in types of toxicity and risk of toxicity. In Chapter 7 we developed 
an extensive DSS to predict the risk of recurrence, different combinations of 
treatment related toxicity, quality adjusted life-years (QALY’s), and costs for both 
types of treatment (Figure 8.1). Since EBRT and RP are different disciplinary fields, 
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The DSS described in Chapter 7 had a number of strengths, among which were 
that it translates the risks of different toxicity types as well as the risk of disease 
progression into a single number, QALYs. This allows for an easy comparison, and 
has the potential to improve decision making, as the numerous clinical parameters, 
disease properties and treatment characteristics are condensed into a much more 
limited number of factors. The extensive nature of the model also makes it very 
suitable for expansion, for example to include the IRS into the EBRT arm. Despite 
the DSS being fully model-based, validation on published clinical trials showed that 
the outcomes reported there could be replicated with a good degree of accuracy, 
despite all the assumptions having to be made. This implicates that it could provide 
relevant information when generally applied. Also, similar to the framework 
described in the DSS for an IRS, this DSS allows the models incorporated in its 
structure to be exchanged relatively easily, meaning that if different models are 
available locally, or newer models become available, these can be used to specify 
or update the DSS. Hypothesis 4 was that the expected quality of life and cost-
effectiveness of patients improved with the use of a DSS to select EBRT or RP as 
primary treatment. We tested this hypothesis by performing a cost-utility analysis 
that compared  a randomized treatment allotment strategy, or even a strategy 
using age, prostate specific antigen (PSA) and Gleason score, to the DSS. This 
showed that the DSS has the potential to not only improve health related outcome, 
but also reduce treatment costs. 
The primary shortcoming of this DSS was how clinical practice was simulated 
after disease progression, namely that secondary treatment was always hormone 
therapy or chemotherapy[9]. Moreover, for clinical practice, this version of the DSS 
is unpractical, as in total 23 clinical, disease and treatment characteristics need 
to be available, among which MRI results and dose parameters. Future research 
should focus on addressing these limitations.
“Synthetic patient data”
In order to do the validation of the DSS as well as perform the cost-utility analysis, 
we required a patient dataset for whom all clinical parameters were available. 
Since no such dataset was available to us, we generated a synthetic patient dataset 
where patients consisted of a set of clinical, treatment and disease characteristics 
representative for the population. These characteristics were generated by 
identifying distributions found in published clinical trials, which were then used to 
randomly generate patients. 
This method has some very significant benefits, first of which was that no actual 
patients were needed, and we were free to generate as many patients as needed. 




patient dataset were adjusted to match the parameters available for those trials, 
while parameters not made available were kept static. This made it possible to assess 
the accuracy of the DSS models without knowing all the available clinical parameters. 
The biggest limitation of this method was that it was assumed there was no 
interaction between the characteristics, which we know to be false. For example, 
age is correlated to pre-treatment sexual function, while this is not simulate in 
the synthetic patient dataset. Another limitation of this approach is that published 
clinical trials were used as a basis, while those are not representative of the actual 
population. Though this is not a limitation that affects our validation approach, it 
does limit the value of the results from the cost-utility analysis. 
Though this method should be improved though exploration of the interaction 
between clinical parameters, and the difference of parameters between the actual 
population and clinical trials, this method has a lot of potential, as demonstrated in 
the various applications for which it was used in this thesis. It is also an important 
step towards in silico clinical trials, which provide the opportunity to perform a “dry 
run” of a clinical trial prior to execution.
In silico clinical trial
Within the context of medicine, in silico refers to the direct use of computer 
simulations in simulating real biological processes. An in silico clinical trial consists 
of developing virtual cohorts to develop or evaluate a medicine or intervention. 
In Chapter 7 we combined the use of the previously described synthetic patient 
dataset with the models compiled in our DSS to develop an in silico clinical trial. The 
trial we designed was to compare the costs and effects of treating an elderly patient 
population (aged 75-80)  with RP, EBRT or with a DSS based treatment allotment 
strategy. The results showed that for 72% of the elderly patients, the DSS advised 
EBRT as the optimal treatment strategy. 
The limitations of the study described here is the limited application; we only 
applied this for a single patient population. However, our success in replicating 
published clinical trials suggests that within the restraints of the synthetic patient 
dataset, valuable information could be provided for sub-sets of patient groups. 
Implications for research and practice
The work presented in this thesis has been done in order to improve the decision 
making process for prostate cancer patients using biomarkers and machine learning 
models. Specifically, the different objectives were set up to either aid in overcoming 
challenges or contributing to the volume of available technologies. 
Within this thesis we proposed two different DSS: one for the placement of an 
IRS during EBRT, and one to compare RP and EBRT. The strengths of these DSS was 




comparisons in relevant dose metrics for both the target volume and the organs 
at risk, comparisons in cure rate and toxicities and providing a cost-effectiveness 
analysis. For both of these DSS existing predictive models were used to assess outcome 
in terms of progression free survival after treatment and risk of treatment related 
toxicity. One of the challenges doctors who want to use machine learning trained 
models are currently faced with is that new machine learning models are constantly 
being published. The quantity and varying quality of these models makes it difficult 
for them to be applied effectively in clinical practice, leading to many valuable models 
being underutilized. Using a DSS as proposed in this work, the selection and curation 
of clinically relevant prediction models has already been done and the clinical 
implications of these models is put into perspective through treatment comparisons 
and translation to QALYs. This holds especially true when external validation has 
been performed of the combination of these models. The way this DSS is developed 
offers the opportunity to replace these with more clinically relevant models as they 
become available, or as local clinical practice requires, which prevents the DSS from 
having to become outdated. Protocols should be followed to ensure that the models 
are applied correctly and that a certain quality is upheld. The work presented here 
offers platform that could function a bridge between literature and clinical practice 
through a comfortable and flexible structure. It could potentially offer clinicians a 
preselection of refined and combined models and biomarkers with a tool that aids 
them in optimized application of those models and biomarkers. Further evolution of 
this tool in replacing outdated models or including new biomarkers should be done 
using approved tools and checklists such as the CHARMS (critical appraisal and data 
extraction for systematic reviews of prediction modelling studies) checklist[10], or the 
PROBAST (prediction model risk of bias assessment tool)[11] for proper curation and 
selection. This fits into our primary aim for our thesis in bridging the gap between 
machine learning models and individualized decision making.
In order to fit a variety of different machine learning models into a single 
framework, we applied a number of creative methods. The first step was to find 
relevant models that predict similar outcomes for different treatment types: e.g. we 
needed models to predict the risk of biochemical failure for both RP and EBRT, and 
the same with different toxicities. Not all models were published in a way that made 
them easily applicable, for instance, many models are published only as nomograms, 
and did not have the complete regression coefficients available in the paper. Using 
reverse engineering we extracted these coefficients from the nomogram. These 
models often predict the risk of developing an event after certain amount of time, 
for example the risk of developing biochemical failure 5 years after treatment. For 
some outcomes, this time period was different between the two treatment arms. In 
order to be able to make a long term comparison, a number of assumptions were 




directly after treatment, and the rate at which the risk changes over time. These 
assumptions were gathered from literature and applied to each model, and in this 
work we showed that despite being rough assumptions and interpolations, the 
trends followed clinical trial results moderately well. 
In order to test our DSS for RP and EBRT, we developed a method of generating 
synthetic data. This has some interesting implications for research, as one of the 
challenges within medical research is obtaining large quantities of patient data. This is 
hampered by a number of factors, such as reluctance to share data (for example due 
to publication pressure or competing research), ensuring patient privacy in keeping 
with the general data protection regulation (GDPR) and monetary motivations. 
Clinical trials often provide a limited perspective of the patient population, as a 
large number of patients falls outside of inclusion criteria. Through our method of 
generating synthetic patients, we provide an aid in overcoming this challenge[12, 13]. 
By resampling patient characteristics, it could be possible to completely synthesize 
patient populations and provide an alternative when sharing real data is not 
feasible. For this to be done well, it is recommended that correlation between 
clinical parameters and to outcome is carefully analyzed and taken into account. 
Another challenge is obtaining enough data of underrepresented sub-populations. 
This method could be used for data augmentation to increase the volume of these 
sub-groups. Such a method could be useful for example in the use of in-vitro clinical 
trials, as proposed in this thesis, as well as for cost-utility modeling. This could be 
used to assess the potential benefit of a medical procedure prior to clinical trials 
or aid in optimizing clinical trial design. An example would be to predict possible 
outcomes for sub-populations, which could be useful information when determining 
the inclusion criteria, or to assess which clinical parameters are likely to be clinically 
relevant. It could also aid in optimizing the desired study size with respect to the goal 
of the clinical trial. It could also be used to add onto clinical trial results in the form 
of data augmentation to improve heterogeneity of the population. 
Future perspectives
Some very important steps towards the facilitation of RLHC have been made in 
this thesis, and the groundwork has been laid for future developments as well. 
In Chapter 3  we found that that especially regarding DSS for treatment selection 
a large literature gap exists. Also the development of PDAs appear to be in an early 
phase but show promise. 
In Chapter 4 we developed a V-IRS as the basis for a DSS. Before this DSS would 
be applicable in clinical practice, additional work needs to be done. The V-IRS would 
have to be critically analyzed through validation on a larger scale. Also, the method 
of applying the V-IRS, which is currently an arbitrarily chosen vector field should 




field or a finite element based model[14]. The models included in the DSS should 
be updated and expanded to include tumor control probability, cancer specific 
survival, and perhaps erectile dysfunction models, as studies have suggested that 
the IRS can impact this as well[15]. An automatic treatment planning step would aid 
in streamlining the clinical integration as well[16, 17]. The automatically generated 
treatment plan would not have to be used for the final treatment strategy, but could 
function to make a fast, fair comparison between the diagnostic CT and the synthetic 
V-IRS CT. 
In Chapter 5 we expanded this DSS with additional biomarkers and by making 
the treatment selection strategy iso-toxic rather than iso-dose, but this chapter 
did not include a cost-utility analysis. An important next step for the improvement 
of this DSS would be to include a cost-effectiveness analysis, which would have to 
include treatment costs, and utility values and costs for follow-up treatment after 
recurrence. This difference with the iso-dose model arises because in the iso-dose 
model it can be assumed that the probability of biochemical failure is the same in 
both treatment arms, and thus this health state was omitted. Also, if dose escalation 
would be done by increasing the number of fractions, differences in treatment costs 
may arise. An improvement for the model would also be to include an automated 
treatment planning algorithm, as discussed before. This is even more important 
here, as this would allow the final comparison to be based on properly generated 
treatment plans, rather than scaled DVHs. Also, the method of including biomarkers 
should be tested on multiple types of machine learning based models, such as cox 
regression and random forest, and different methods should be explored. Methodical 
validation of these methods is vitally important before implementation on clinically 
applied models.
Chapter 6 challenged the robustness of the V-IRS by assessing impact of IRS 
dynamics on rectal toxicity. Though initial results are promising, a more extensive 
sensitivity analysis should be performed to assess the robustness of the V-IRS in 
terms of placement and shape. Also the impact on tumor control probability and the 
bladder toxicity should be taken into this analysis.
In Chapter 7 we developed a DSS for the treatment of prostate cancer with EBRT 
or RP. Direct future works would be to merge this DSS with the IRS DSS and expand 
to include different treatment modalities. This chapter also described a synthetic 
dataset. This concept should be further explored and validated. The in silico 
clinical trial that was done based on the synthetic dataset showed potential, but 
the application in this chapter was limited. Future works should include developing 
more in silico clinical trials, and replicating existing clinical trials for validation.




Improvement and expansion current models
This thesis developed models for the IRS during EBRT, and made a comparison 
between EBRT and RP, however, other viable treatment options should be imbedded 
into these DSS in the future. 
Brachytherapy is another active treatment that is being applied for prostate 
cancer with high success rates, and more models are becoming available that predict 
both outcome and toxicity, making it an excellent candidate for incorporation into 
this DSS[18-20]. The advantage of brachytherapy compared to EBRT is that the risk 
of rectal toxicity is much lower due to no additional treatment planning margins 
being needed to account for uncertainty, while applying higher doses to the region 
of interest. Also, the treatment is delivered in a single day, with no recovery time, 
as opposed to multiple treatments over a longer period of time. The disadvantage 
is that the risk of urinary toxicity is higher, and the patient will require anesthesia. 
Despite brachytherapy being a radiation based treatment, rectum spacing devices 
have less impact combined with brachytherapy as primary treatment, reducing 
mostly grade 1 rectal toxicity. However, studies have shown that during re-
irradiation some patients would stand to benefit from additional rectum spacing[21, 
22]. When the DSS is expanded to include follow-up treatment, the IRS could be 
included as an additional treatment option within the brachytherapy arm. 
Another treatment decision that needs to be made, in particular for low-
risk prostate cancer patients, is whether to use an active treatment or not. 
Active surveillance is gaining popularity as a viable treatment option, but is not 
without risks[23, 24]. The distinct advantage of active surveillance is that there are 
not treatment-related side effects, but the disadvantage is that there is a risk of 
progression. Patient selection for this passive treatment option is therefore very 
important in order not to reduce patient outcome while reducing treatment 
related side-effects from active treatment. The patient specific risk of progression 
during surveillance would be a critical model in order to expand the DSS with this 
treatment option. Also, follow-up treatment would have to be incorporated in 
case of progression, taking into account different active treatment options and the 
different treatment related side-effects. 
In addition to expansion, the DSS for the IRS and the DSS for EBRT versus RP 
should be combined into a single framework. This integration will be seamless 
once automatic treatment planning is incorporated into the former. 
The methods with which the DSS were developed used machine learning 
models published in literature and combined these into a single framework. In 
order to create a proper comparison and obtain transition probabilities for a 
Markov model to calculate the QALYs, assumptions were made and interpolation 
and extrapolation was done over time. Also, a number of models were only 




engineering. This approach worked well for the scope of this thesis, however it 
is a sub-optimal approach. For the development of DSS using literature reported 
models, ideally all details of the models should be reported in publications, or 
even better, access to the data where the models were trained on. Adherence 
to the “Transparent reporting of a multivariable prediction model for individual 
prognosis or diagnosis” (TRIPOD) statement would aid in former of these solutions. 
The latter is a more complex matter, but the idea of Open Data[25] and adhering 
to the guidelines written to improve Findability, Accessibility, Interoperability, and 
Reuse (FAIR) of digital assets[26] would make future curation and combination of 
these models more reliable.
Integration current models to clinical practice
One of the large challenges this DSS will have to overcome is integration into 
clinical practice. Currently, the DSS presented in this thesis are not in a form ready 
for use by medical professionals, as they lack (external) validation, a proper user 
interface and certification from a regulatory body. 
Prior to integration into the clinic, proper validation needs to be done of the 
DSS after the developments in the previous section have been completed. Since 
the models incorporated in the DSS should already be validated, it is the tool as a 
whole that should be subjected to multi-centric and international validation, where 
both doctors and patients should have the possibility to provide feedback on the 
additional value the DSS provides in the decision making process. 
Currently the DSS exist only in the form of equations implemented in raw code. 
An important step that needs to be done is to create an intuitive, easy to use user 
interface that connects the target user to the framework. This should be both for 
regular application, e.g. support of treatment decision making, as well as for the 
selection of local models to embed into the DSS. 
For this to be effective, it is crucial that the DSS is further developed in cooperation 
with clinical experts who can provide feedback on the needs of clinical practice. 
This will provide valuable feedback and prevent unusable technologies from being 
developed. This should be followed by try-outs in the form of prototypes that are 
offered to partnered hospitals or clinics in order to provide validation results. 
Finally, the DSS should be subjected to proper certification, such as CE marking or 
FDA approval, to ensure safe usage and confidence from medical professionals. Once 
the model is determined to be clinically relevant and safe for use, clinical integration 
needs to take place. This will require a number of steps[27], such as training medical 
professionals to effectively apply the DSS, develop a positive attitude and confidence 
towards the DSS from the clinic, set-up try-outs if clinical integration followed by full 
integration. The software should be maintained and the models will have to be kept 





The DSS presented in this thesis have the aim of aiding the clinical professional 
in the decision-making process for the treatment of prostate cancer (PCa) patients. 
Although there is evidence that these DSS have the potential to improve patient 
quality of life (QoL) and reduce costs, it remains true that for a large group of 
patients, multiple treatment options have similar outcome[28]. For this group 
of patients, personal preferences, patient background and life-style come to 
dominate which treatment is the best fit. In these cases, shared-decision making 
(SDM) is a beneficial extension to the clinical decision-making process[29, 30]. 
In order to implement SDM, a number of challenges need to be overcome, of 
which the first one is informing the patient. In order to fully involve the patient in 
the decision for his treatment, he needs to be aware of the different treatment 
options for which he is eligible, and what the risks and benefits of each of these 
are. Unfortunately regular consultations are not sufficient for the transference of 
this information, as has been shown in previous studies[31]. This can result in under-
informed decisions which impact QoL, or a biased decision due to the limited 
knowledge of specialists (urologist, radiologist) within the multi-disciplinary field 
of PCa[32]. Patient decision aids (PDAs) could be a way of addressing this issue. 
Using PDAs, the patient can receive both high level and in depth information 
regarding different treatment options considering procedure, outcomes and side-
effects, including side by side comparisons. This information can be presented in 
an accessible way and is not limited to the short consultation times that clinical 
professionals can offer. 
This potential in PDAs has been recognized, and tools have previously been 
developed to provide the patient with additional information regarding treatment 
decision-making[33-35]. However, these do not take into account patient specific 
characteristics and do not aid in personalized decision-making, rather focusing 
on informed decision making. To further capitalize on the platform provided by 
PDAs, they could combined with predictive models, similar to the previously 
discussed DSS, and provide individualized outcome predictions. PDA’s would be 
the patient version of the DSS and could stand to benefit from a link between 
these two platforms. Using the DSS, the clinician could select patient specific 
treatment options (e.g. treatments for which the patient is eligible) and use the 
clinical, disease and treatment parameters to calculate personalized outcome 
probabilities (Figure 8.2). This information could then be presented to the patient 
through the interface of the PDA in an understandable and interpretable manner. 
This could improve the effectiveness of patient-doctor consults as well as better 
inform the patient and empower him in the decision making process without 




This presents two different challenges for this to be achieved: how to 
communicate the results of the DSS to the patient clearly without possible 
misinterpretation, and how to take into account patient preferences to affect 
the DSS results. The results of a DSS have large uncertainties and the models 
incorporated are often based on clinical trials, which may not be representative 
for the patient. A medical professional has the skills and knowledge to properly 
interpret these results and apply them accordingly, but a patient might not. This 
is why it is crucial to consider how to present these results to a patient. A possible 
solution could be to indicate a risk level for certain comorbidities or cancer free 
survival, rather than exact risk levels. 
The second challenge arises due to the way the impact on the quality of life a 
certain comorbidity has, expressed in utility values, is averaged over a population, 
and thus might not reflect a specific patient. A possible solution to this issue could 
be to allow the patient to indicate impact of certain comorbidities on his perceived 
quality of life, and scale the utility values accordingly.






The aim of this thesis was to bridge the gap between machine learning based 
models and the decision making process through the development of DSS for 
prostate cancer patients. We made the first steps towards meeting this aim by 
developing two new DSS. We discussed different challenges and methods to 
develop and apply these DSS and challenged their robustness and clinical benefit. 
The results implicate that the application of these DSS has the potential to 
increase effectivity and reduce treatment related toxicity. Although the models 
and frameworks presented require external validation, expansion and refinement 
before being ready for clinical practice, this work facilitates some important steps 
towards bringing the gap between machine learning models towards tailored 
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Prostate cancer (PCa) is the second most commonly diagnosed cancer for 
men, and therefor forms a topic of significant research interest. Especially low-
intermediate risk PCa, which forms 40% of the newly diagnosed PCa, has a variety 
of viable treatment options. The options include passive treatments such as active 
surveillance, and active treatments such as radiotherapy and prostatectomy. Within 
treatment types there are still a number of options, such as within radiotherapy 
the choice exists between brachytherapy or external beam radiotherapy (EBRT), 
and additional options, such as hormonal therapy or rectum sparing devices can 
be considered. This, combined with an increasing number of biomarkers make that 
PCa is an excellent candidate for improvement via personalized medicine.
The importance of personalized medicine has become progressively evident 
over the past few years, focusing on patient variations, outcome predictions 
and patient preferences. An important step towards personalized PCa treatment 
would be a clinical decision support system (DSS), that aids optimizing treatment 
selection. DSS are typically software applications such as recursive partitioning 
analyses models, nomograms or websites such as https://www.ai4cancer.ai. A DSS 
is used to support the groups responsible for deciding on patient treatment, such 
as the physician, the tumor board and the patient, in making a knowledgeable 
decision regarding treatment options. The development of such DSS was the 
primary focus of this thesis.
In Chapter 3 we provided an overview of existing literature on the topic of DSS 
in the field of PCa. It was found that a large number of diagnosis and staging DSS 
are becoming available as well as tools that improve cancer detection, predicting 
treatment outcome and outcome stratifications. However, limited DSS for treatment 
selection were found in this literature study, which were mostly centered around 
EBRT. A lack of DSS for other treatment modalities suggests that the development 
of new tools are necessary to compare objectively different treatment modalities. 
Additionally, the field of patient informed decision-making is still in its infancy, but 
essential for the growth towards individualized medicine. 
Other chapters in this work focus on developing, improving and challenging 
treatment DSS both within the field of EBRT, as well as interdisciplinary comparisons.
Chapter 4 describes the development of a Virtual Implantable Rectum Spacer 
(V-IRS) that can be used to support the decision for the implantation of an 
implantable rectum spacer (IRS) for a specified patient or not. An IRS is a device 
(such as a hydrogel or a biodegradable balloon implant) that is placed between 
the anorectum wall and the prostate prior to the start of EBRT. This device spares 
the rectum from high dose levels and reduces the risk of long term treatment 




scan of a patient to render a virtual CT scan of the same patient with a V-IRS. The 
advantage of this method is that a CT of a patient with an IRS can be generated 
and made available for treatment planning purposes without the real implantation 
of the IRS itself. Moreover, we used this method to develop a DSS that, instead of 
only looking at the improved dose reduction by implanting the IRS, also calculated 
the toxicity risk reduction and the cost-effectiveness (CE) for comparison. This 
allows for a decision based not only on dose reduction, but also on the health 
gain and the costs associated with the health gain.  We tested this V-IRS in the 
following manner: we generated virtual CT scans and performed dose planning on 
these. We then calculated relevant dose metrics, toxicity risk and performed a CE 
analysis. This was repeated on  CT scans of the same patients with a real IRS, and 
the results were compared to those of the virtual CTs. The V-IRS resulted in the 
same classification (place an IRS or don’t place an IRS) as the real IRS.
In this study we found that the implantation of an IRS is not cost-effective for 
all patients, but does provide significant benefit for some, so individual patient 
assessment could improve the quality of care. We concluded that the V-IRS 
approach in combination with a toxicity model and a CE analysis can serve as the 
basis for a decision support system for the implantation of either a hydrogel IRS or 
a rectum balloon implant.
To expand on the DSS described in the previous chapter, in Chapter 5 we 
developed an isotoxic method integrating genetic markers of rectal radio-sensitivity 
combined to integrate into this DSS. The method calculates the maximum dose per 
fraction that can be given without exceeding an upfront determined limit for the 
risk of toxicity, rather than calculating the risk of toxicity resulting from a given dose.
The results show that a higher prescribed dose should be given to improve 
tumor control, and can be safely administered when combined with an IRS. 
The isotoxic model integrating genetic markers for rectal toxicity developed in 
this study can be used to evaluate a treatment plan, and test how much dose can 
be given without causing excessive damage to the rectum. Thus sparing the organs 
at risk at a chosen described level while optimizing the TCP. In combination with the 
V-IRS, this method can serve as the basis for a DSS for the implantation of an IRS.
One type of IRS is the saline-filled biodegradable balloon implant. Chapter 6 
provides an evaluation of the balloon volume stability that is based on weekly 
cone-beam CT measurements during the full course of EBRT, because a RBI volume 
decrease can be expected over time. In this study, we analyzed the dosimetric 
consequences of this phenomenon and predicted the increase in risk of late rectal 
bleeding (LRB) resulting from a shrinking balloon implant to assess its potential clinical 




neither significant increase in absolute volume or the anorectum receiving at least 75 
Gy, nor in predicted LRB risk were observed over the full treatment course. Only when 
the prostate-rectum distance decreased to under 1 cm a treatment plan adaptation 
would be advisable. The advantage of this work with relation to the previous chapters 
is that it shows that the exact shape of the V-IRS is not crucial to proper classification 
considering treatment advice. This is important as the exact shape and position of both 
the anorectum and the IRS are difficult to accurately predict from a single CT scan.
In Chapter 7 we developed an interdisciplinary DSS, which would aid in the 
treatment selection of either EBRT or radical prostatectomy (RP) and tested this on 
a synthetic patient dataset. We validated the DSS against published clinical studies 
and set up an in silico trial for patients between 75 and 80, eligible for both RP 
and EBRT. We also assessed the CE of a treatment allotment strategy based on the 
DSS compared to a randomized treatment allotment strategy. Our first hypothesis 
was that we could accurately replicate results from published studies, which we 
aimed to confirm by generating synthetic datasets with clinical parameters similar 
to published trials. The DSS largely replicated the published results accurately. 
The relative differences between the treatment modalities and fractionation plans 
were replicated by the model, and the conclusions of the DSS and the studies 
agreed. We also performed an in silico trial using the DSS, exclusively including 
elderly patients both without and with prior ED and found that for the first group 
EBRT was preferred, and for the second RP performed better in terms of QALYs. 
Additionally, we hypothesized that a treatment selection strategy based on the 
DSS would improve tumor control, reduce toxicity, and improve CE as opposed 
to randomized treatment selection. Our CE analyses suggest that not only do the 
costs of treatment decrease with the application of a DSS, but the number of QALYs 
also increases, making the integration of a DSS dominantly cost-effective compared 
to current clinical practice. The expected cost savings within the Netherlands 
when using a DSS could be as high as EUR 3.8 million ‬over five years, assuming 
2400 patients are affected every year. Additionally, the number of patients with 
recurrence after treatment could be reduced slightly by 2%.
This chapter lays the groundwork for a detailed, personalized treatment DSS that 
aids in the choice between EBRT and RP for low to intermediate risk PCa patients. 
This DSS could be used for in silico clinical trials when applied to a synthetic dataset, 
which would be a valuable precursor to clinical trials. 
Chapter 8 provides a general discussion and future perspectives, which is closed 
with a concluding message. It is discussed that one strength of this thesis is that it 
lays the groundwork for an extensive DSS for treatment selection for PCa. A variety 




new biomarkers into existing models, the use of synthetic patient datasets, and in 
silico clinical trials, all of which could aid in the development of future DSS. 
Future works should include the improvement, optimization and validation 
of the DSS developed in this thesis. It is also advisable to combine the IRS DSS 
and the EBRT versus RP DSS into a single framework and expand this with other 
treatment modalities such as watchful waiting and brachytherapy. Finally, the 
next step towards personalized treatment for PCa would be to combine the DSS 
framework with a patient decision aid, so that patient preferences would provide 
valuable input to the DSS and the DSS could be used to customize information for 









Social relevance and target groups
Prostate cancer is a very common cancer type, and although mortality rates 
are low, it touches the lives of a large number of men. This disease has a range of 
viable treatment options and a large number of clinical parameters and biomarkers 
predictive for the primary outcome of these treatments, as well as treatment related 
side effects. Ideally these factors should therefore guide optimized treatment 
selection. In practice, however, this is rarely applied and treatment selection is 
often based on factors largely unrelated to the patients clinical characteristics and 
treatment outcomes. 
Both previously published studies and the research done in this thesis suggest 
that the quality of life of prostate cancer patients has the potential to be improved 
through personalized treatment selection. This, combined with the large number 
of patients diagnosed every year, effectuates optimized treatment selection would 
have large social impact. 
The primary aim of this thesis was to combine existing models predictive of 
treatment outcome and published biomarkers into clinical decision support 
systems in order to bridge the gap between literature and clinical practice. This 
has as an advantage that the large number of clinical factors such as disease 
parameters, treatment parameters, patient characteristics and genetic markers 
could be condensed into an easy to handle number of factors, such as expected 
cure rate, risk of treatment related side-effects and cost-effectiveness. Since the 
human cognitive ability is limited, and only a number attributes can be recalled 
during decision making, this condensation of information would streamline the 
decision making process. Therefore not only the patient is ultimately benefited by 
the application of such tools, but clinical professionals will be empowered during 
treatment selection as well.
Primary findings and products
The primary output of the work presented in this thesis are the methodologies 
and algorithms that form the basis of the developed decision support systems. All 
the studies published in this thesis suggest that the application of these models in 
a clinical environment has the potential to improve the quality of life of patients, 
often providing monetary value, which underscores the advantage of the developed 
decision support systems. 
The methodologies have been published and described in great detail, sufficient 
for anyone with access to the publications to replicate the work that was done. This 
makes it possible for the methods used to be applied in other projects, either for 
different ends or to follow-up the work that was published.
In addition to the descriptions of model parameters and methods, the code written 




this thesis were made available on GitHub, so that they may be applied, reused, 
adapted and improved in future projects. The models as a whole will also be made 
available on a public platform currently under construction.
Innovation 
The platform that forms the basis of all the decision support systems presented 
in this thesis incorporate different models and combine them in a single application. 
Models eligible for integration are those that predict outcome or toxicity, dose 
metrics or cost-utility. From a scientific point of view this is beneficial as the 
methods described combine separate instances of previously published models 
and biomarkers and provides a bridge for them to be directly applied towards the 
benefit of the clinical professional and the patient. This improves the prospects 
with respect to the usefulness and impact of valuable scientific research. To our 
knowledge, our methods are the first within the field of prostate cancer that work 
to actively selecting, refining and adapting existing knowledge towards clinical 
benefit in such a manner.
As mentioned before, the methodologies and code have been made available 
for further use. Especially the Markov model described in Chapter 7 was developed 
and described in great detail, including transition probabilities to a large number 
of health states and detailed descriptions of treatment costs. This information can 
prove invaluable for other researchers looking to build a cost-effectiveness model 
concerning the primary treatment of prostate cancer, as many of these model 
parameters can be recycled, which would streamline and simplify this part of the 
work for future researchers. 
The method for generating synthetic patients is an emerging field, and has to 
potential to be useful to validate newly developed models against published clinical 
trials, even when available patient and treatment parameters are incomplete, such 
as was done in Chapter 7. This allows for relatively cheap and fast testing of models 
prior to (and potentially to inform) setting up expensive and time consuming 
retrospective or prospective clinical trials. Similarly, the in silico trial is a possible 
application of the synthetic patient datasets. An in silico trial could be used to test 
new methods or technologies, as well as to gain insight into underrepresented 
patient populations. The information gained from this could be used to better 
prepare prospective or retrospective clinical trials prior to investing the time and 
expenses required of such a project. This could result in better designed clinical 
trials and possibly preventing waste in the form of effort, time and money.
Implementation
As discussed in the general discussion of this thesis, the developed decision 




validation before further steps can be made toward introducing them into clinical 
practice. Projects have already been set up for these developments, one of which 
with the particular aim of including active surveillance into the framework and 
validation on a patient cohort through a clinical trial. In parallel, work is being done 
to adapt the framework presented here into a personalized patient decision aid.
When these important developments have taken place, the framework could 
be properly developed into a software application that would be suitable for 
commercial use. This development should take place with close cooperation 
between the developing party (such as a company or a research group) and 
the potential end users (clinical professionals). This final product could then 
be subjected to regulatory bodies and presented to hospitals and clinics. This 
would make the technologies developed in this work available to the end user 
(the medical professional) and the target group (prostate cancer patients) and 





As I am putting the finishing touches on my dissertation, I am looking upon my work 
with no small degree of satisfaction. It has been a long road, and by no means an easy 
one, but I am happy I took it. This reflection brings to mind the large group of people 
who aided in my achievements, helped pave this road or ease the way for me, and this 
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colleagues, which helped me shape my work into its final form. Dr. Seán Walsh 
provided me with some much needed guidance during the start of my PhD years, 
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So thank you very much for the pleasant welcome. Later, the task of gently directing 
me along the correct course of my PhD fell upon dr. Cary Oberije. Thank you, Cary, for 
helping me through some tough challenges and for the pleasant trip we shared to MD 
Anderson. Another strong influence on my work through supervision, brainstorming 
sessions and general expertise was dr. Henry Woodruff, who helped me in writing one 
of my toughest papers during one of the more difficult years of my PhD. Thank you for 
your patience and constant support.
I am also very grateful to some of the key contributors to my work. Iva Halilaj strongly 




Dekker provided me with early inspirations and idea’s for my first paper, dr. Arthur 
Jochems who helped ensure the quality of my coding, and all other co-authors who 
provided valuable feedback to my work over the years. 
For a large project I really enjoyed working together with dr. Marc Lobbes. This 
collaboration was really insightful to me, especially since this gave me the opportunity 
to see the patients we were trying to help. Together with dr. Henry Woodruff, Yousif 
Widaatalla, Renée Granzier and Manon Beuque, this was a great team to be a part of.
The contribution of two people cannot be overstated when considering the logistics 
of publishing papers, submitting for grants, attending conferences and obtaining a 
PhD: Rianne Herben and Floor Franssen. For any and all questions relating to these 
matters, these two people were sources of information, help and effort, and for this I 
extend my sincere thanks to them. 
Aside from professional collaborations and input, a pleasant work environment can 
make the challenging years one spends on obtaining a PhD a satisfying and enriching 
experience. The group of people I found myself working with changed over the years, 
but was constantly agreeable, welcoming and engaging. For me it was often exhausting 
to make the trip between Eindhoven and Maastricht, but luckily I had this team of 
colleagues who were worth the trip. Evelyn, you were one of the first people who 
welcomed me to the D-lab and made me feel comfortable as a colleague, and your 
kind and empathetic character is something I was very grateful for. Iva, thank you for 
being my friend and being such excellent company during the second half of my PhD. I 
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Relinde, Elizaveta and Martha, my other roommates, thank you for making the trip to 
Maastricht worth it, I already miss sharing a room with you. Sergey, Yousif, Esma and 
Henry I would in particular like to thank for the pleasant conversations during parties 
and coffee breaks and lunches. Cary, Timo, Ralph and Janita, thanks for making my 
first two trips abroad for work a lot easier and less daunting, you were great traveling 
companions. And of course a big thanks to all my other colleagues who have come 
and gone and made these past few years as pleasant as they were: Abdalla, Alberto, 
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Professional support from supervisors, collaborators and colleagues is invaluable 
during the completion of a PhD, but the support I felt from the personal side of my 
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2016-2021 PhD Student at Department of Radiotherapy (Precision 
Medicine, D-lab)
Thesis subject: Development of decision support tools for 
prostate cancer patients, focusing on radiation therapy.
University of 
Maastricht
2013-2015 Master Biomedical engineering
Thesis: “Treatment planning for Microwave ablation of 
hepatic tumors in the proximity of hepatic veins.” 
Eindhoven University of 
Technology
2008-2013 Bachelor Biomedical engineering
Thesis: “Simulation of Ultrasound in Bone and Muscle 
using Ray-tracing”
Eindhoven University of 
Technology
Practical Experience
2020-NOW Validation Lead at the Interventional Applications Cluster Philips Healthcare
2020-NOW Employeneur at TMC Data Science
Responsibilities:
Personal development; Contributing to the business; 
Professional Socializing; Furthering the business
TMC
2016-2021 PhD Student at Department of Radiotherapy (Precision 
Medicine, D-lab)
Responsibilities: 
Developing models; Conducting research; Writing 






2017-2020 Consultant for ptTheragnostic
Responsibilities:
CE marking; Developing models; Preparing and giving 
demos; Giving pitches
DNAmito
2014-2015 Master Thesis Internship
Responsibilities: 













Description Level of mastery
Matlab arithmetic program excellent
Comsol Multiphysics Multiphysics FEM package excellent
Wolfram Mathematica computation package good
Python programming language moderate
R Computation package good
General Skills  
Experience Level of mastery
Classification (Random forest) Hands on excellent
Radiomics Hands on excellent
CE modelling PhD courses excellent
Regression Master courses, hands on good
Signal analyses Master courses good
Statistics Master courses good





2019 CE modelling in R Maastricht University
2019 European Congress of Radiology Vienna, Austria
2018 EUSOBI 2018 Athens, Greece
2018 PhD Writing 2 Maastricht University
2018 Presentations Course for PhD Researchers (PhD-4) Maastricht University
2017 Prediction and Modeling of response to Molecular and 
External Beam Radiotherapies
Cancéropôle Grand Ouest
2017 BiGART 2017 Aarhus, Denmark
2016 PhD Writing 1 Maastricht University
2016 Introduction modelling cost-effectiveness Erasmus Academie
2016 Advanced health economic modelling Erasmus Academie
Publications
“Modeling-Based Decision Support System for Radical 
Prostatectomy Versus External Beam Radiotherapy for 
Prostate Cancer Incorporating an In Silico Clinical Trial 
and a Cost–Utility Study”
Cancers 2021 1st author





“Decision support systems in oncology” JCO Clin Cancer Inform 
2019
Co-author
“Development of an isotoxic decision support system inte-
grating genetic markers of toxicity for the implantation of 
a rectum spacer.”
Acta Oncol 2018 1st author
“Big Data-Based Decision Support Systems for Hadron 
Therapy” (book chapter)
Advances in Particle 
Therapy 2018
1st author
“Dynamics of rectal balloon implant shrinkage in prostate 





“Development of a virtual spacer to support the decision 
for the placement of an implantable rectum spacer for 
prostate cancer radiotherapy: Comparison of dose, toxic-
ity and cost-effectiveness.”
Radiother Oncol 2017 1st author
“Radiomics: the bridge between medical imaging and 
personalized medicine”
Nat Rev Clin Oncol 
2017
Co-author
“Big Data in radiation therapy: challenges and opportuni-
ties”
Br J Radiol 2017 Co-author
“Modelling the temperature evolution of bone under high 
intensity focused ultrasound.”
Phys Med Biol 2016 Co-author

